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ABSTRACT
Cancers of the colon and prostate, though treatable, necessitate early detection to
improve patient outcomes. Current diagnostics, (visual methods or biopsies) besides
being invasive, are subjective towards interpretation, thus decreasing accuracy.
Alternatively, blood-based tests involving measuring of specific biomarkers (like CEA
and PSA for colon and prostate cancers, respectively) are associated with high falsepositive rates and are more useful for monitoring post-treatment patient health, thus
driving efforts to identify better screening and diagnostic techniques.
Abnormal glycosylation of integral membrane and secreted glycoproteins is known to
take place at the onset of many diseases, including cancer, and presents as the over, under
or new occurrence of certain glycans. The aim of this study is to design synthetic lectins
(SLs) that could discriminate cancer-associated glycans (CAGs) and to investigate global
glycosylation changes associated with colon and prostate cancers. Further, the ability of
an array of SLs to discriminate cells based upon their metastatic potential, demonstrates
an alternative approach to detect colon and prostate cancers by looking at aberrant
glycosylation changes rather than hunting for a specific biomarker.
Chapter 1 details on abnormal protein glycosylations. An account of how diols in
glycans can be investigated using boronic acids mediated glycan sensors in the past. This
follows introduction to Lavigne group peptide-boronic acid conjugates (Synthetic
Lectins). A discussion of SL-array platform and its utility at discriminating proteins
extracted from colon cell lines

.
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Chapter 2 describes various chemical modifications done to the SLs (peptide
sequences and boronic acid moieties) in order to establish structure and activity
relationships against purified glycoprotein analytes. Purified glycoproteins were used
since the glycans displayed in them are also present in CAGs and have a positive disease
correlation. The aim of these experiments is to gain an insight on chemical basis of SLglycoprotein interactions. Several hypothesis were drawn on the design of new SLs.
Positive charges on SLs helped pre-organization of SL-glycoprotein interaction.
Chapter 3 aims at incorporating new SLs into the pre-existing SL array to investigate
colon and prostate cancer in vitro. The chemical make-up of the SLs that statistically
contributed the most to discriminate cancer is evaluated. An extended SL array
(combining old and new SLs), can discriminate normal, low metastatic and high
metastatic states from secreted proteins of different prostate and colon cells with >99%
accuracy. Metastatic potential of colon and prostate correlate with variation in i). number
of Arginine (R) residues and ii). number of phenyl rings in SL peptide sequences.
Chapter 4 details on quantifying sialic acid content in vitro and investigating any
correlations with the metastatic potential of colon and prostate cell lines. Further, several
CAGs were classified using SL array with >99% accuracy. The positively charged amino
acids (e.g., Arg) and those containing phenyl ring residues (e.g., Tyr, Phe) appear to be
the principal factors involved in discriminating CAGs. Based on the relative importance
that charged amino acids and phenyl boronic acids in SLs have at evaluating metastatic
potential; several tissue specific SLs were found and their peptide sequence homology
was studied.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
1.0 OVERVIEW
Cancer, the rampant growth and invasion of abnormal cells in the body, is one of
the leading causes of death not only in the United States but also worldwide. Colon
cancer ranks as the third leading cause of death for both men and women. Whereas,
prostate cancer is the second leading cause of death from cancer in men, here in the
States. It is a well-known fact that the early diagnosis is a paramount for an optimal
patient outcome. Post-translational modifications causing an advent of abnormal changes
in glycosylation during the onset and progression of the disease, is a cancer hallmark.
This anomalous glycosylation allows several glycans to serve as biomarkers. This chapter
will shed some light upon the current cancer diagnostics and the necessity for the new
ones. It will then discuss how polymeric boronic acid-peptide conjugates: also known as
synthetic lectins (SLs) develop as glycan sensors. Later, how an array of such crossreactive sensors are useful in designing a novel cancer diagnostic.
1.1 COLON AND PROSTATE CANCER STATISTICS
Cancer is one of the leading causes of morbidity and mortality worldwide, with
approximately 14 million new cases in 2012.1 American Cancer Society estimates that
there will be 1,688,780 new cases of cancer and reports 600,920 deaths in the year 2017.
2

In the United States, Colorectal cancer is the third deadliest in both sexes and prostate
1

cancer is the second deadliest of the cancers in men. In 2017, there will approximately
50,000 deaths and 27,000 deaths due to colorectal and prostate cancer respectively.2
1.2 COLORECTAL AND PROSTATE CANCER DETECTION AND DIAGNOSIS
WHO funded International Agency for Research on Cancer establishes that cancer
mortality can reduce, provided there is an earlier detection and treatment available.
Approximately 30-50% percent of cancers are preventable through screening and early
detection strategies. There is a high five-year survival rate in case of colon cancer of 90%
when the diagnosis reports the disease is localized within the bowel walls (Stage I). The
rate of survival plummets to 68%, once cancer metastasizes in to the lymph nodes (stage
III): thus necessitating early detection.3
There are some non-invasive colorectal cancer screening techniques too (gFOBT,
FIT, stool DNA test), which look for blood in the stools, collectively have an accuracy
rate of 38-51% hence they present high false-positive rates.4 On the other hand, invasive
visual methods of screening, such as colonoscopy are also present.5 Colonoscopy
although quite sensitive yet it has a set of complications, e.g. bleeding, lacerations,
increased risk of infection and high price-point.6-8 Yet, colonoscopy provides a more
accurate detection than the non-invasive procedures like FIT and gFOBT albeit
associated with high false-negative rates.9 While the FIT has success with identifying
advances neoplasms, the main disadvantage with the FIT over colonoscopy is that it has
higher false-negative results in detecting T1 cancer versus T2- T4.10
There are invasive diagnostic techniques to determine prostate cancer, like Digital
Rectal Exam (DRE) and Trans Rectal Ultrasound (TRUS). These involve monitoring
abnormalities in the shape and size of the gland using touch and vision. The disadvantage

2

of TRUS is its invasive nature, leading to morbidity related to diagnosis due to infections,
hematuria and haematospermia.11 DRE lacked sensitivity in general especially at the
onset of prostate cancer.12, 13 Increasing the specificity and sensitivity, while at the same
time reducing the ‘invasiveness’ of a diagnostic procedure, has been a driving factor in
the search for colorectal cancer biomarkers.
The other method of diagnosis is with use of biomarkers to diagnose and stage
cancers. For example, Carcinoembryonic antigen (CEA) is a glycosylated cell-surface
glycoprotein and in healthy patients, CEA levels can range from 2.5 to 5 ng/mL. The
correlation of colorectal cancer with an increased CEA levels in patients with Stage I
cancer is only 4%, while in patients with stage II cancer is 25%.14 Similarly there is CA
19-9 test, which measures the antibody against sialylated-Lewis a (sLea) (which typically
increases in colorectal cancer) showed lack of disease specificity Both CEA and CA 199 tests are associated with high false-positive rates of 16 and 60% respectively.15 In 2000,
the American Society of Clinical Oncology (ASCO) recommended that the CEA and CA
19-9 tests no longer be used as a diagnostic tool, but rather be used to monitor disease
progression.16
Along with DRE and TRUS, monitoring of a serum-based glycoprotein called
Prostate-Specific Antigen (PSA) completes the diagnostic triad for prostate cancer.17 PSA
levels above 4.0 ng/mL, meant some abnormality and the patient is recommended
biopsy.18 Besides prostate cancer, age, level of activity and inflammation are also the
reasons for elevated PSA, thus deeming it non-specific. PSA has notoriously high falsepositive rate and only 25% of the men that undergo biopsies actually have cancer.19 Not
only are cancer diagnostics associated with high false positive and false-negative rates,
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most are also ineffective in early stages of cancer, when the disease is most treatable.
This calls for a development of a detection procedure with high positive correlations and
minimal invasion. Hence, the long-term goal of this project is the development of a
sensitive and preferably easy to use sensor, with the ability to detect colon and prostate
cancer related targets.
1.3 ABERRANT GLYCOSYLATION: HALLMARK OF CANCER
Aberrant glycosylation (term coined by Meezan et. al. in 1969) of integral cell
membrane proteins and secreted glycoproteins occurs during carcinogenesis.20, 21 Over
70% of proteins (both membrane-bound and secreted) undergo glycosylation.22 Posttranslational glycan modifications associated with cancer are termed as CancerAssociated Glycans (CAGs) (Figure 1.1). Aberrant glycosylation also takes place at the
onset of many diseases including cancers, inflammation, as well as lysosomal storage
diseases. The glycans on the glycoproteins can be under, over, or neo-expressed.
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Figure 1.1: Some examples of cancer-associated glycans (CAGs) that are often
involved in aberrant glycosylation during oncogenesis and disease
progression.14. 15, 20
Most include sialic acid, fucose and mannose residues.

4

Figure 1.2: Showing two major types of protein glycosylation.
N-glycans are shown covalently linked to asparagine (Asn) residue of proteins,
specifically the Asn-X-Ser/Thr motif. O-glycans are linked hydroxyl groups of the
amino acids serine (Ser) and threonine (Thr).21
This altered glycosylation occurs on both the membrane-bound proteins as well as the
secretory proteins.23 Aberrant glycosylation process takes place at the onset of cancer and
continues as the disease progresses.24 There are two sites for protein glycosylation: Nlinked and O-linked glycosylation (Figure 1.2) For instance, sialyl Lewis X (sLex) and
sialyl Lewis A (sLea) are CAGs that have increased abundance in colon cancer cells, they
are few of the glycans looked at with the SL array.23 There never is one CAG associated
with one type of tissue malignancy, but a mélange of glycosylations alter, which change
the overall glycan makeup by changing the amount of sialylation or fucosylation.25
Taking this as a phenotypical characteristic of cancerous tissue.26, 27, cells are probed with
lectins (carbohydrate binding peptides), specifically synthetic lectins (SLs) to detect
abnormal glycosylation.28, 29 For instance, sialyl Lewis X (sLex) and sialyl Lewis A (sLea)
are CAGs that have increased abundance in colon cancer cells, they are few of the
glycans looked at with the SL array.29 While many glycoproteins are used to detect
cancer (PSA and CEA), these diagnostics rely on detecting the amount of the
glycoproteins themselves and not the changes in the glycan structures of the
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glycoproteins. Harnessing the overall change in glycosylation pattern can prove to be a
useful tool for cancer detection.
1.4 LECTINS: CARBOHYDRATE BINDING PROTEINS
CAGs can also be monitored using antibodies30 and natural lectins31,

32

, Lectins are

carbohydrate-binding proteins that serve a variety of functions in the body. Lectins can
serve as recognition signals on the surface of the cell31, play a role in protein folding and
cell-cell interaction.33 They can also be involved in cellular functions like cell adhesion,
and cell migration.21 Figure 1.3 shows the impact of glycosylation on E-cadherin and
integrin (common glycoproteins involved in cell adhesion). Different type of
glycosylations instigate different form of cellular functions. Lectins have high selectivity
for a particular target, natural lectins and natural lectin arrays have been of interest in
research in a variety of research areas (endocytosis, adhesion, EMT), but, we will limit
this discussion to cancer-related areas. Studies are looking at lectins as diagnostic tools.
One such study investigated natural lectin microarrays as a means for distinguishing
glycosylation patterns in serum from 24 different patients (model including 10 normal
patients, 8 patients with chronic pancreatitis and 6 patients with pancreatic cancer).
This microarray included five different natural lectins, however, due to the specificity
of lectins only five different glycan structures could be detected. The researchers were
able to distinguish between serum samples; however, the experiments required a large
amount of sample preparation (including glycoprotein enrichment followed by RP-HPLC
to isolate glycoproteins before they are blotting them on a microarray and analyzed using
lectins). This study also found several glycoproteins that over-expressed sialylation and
fucosylation.34, 35
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Figure 1.3: Glycosylation reactions catalyzed by the action of glycosyltransferase
causing several regulatory functions.21
Enhanced expression of GnT-V in epithelial cells results in a loss of cell-cell
adhesion, increasing integrin-mediated cell migration. In contrast, overexpression of
GnT-III strengthens cell-cell interaction and downregulates integrin-mediated cell
migration, which may contribute to the suppression of cancer metastasis.
Natural lectins are expensive, unstable and give incomplete results. Natural lectins
tend to loose binding specificity when they are extracted out of their native protein
conformation. Besides this, the number glycan motifs and the number of glycan linkages
severely outweigh the number of known natural lectins. For instance, the accuracy of an
assay developed for Carcinoembryonic Antigen (CEA) is only 4% and 25%, respectively
in the diagnosis of colorectal cancer of stage I and II respectively, thus making it an
unsuitable candidate for screening and more useful for prognosis of colon cancer.14
1.5 INTERACTIONS BETWEEN BORONIC ACIDS AND DIOLS
In an attempt to cross-over the previously stated disadvantages of using natural
lectins, boronic acids have been utilized in several different glycan sensors because
7

boronic acids are known to form covalent yet reversible boronate esters with 1,2- and 1,3diols, which are found on glycans, to produce cyclic boronate esters. The interaction
between
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HO
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- 2H
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Figure 1.4: Interaction between boronic acids and 1,2- or 1,3-cis diols commonly
present in glycans.
This leads to formation of proposed reversible and covalent boronate ester bond
between boronic acid found on SLs and cis (1, 2- or 1, 3- ) diols of the CAGs.
is illustrated (Figure 1.4). When using boronic acids in glycan sensors, it is important to
understand what influences the boronic acid-diol interaction. The equilibrium exists
between phenylboronic acid and a diol in solution and illustrated in (Figure 1.5).

Figure 1.5: The equilibrium between phenylboronic acid and a diol lies towards
boronate ester formation (2 &4) in basic aqueous solution.
The equilibrium is very dependent on pH. At lower pH, the acid and diol stay
unbound since any boronic ester that forms, contains an empty p-orbital in Boron. At
higher pH, (when pH increases more than pK a of phenylboronic acid: 8.8) boronic acid
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stays as a boronate anion (in Figure 1.5, 1  2 or 3  4). The boronate anion has a
tetrahedral geometry, making the bond angles around the boron similar to the bond angle
of the cycle boronate ester. Therefore, at physiological pH, phenylboronic acid does not
form boronate ester and this limits its use in carbohydrate detection sensors.36
In order to use phenyl boronic acids on sensors at physiological pH, the Anslyn group
investigated intramolecular boron-nitrogen interactions. In neutral aqueous solutions, the
incorporation of an ortho-aminomethyl group on to phenylboronic acid facilitated
boronic ester formation with diols.37 The amino methyl group interacts with the empty porbital on the boron transforming the geometry into the favored tetrahedral conformation.

Increasing pH

Increasing pH

Increased binding

Increased binding

Figure 1.6: Showing proposed equilibrium by Anslyn group by incorporating
an aminomethyl group ortho to phenylboronic acid and facilitating binding of
phenyl boronic acid with diols at physiological pH.
This happens in two ways, either by increase solvolysis of the boron (left
equilibrium) or take place of the coordinating hydroxide molecule and hence acting
as an internal base (right equilibrium).
The Anslyn group proposes two reasons for this increase in boronate ester formation.
First, the neutral aqueous stability of the boron is promoted because the nitrogen can act
as an internal Lewis base and increasing boron’s solvolysis. Second, due to this nitrogen
behaving as a base, it donates lone pair to the empty p-orbital to form a weak co-
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ordinate/dative bond between the nitrogen and the boron. Both of these explanations
facilitate the boronate ester formation at physiological pH (Figure 1.6).37
1.6 ADVENT OF BORONIC ACID FUNCTIONALIZED GLYCAN SENSORS
Over the years, several phenylboronic acid functionalized sensors were developed
for different types of saccharide sensing, specifically keeping an interest of detection of
D-glucose. It is mentioned in previous sections, that sensing glycans can be valuable
when trying to diagnose and prognose cancer. The specific recognition of boronic acid
for cis-diols provides selectivity in sensing. Some of the structures of different phenyl
boronic acid functionalized sensors that employed fluorescent, colorimetric, and
electrochemical methods are in (Figure 1.7).
Yoon and Czarnik generated the first aqueous fluorescent chemo-sensing probe using
anthrylboronic acid (Figure 1.7a).38 When the anthrylboronic acid was bound to fructose,
the anionic boronate ester formed and fluorescence intensity decreased. The resulting
cyclic ester of anthrylboronic acid and fructose had pKa of 5.9. The causation of decrease
in fluorescence intensity was proposed to be by the boronate ester formation, which
quenched the fluorescence due to electron transfer from anthracene ring.
Several other groups began to work on development of fluorescent glycan-sensors with
similar intramolecular charge transfer (ICT) complexation. For example, boronic acid
substituted stilbenes were synthesized as glycan sensors by DiCesare-Lakowicz group
(Figure 1.7b).39 The boronate anion acted as the electron-donor and the photo-induced
CT would complete when the fluorophore contained an electron-withdrawing R group
(e.g. –CN). Therefore, whenever the glycan formed boronate ester, the resulting boronate
anion would register blue shift due to CT. When the boronic acid converted to the
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boronate ester in the addition of a sugar at high pH, the boron does not accept electrons
anymore and this loss of charge transfer disrupts the fluorescent properties.
Shinkai’s group was the first to design Photoinduced Electron Transfer boronic acid
sensors for sugars (Figure 1.7c).40 They introduced N-methyl-o-(aminomethyl)
appendage on to the phenylboronic acid as the recognition motif and connected to a
fluorophore anthracene through a methylene spacer. The amine being ortho to the
boronic acid allowed for the interaction between the boronic acid and diols at neutral pH.

Figure 1.7: Structures of boronic acid functionalized sensors used for glycan
sensing. (a) Yoon and Czarnik first fluorescent probe, (b) Lakowicz group’s
Intramolecular charge transfer (ICT) sensors, (c-d) Shinkai’s and Wang’s group (e)
Photoinduced electron transfer (PET) sensors, (f-g) James’ group electrochemical
sensors.
The amine-boron interaction, besides assisting formation of boronate ester also
dictated the molecule’s ability to partake in fluorescence. Without the sugar binding, the
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sensor remains in an “off” state due to the nitrogen’s lone pair. While binding the sugar,
the nitrogen coordinates with the boron, causing formation of boronate ester, which
prevented electron transfer and induced fluorescence quenching. These sensors exhibited
some selectivity for sugars with it being the selective for D-Fructose and D-Glucose
equally. The molecule c in Figure 1.7 would lose selectivity when the amounts of
boronic acid or the geometry around the boron was changed. Several other PET based BN molecules were made where Figure 1.7d represents yet another example of an
anthracene-based system, this time containing di-boronic acids.41 It had a high selectivity
for D-Glucose over other glycans.
Binghe Wang’s group used a similar strategy to the Shinkai’s PET mechanism and
developed a series of di-boronic acid sensors. These molecules had different linkers
between two anthracene fluorophores (Figure 1.7e).42 Wang’s group found that the
compounds with the para-benzene linker showed moderate selectivity for sialyl Lewis X
in aqueous solution. Di-boronic acid sensor was found to show the strongest fluorescence
enhancement upon binding with sLex. After binding in situ to sLex, the sensor enabled
labeling of hepatocellular carcinoma (HEPG2) cells selectively via binding sLex over Ley
expressing HEP3B cells and COS7 cells, either of which do not express sLex.43 NonsLex-expressing cells remained un-labeled.
James’s group developed electrochemical sensors, which contained electro-active
ferrocene attached to mono-boronic acid (Figure 1.7f) or di-boronic acid (Figure 1.7g).
Overall, the di-boronic acid sensor was more selective for D-glucose and D-galactose
compared to the mono-boronic acid sensor.
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As discussed earlier, the recognition of more complex saccharides can play a valuable
role in the detection of many different diseases. This is due to the cis-diols that are found
on glycans and glycoproteins and their ability to interact with boronic acids. The variety
of glycan conjugates and glycoproteins that show up during oncogenesis, create the dire
need for glycan-sensing and therefore, boronic acids have been incorporated into many
biosensors for their application in cancer diagnostics.
Borono-lectins are the bio-sensing probes that were developed by Hall and Anslyn
groups. They are boronic acid conjugated short peptide sequences. The selectivity of
these sensors has been greatly improved over the years. One important issue of these
sensors was their biocompatibility. In order to optimize these sensors, they needed to
have good water solubility, low toxicity, and greater stability than the other glycan
sensors. Most of the fluorescent boronic acid sensors had poor water solubility and
therefore needed organic co-solvents for sugar binding studies. Wang’s group after
enjoying the success of anthracene based PET sensors, developed different sensors that
contained quinoline and naphthalene instead. These structures improved water solubility
and stability. When binding to glycans, the fluorescence of these sensors changed. The
changes were specific to each glycan. However, these polycyclic aromatic compounds
are known to be carcinogenic, hence could not be used for sensing in vivo.44-50
While all of these sensors were promising in glycan sensing, they still had limitations.
In order to overcome these limitations, Hall used a library technique to find sensors that
targeted the TF antigen, which is a cancer-associated glycan. He used a peptide backbone
due to its biocompatible properties. The peptide backbone also had the potential to have
secondary interactions with the glycans, which could enhance binding affinity and
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selectivity. Hall found that peptides functionalized with boroxoles or boronic acids had
more selectivity for the TF antigen compared to peptides without those groups.51
1.7 CROSS-REACTIVE SYNTHETIC LECTIN ARRAYS
Previously, the discussion involved application of natural lectins binding and
recognizing specific glycan residues with high affinity. The specificity of this interaction
is analogous to a lock-key model, which is similar to an antigen/antibody interaction.
Since, one specific glycan does not correspond to one type of cancer, hence oncogenesis
involves a gross change in glycosylation. Therefore, looking for one biomarker that has a
high affinity may not be the best approach. Rather than thinking about one sensor for one
analyte, one can think about a set of cross-reactive sensors forming a sensor array.
(Figure 1.8).52 shows a signal output after interaction of single analyte with many
receptors.

Figure 1.8: Animated view of cross-reactive sensors/receptors arranged into a
sensor array.
In this figure, four of the receptors bind to a single analyte differently. The
combined signals from the receptors create a unique pattern for the analyte. The
replicability of this pattern helps in analyte recognition.
Although aberrant glycosylation is a characteristic of cancer, there are no specific
glycans that have been identified for a specific cancer type. Therefore, instead of looking
for a specific biomarker, we should be looking for a global pattern of glycosylation.
14

Hence monitoring changes in the abundance of more than one glycan makes it more
useful for the diagnosis of abnormal cells. The basis of utilization of SL sensor array is
the principle of cross-reactivity. As explained earlier, cross-reactive sensor arrays are
composed of multiple ‘receptors’ (SLs in this case), with each receptor interacting
differently with different glycans. Information from these binding interactions, as a
whole, leads to the formation of a reproducible unique pattern for the “analyte” (glycans
in this case). This approach enables the discrimination of cells into normal, cancerous or
metastatic groups. These sensor arrays resemble, in principle, the electronic nose53 or
electronic tongue54 sensors, which involve pattern recognition systems. Each sensor only
has to be incrementally different to create a fingerprint that maximizes variation of the
array response binding to different analytes.
1.8 OUR APPROACH: BORONIC ACID FUNCTIONALIZED SYNTHETIC LECTIN
Keeping natural lectin arrays and their binding interactions with glycans in mind,
one can synthesize lectins and then generate a synthetic lectin array to investigate binding
to glycans. In doing so, the cross-reactive property of the lectin array is harnessed, while
avoiding an elaborate usage of too many natural lectins. The Lavigne lab synthesized
Polymeric Lectins and its array. These synthetic lectins (SLs) are short peptide chains
having with Phenyl Boronic acids attached on to them as a side-chain functionality.
These peptide-boronic acid conjugates have several copies of them on each polymeric
resinous bead (typically 300µm size). The advantages to using synthetic lectins are that
they are easy to make, biocompatible, and have low toxicity. (Figure 1.9) depicts a
general synthetic lectin on a resin. It depicts one synthetic lectin on a bead; however,
there is more than one (bead capacity on the resin 0.3µM/mg). The C-terminus of the
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peptide starts with a Methionine (M, for orthogonal binding), followed by Arginine (R)
and two β-Alanine (B, as spacers). The resin-MRBB unit is followed by eight X amino
acid residues, where X represents a random amino acid chosen (natural as well as nonnatural). The non-natural amino acid which is commonly used is diaminobutanoic acid,
represented as Dab. Dab contains –NH 2 on its side chain and each peptide chain contains
two Dab units. The boronic acids (2-formyl phenyl boronic acid) are attached on to this
side chain via reductive amination. As seen in Figure 1.9 there are two phenyl boronic
acid units in each peptide sequence. The N-terminus of the SL sequence is usually
acylated (Ac).
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Figure 1.9: General scheme of a synthetic lectin (SL) attached to a polymeric
resin bead.
There are multiple copies of SL on each bead, making it a multivalent system.

1.9 PROPOSED SYNTHETIC LECTIN AND GLYCAN BINDING
Several other research groups have targeted carbohydrates/ CAGs using boronic
acids in their receptors55-60 because they form covalent yet reversible boronate esters with
cis diols (1,2- or 1,3-) present on CAGs.61-63 Our results indicate that boronic acid
incorporation causes enhancement of SL-sugar interaction because of the covalent nature
of its bond formation i.e. a boronate ester linkage.28 Since purified and quantified CAGs
were very expensive for initial studies, the SL-glycan binding were studied by making
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use of glycoproteins from chickens, cows and pigs. The glycoproteins used were albumin
from chicken ovalalbumin (OVA) and, mucins of porcine stomach (PSM) and bovine
submaxillary glands (BSM). The mucins were selected because they are enriched in high
mannose, hybrid and complex N-linked and O-linked glycans; all usually being present in
cancer related targets.23 Similarly, OVA also includes complex N-linked glycans which
also make up the core of CAGs. Bovine Serum Albumin (BSA) is a negative glycan
control protein since it remains un-glycosylated.
These glycoproteins/ proteins were fluorescently tagged and incubated with SLs. It is
established that higher the SL-glycoprotein binding, higher would be the fluorescence of
polymeric SL bead (Figure 1.10).
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Figure 1.10: Schematic representation of Boronic acid and SL interaction with a
glycan or glycoprotein.
Greater SL-glycoprotein binding interaction involves greater bead fluorescence. Inset
A depicts image of a single polymeric SL bead under microscope.
Synthetic lectin library design, optimization and peptide sequencing of the synthetic
lectins have been discussed in previous Lavigne et. al. work29, they will also be discussed
later in chapter 4.
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From the previously established work, several SLs were found to have higher
selectivity for a particular proof-of-concept glycoprotein (e.g. SL5 for PSM), have been
identified as SL ‘hits’. There are several SLs which are cross-reactive i.e. recognize more
than one glycoprotein in a unique manner (e.g. SL1). The earliest of selective hits and
cross-reactive SLs have been identified and their sequence is depicted in (Table 1.1).
Table 1.1: Synthetic Lectins (SLs) with their peptide sequences that show binding
with the proof of concept glycoproteins.
(Dab)* means diaminobutanoic acid, the linker amino acid with phenyl boronic acid
on its side chain. Each sequence has 3 arginines hence an overall charge of +3. Ac
stands for acylation of N-terminus of the peptide sequence.
SL
Overall SL
Sequence
Type
Hit
charge
SL1 Ac-RG(Dab)*VTF(Dab)*R-BBRM-resin
+3
cross-reactive
SL2

Ac-RT(Dab)*RFL(Dab)*V-BBRM-resin

+3

moderately selective

SL3

Ac-RS(Dab)*VTT(Dab)*R-BBRM-resin

+3

moderately selective

SL4

Ac-RR(Dab)*TQT(Dab)*Q-BBRM-resin

+3

moderately selective

SL5

Ac-RA(Dab)*TRV(Dab)*V-BBRM-resin

+3

highly selective

From the analysis, five SLs (designated SL1-SL5) were validated as hits, out of
which SL1 was highly cross-reactive towards all four glycoproteins, whereas SL2 and
SL5 showed selectivity towards a specific glycoprotein. A percentage change in binding,
(Figure 1.11) was obtained by dividing the fluorescence of a similarly sized set of SL
library from the difference between the fluorescence value of re-synthesized SL and
fluorescence value of the library. (Eq 1)
%∆ 𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅𝐅 =

𝐒𝐒𝐒𝐒 𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟 𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐭𝐭𝐭𝐭 − 𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥 𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟 𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢
𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥𝐥 𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟𝐟 𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢𝐢
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Eq 1
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Figure 1.11: Detected response from SL1-5 binding with four purified proteins
as measured by fluorescence.
Certain SLs reported high selectivity for a specific protein (e.g. SL5 for PSM). SL1
remained cross-reactive for all four proteins. A percentage change in fluorescence
obtained by using the average fluorescence of a set of SL library beads as a control.
(The library control used because it contained all selective and cross-reactive
elements that could have interfered with the assessment of binding). Signals
represent average percentage change in luminosity with error bars displaying ±1
standard deviation.
The library was used as a control because it contained all selective and cross-reactive
elements that could have interfered with the assessment of our binding.23
1.10 SYNTHETIC LECTINS AND THEIR BINDING WITH CELL LINE PROTEINS
A four-component lectin array was assembled, which included both selective and
cross-reactive SLs (SL1, SL3, SL4 and SL5). This array could discriminate between five
common CAGs (TF antigen, Lea, Lex, sLea and sLex) with 95% accuracy.23 (figure not
included and this work will be discussed in detail later in chapter 4). Being that the SL
array response was able to discriminate between structurally similar polysaccharides (e.g.
sLea and sLex), the next step was to determine if the SLs were able to distinguish
differing cell lines of varying metastatic potential. Metastatic potential will be used
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throughout the duration of this dissertation. It will mean whether the cell line is
considered healthy/normal, cancerous non-metastatic/lowly-metastatic, and highly
metastatic. (Table 1.2) lists the cell lines used in the experiment described.

Table 1.2 Colon cell lines used for SL binding analysis; listed is the species, cell
type and origin of the cell lines.
Cell Line name

Species type

Type

Cancerous tissue area

3T3/NIH

Mouse

Healthy

N/A

CT-26

Mouse

Low metastatic

colon

CT-26-FL1

Mouse

High metastatic

colon

CT-26-FL3

Mouse

High metastatic

colon

HT-29

Human

Low metastatic

colon

HCT-116

Human

Low metastatic

colon

LoVo

Human

High metastatic

colon

For each cell line the table lists the metastatic potential, cancer type (if applicable), and
the origin of the cancer cell line if it was metastatic, and the species this cancer is derived
from. For instance, LoVo is a human colon cancer metastatic cell line. While it is from
colon cancer, it had metastasized to its secondary site, lymph nodes. CT26-F1 and CT26FL3 are isogenic mouse cell lines meaning that they are derived from the same cell line,
CT26. For clarity, CT26 is non-metastatic/lowly metastatic with being only 0-5%
metastatic. CT26-F1 is metastatic with a rate of 50% metastatic, and CT26-FL3 is highly
metastatic with a rate of being 95% metastatic. The cell lines were grown according to
ATCC guidelines and the membrane proteins/glycoproteins were extracted using the
Qiagen® membrane extraction kit. Later, these proteins were fluorescently tagged using
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FITC and incubated with SL array containing only four lectins. The beads were analyzed
using fluorescence microscopy and imaged. The bright values were obtained using Adobe
Photoshop® as described earlier in this chapter. It is challenging to look at a bar graph to
decipher which responses are different, which is why a statistical method called linear
discriminant analysis (LDA) is used. LDA is a statistical program that tries to minimize
the separation within the same group, while maximizing the differences between other
groups. LDA is a guided statistical method, which means that the program knows which

Figure 1.12: Discrimination of healthy (♦), cancerous low metastatic (●) and
metastatic (▲) colon cell lines using SL array shown by guided statistical
grouping using linear discriminant analysis score plot.
The x-axis for discrimination correlates metastatic potential. This type of analysis
minimizes the differences within a cell line and maximizes the variations among the
cell lines. With SL array, we could observe 97% classification accuracy for three
classes (N=340). Circles around the data represent 95% confidence intervals.
group each data point should be in. (Figure 1.11) is the LDA plot generated from the data
obtained by incubating four SLs with six cell lines.
The fingerprint pattern was obtained and LDA was used to better distinguish the
similarities and differences in the array response. Interestingly, the four SLs selected for
this study were selected against ‘proof-of-concept’ glycoproteins. None of those
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glycoproteins were present in the cancer cell lines studied, thus illustrating the ability of
array to classify glycoproteins for which it was not originally designed. This fourcomponent SL array was assembled, and included both selective and cross-reactive SLs
(SL1, SL3, SL4 and SL5). They were able to discriminate classify seven different colon
cancer cell lines in three classes (healthy/cancerous/metastatic) with 97% accuracy23
1.11 NON-COVALENT PROTEIN INTERACTIONS IN AQUEOUS ENVIRONMENT
The strongest of the non-covalent interactions include ionic and hydrogen
bonding, but while investigating proteins in aqueous solutions, these interactions become
irrelevant.64 Weaker or “non-conventional” hydrogen bonding interactions, like CH-π
interactions become stronger and more specific. CH-π interactions (first postulated by
Tamres in 1952) involve a CH group, which acts as the hydrogen bond donor (soft acid)
and the electrons of a π-system act as hydrogen acceptor (soft base).65 Nishio et. al.
reported that roughly 29% of all known organic crystal structures in the Cambridge
database containing a phenyl ring and an alkane region show an evidence of a CH-π
interaction. There exists a remarkable difference between the nature of a traditional
Pauling postulated strong hydrogen bond interactions and CH-π interactions.66
The conventional hydrogen bonds mainly contain electrostatic forces, whereas
“typical” CH-π interactions have a major contribution from London dispersion forces,
electrostatic forces and directional polarization.67 However, the magnitude of CH-π
interactions, is considerably smaller than that of a conventional H-bond. In gas phase, an
isolated and conventional neutral H-bond in chloroform solution has an enthalpy gain that
ranges from 1 to 7 kcal·mol-1. Conversely, the enthalpy of a single CH-π interaction is
less than one kcal·mol-1.65
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Figure 1.13: (A) Parameters used to identify CH−π interactions:
CH−π angle (θ, ≤ 40°), CH−π distance (C-X, ≤ 4.5 Å), (B) Raw-count distribution of
aromatic side chains identified making CH−π interactions with carbohydrates. For
Trp, CH−π interactions identified for for both rings interacting with separate CH
proton. (C) Structure of aromatic amino acids, with corresponding electrostatic
surface potentials for the π-systems (highlighted in beige) of the side-chain moieties:
indole (Trp); phenol (Tyr); benzene (Phe); imidazole (His). To show the differences
in the π-systems, the scale is shown from ≥130 kJ mol–1 (electropositive, blue) to ≤
−130 kJ mol–1 (electronegative, red).
Despite of the low enthalpic contribution, the total energy provided by CH-π
interactions is significantly greater and thus is due to the participation of multiple CH
and/or π-groups acting together in-sync (multivalency). The occurrence of multiple CH-π
interactions in a supramolecular assembly renders them quite important in terms of total
energy and preferred structure, but they do not have a significant role in controlling
relative orientations of molecules.
Consequently, CH-π interactions exist in a variety of phenomena including molecular
recognition, crystal engineering, supramolecular adhesives and the structure of many
biomolecules.68-70 In (Figure 1.13) Hudson et. al. describe the parameters used to define
the strength of CH-π interactions between C-H donor of carbohydrates and pi-system of
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aromatic amino acids in proteins. While studying CH-π binding, they collected all data
(Protein Data Bank) for any interaction between atoms of amino acids with and any atom
of a carbohydrate moiety within 4.0 Å distance. Using this dataset and applying CH-π
measurement parameters (Figure 1.13A), they found out that aromatic residues contacted
carbohydrates in the order tryptophan (Trp) ≫ tyrosine (Tyr), Phenylalanine (Phe) >
histidine (His) (Figure 1.13B).71

Brandl et. al. examined a set of 1154 protein structures from the Protein Data Bank
for any CH-donor and pi-acceptor type interactions. They found out that the most
prominent interactions were between aliphatic CH donors and aromatic pi-acceptors and
interactions between aromatic CH donors and aromatic pi-acceptors. About half of all
Phenylalanine (Phe, F) and Tyrosine (Tyr, Y) –rings, were involved as acceptors in CHπ-interactions. Aromatic CH groups as well as aliphatic side-chains of the long, extended
amino acid residues Lys, Arg and Met, and the Pro ring were preferred as donors.72
Besides CH-π interaction, there also exists cation-π type interactions that contribute to
protein folding as well. In gas phase the cation-π interaction energies between aromatic
amino acids (Phe, Tyr, and Trp) and the interaction energies of protonated amino acids
(Arg (+) and Lys (+)) are in the range from -9 to -18 kcal∙mol-1. In aqueous solutions, the
cation-π energies of H 3 O (+) and protonated amino acids are less affected by solvation
effects.73
The next chapter (chapter 2) describes various chemical modifications done to the
SLs (peptide sequences and boronic acid moieties) in order to establish structure and
activity relationships against purified glycoprotein analytes. The aim of these
experiments is to gain an insight on chemical basis of SL-glycoprotein interactions.
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Using what was learnt in chapter 2, several hypotheses were drawn on the design of new
SLs.
Chapter 3 aims at incorporating new SLs into the pre-existing SL array to investigate
colon and prostate cancer in vitro. The chemical makeup of the SLs which statistically
contributed the most to the cancer discrimination, is evaluated.
Chapter 4 details on quantifying sialic acid content in vitro and investigating any
correlations with the metastatic potential of colon and prostate cell lines. Based on the
relative importance that charged amino acids and phenyl boronic acids in SLs have at
evaluating metastatic potential; several tissue-specific SLs were found and their peptide
sequence homology was studied.
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CHAPTER 2:
INVESTIGATION OF STRUCTURE-ACTIVITY RELATIONSHIP
BETWEEN SYNTHETIC LECTINS AND GLYCO-PROTEINS
2.0 OVERVIEW
In order to investigate virulence of cancers, as discussed in the previous chapter,
an array of SLs was made (section 1.10). Some of the SLs in the array were ‘crossreactive’ for different proteins (i.e. they bound to different analytes), and some SLs were
‘selective’ (towards a specific analyte). When the output of all the SLs was taken
together, including the ‘cross-reactive SLs, they help us in generation of unique
‘fingerprint’ for a particular cancer.1 The applicability of an SL array lies in the
generation of unique fingerprints for healthy and cancerous samples.
Although, it is unclear that which protein/glycoprotein structure is causing the
intended discrimination in patterns, the focus of this chapter is to investigate the
factors/sites that are important, on the synthetic lectin (SL) which enable it to bind with
proteins to generate a representative “signature” pattern. To determine the chemical
rationale behind SL-protein binding, the SL undergoes structural alteration. After altering
the SL, we observe the impact of the proposed modifications on the binding of that SL to
the proteins. SL5 is selected for the alteration/mutation studies, because of its ability to
bind selectively to one protein (porcine stomach mucin, PSM) over the others (i.e. Bovine
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submaxillary mucin (BSM), Ovalalbumin (OVA) and Bovine serum albumin
(BSA)).2 SL5 underwent the following structural modifications as listed below,
including:
1. Variation of intra-diamino butanoic acid distance (ref: section 2.1)
2. Altering the boronic acid attachments (ref: sections 2.2 and 2.3)
3. Altering the peptide sequence: by replacing amino acid with Alanine (A) on to
I.

Other amino acids (both polar (Dab), Threonine (T) and non-polar Valine (V))
(ref: section 2.4)

II.

Positively charged amino acids (e.g. Arginine (R)) (ref: section 2.5)

2.1 VARIATION OF INTRA-DIAMINO BUTANOIC ACID DISTANCE
The peptide sequence of SL5 contains two diamino butanoic acids (Dab) which
have -NH 2 on their side chains and they act as the binding site for two 2-formyl phenyl
boronic acids (2-PBA) respectively. The -NH 2 of the Dab and the carbonyl carbon of 2PBA bind to each other via reductive amination. Dab is a non-natural amino acid with
two less methylene groups than Lysine on its side chain.3 Dab is preferred over Lysine
because of its shorter side chain providing a pre-organization to bind SL to diols.4
Together, Dab and 2-PBA abbreviate as (Dab)*. The two (Dab)* in SL5 are three amino
acids apart. We want to investigate the proposed covalent bonding between 2-PBA on
SLs and diols on the proteins. In order to do so, we study the impact on protein binding
by varying distance between two 2-PBA units, by changing the intra-(Dab)* distance.
Doing so, we aim to understand whether spreading the two boronic acids far apart
improves the SL/diol interaction or confining the two boronic acids near each other
serves to limit the covalent interaction. Several ‘SL5 positional mutants’ (Table 2.1)
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were prepared In these mutants, the intra-(Dab)* distance was reduced up to one and
stretched up to a maximum of six AA distance. These seven mutants along with the
original SL5 (as a reference) were tested by incubating each one of them with four
different purified proteins, and imaging under fluorescent microscope (Figure 2.1)

Table 2.1: Representing “SL5 positional mutants” to investigate impact of
variation of intra-(Dab)* distance on SL5 binding with proteins.

3 Ac-RAT(Dab)*R(Dab)*VV

Fold
selectivity
PSM/BSA
2.6

Fold
selectivity
PSM/BSM
1.8

2

3 Ac-RA(Dab)*TR(Dab)*VV

2.5

1.9

(Dab)*4,7

2

3 Ac-RAT(Dab)*RV(Dab)*V

2.3

1.6

(Dab)*3,7(SL5)

3

3 Ac-RA(Dab)*TRV(Dab)*V

2.2

1.6

(Dab)*3,8

4

3 Ac-RA(Dab)*TRVV(Dab)*

2.9

1.8

(Dab)*2,7

4

3 Ac-R(Dab)*ATRV(Dab)*V

2.6

1.8

(Dab)*2,8

5

3 Ac-R(Dab)*ATRVV(Dab)*

2.8

1.8

(Dab)*1,8

6

3 Ac-(Dab)*RATRVV(Dab)*

2.3

1.9

Mutant name

Dab*
space

(Dab)*4,6

1

(Dab)*3,6

+

Peptide sequence after
BBRM-resin

Grey indicates the positions of diamino butanoic acid functionalized with boronic acid
(Dab)* present on the peptide sequence. The numbers in the mutant names refer to
positions of (Dab)* moieties while counting from N-terminus of the peptide. Ac
stands for Acetylation of N-terminus of peptide sequence. B stands for β-Alanine AA.
Fold selectivity describes propensity of mutant to bind to one protein over the other.
BSA is a no-glycosylated protein serving as a negative control. BSM has the closest
glycan homology to PSM.
The experiment was conducted multiple times and the following discussion is the
result of them together. As mentioned in previous chapter, SL5 binds well to PSM (SL5
was selected out of a SL library pool against PSM protein) and it is reflected in Figure
2.1A under the response of PSM with eight SLs. Also, looking at the fold selectivity of
PSM/BSM from Table 2.1, it can be seen that PSM response with the eight SLs is nearly
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twice as much as their response with BSM. It indicates that changing the (Dab)* distance
made no significant change to the binding of SL5 with PSM. This can be explained by
the fact that all of the mutants have three Arginine (R) residues, giving the SL a +3
charge as shown in Table 2.1. Further, looking at the overall binding paradigm of SLs

2.5

fold selectivity of fluorescence over SL5-BSA

A
2

1.5

1

0.5

0

BSA

BSM

OVA

PSM

(Dab)*4,6(1)

(Dab)*3,6(2)

(Dab)*4,7(2)

SL5(3) [(Dab)*3,7]

(Dab)*3,8(4)

(Dab)*2,7(4)

(Dab)*2,8(5)

(Dab)*1,8(6)

C
Name

pI

Glycan
content

BSA

5.6

0

OVA

4.5

3.2%

BSM

3

>50%

PSM

2.5

60-90%

Figure 2.1: Showing impact of changing (Dab)* distance on SL5 with four
purified proteins.
A. The binding capability of SL5 and its “positional mutants” correlates with the
decreasing pI of the four proteins. The numerical in parentheses represents intra(Dab)* distance. B. Representing the same output of five SLs with four proteins in an
unguided statistical grouping, (from left to right, BSA: red, OVA: green, BSM: light
blue and PSM: dark blue). Circles around each protein output is representing that
each protein signal (with five SLs shown in A) is significantly different from the
other with 95% confidence. C. Showing pI and glycan contents of the proteins that
are involved in binding.
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with four proteins, the binding to SLs seems to correlate with the pI of the proteins
involved. For example, PSM has the lowest pI and it showed the greatest binding,
followed by BSM, then OVA and finally followed by BSA (which is negative control as
it has no glycans) as shown in Figure 2.1C.
PSM has the lowest pI because out of all proteins used, it has the maximum amount
of negatively charged glycans (like sialic acid residues).5 It was hypothesized that the
positively charged guanidinium group of Arginine (R) would form a favorable salt bridge
with negatively charged sialic acid moieties commonly found on cancer related
glycoproteins, as well as on two of our proof-of-concept glycoproteins (i.e., BSM and
PSM). Moreover, protein with highest pI (e.g. BSA) binds the least to SL5. This is seen
in Table 2.1, where the fold-selectivity of PSM for SL5 over BSA (negative glycan
control protein) is nearly 2.5 times. As expected, the fold-selectivity of PSM for SL5 over
its structurally closest mucin (BSM, containing the same type of glycans as PSM, but in a
much lower quantity) represents that BSM is the next best binder to SL5 over OVA and
BSA. These three results indicate that +3 charge in SL5 sequence might be more
important at addressing protein to SL binding, rather than the positional placement of 2PBA in the SL structure.
In order to comprehend whether the SL outputs with four proteins are significantly
different from each other, we employed Principal Component Analysis (PCA).6, 7 PCA is
a statistical analytical method, which provides us a platform to perform unguided
groupings of data. As seen in Figure 2.1B, the four sets of outputs with four proteins (as
seen in Figure 2.1A) are represented by squares. The circles around the set of squares
mean that the SL binding with each protein is significantly different from the other with
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95% confidence. Besides this, the X-axes in Figure 2.1B is correlating to the pI of the
proteins involved, thus hinting upon the impetus of positively charged AA residues in
SL5 sequence towards protein classification.
2.2 VARIATION ON SL5 BY ALTERING BORONIC ACID ATTACHMENTS
The previous experiment exemplified the importance of positively charged AA in
SL5 in establishment of binding with proteins of different pI. It also indicated no
significant impact on change in binding when two 2-phenyl boronic acids (2-PBA) were
moved around in the SL5 peptide. This then lead to the question whether 2-PBA is
involved in binding proteins to the SL or not. To address this question, several mutations
to SL5 structures were made. SL5 normally has two units of 2-PBA in its structure, so
will be referred to as 2-PBA (in this section) and is being taken as the control SL. Regioisomer of 2-PBA was made and named 4-PBA (refer to Table 2.2 for the structure of
boronic acid used in this mutant). Also, a mutant named SL5-Bn was made that only had
the phenyl rings and no boronic acid on them. SL5-(Dab)3,7A mutant has two Dabs
(which were on AA positions 3 and 7 in SL5) being replaced with alanine (a non-polar,
small AA), thus having no 2-PBA in the SL. Finally, mutant SL5-Dab, has no 2-PBA but
contains 2 Dabs in the SL. In totality, there are four mutants for testing four situations
1. Alteration of boronic acid (2-PBA) position on the phenyl ring
2. Removal of boronic acid but retention of phenyl ring
3. Removal of boronic acid and phenyl ring and both Dabs
4. Removal of (2-PBA) but retention of both Dabs
The structures of the mutants discussed in (Table 2.2)
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The corresponding output from these SL5 ‘boronic acid mutants’ with 4 proteins is as
Table 2.2: Showing “SL5 Boronic acid mutants’

#

Mutant name

Fold
selectivity
PSM/BSA

Fold
selectivity
PSM/BSM

2.0

1.5

2.1

1.7

2.7

1.5

Peptide sequence mutation & no
2PBA

PSM/BSA

PSM/BSM

Ac-RAATRVAV-BBRM-resin

2.9

1.7

3.0

2.2

Boronic acid structural mutation
a

SL5a or
1

peptide
B(OH)2

(2PBA)

2

SL5a-4PBA

3

SL5a-3,7Bn

#

Mutant name

a

B(OH)2

peptide

a

peptide

SL54
(Dab)3,7Ab
Ac-RA(Dab)TRV(Dab)V-BBRM5

SL5-(Dab)c
resin

a: mutants (1, 2 & 3) contain a peptide sequence of Ac-RA(Dab)*TRV(Dab)*VBBRM-resin. (Dab)* indicates Dab with some boronic acid or phenyl ring attached to
it; b: SL5-(Dab)3,7A mutant, has diaminobutanoic acids replaced by alanines on 3 &
7 position of peptide while counting from N-terminus represented by Bold Ala (A); c:
(Dab) stands for diaminobutanoic acid without boronic acid attached to it.
illustrated (Figure 2.2) The experiment is conducted multiple times and the following
discussion is the result of them together. From Figure 2.2A there are several things that
come to the fore. Firstly, the binding paradigm of all four proteins correlated with the
decreasing trend of pI of these proteins, showing highest binding with PSM and lowest
with the negative glycan control (BSA).
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fold selectivity of fluorescent intensity over SL5-BSA

2.5

A

B

2.0

1.5

1.0

C
0.5

0.0

BSA

SL5-2PBA(SL5)

OVA

SL5-4PBA

BSM

SL5-3,7Bn

PSM

SL5(Dab)3,7A

SL5-Dab

Figure 2.2: Impact of mutating boronic acid in SL5 on binding with proteins.
Impact of mutating boronic acid in SL5 on binding with proteins. A. shows binding
capability of SL5 and its “boronic acid mutants” correlating with the decreasing order
of pI of the 4 proteins. B. Showed the same output of five SLs with four proteins in an
unguided statistical grouping, (where from left to right (■), BSA: red, OVA: green,
BSM: light blue and PSM: dark blue). Circles around each protein output is
representing that each protein output (with five SLs shown in 2.2A) is significantly
different from the other with 95% confidence. C. Unguided grouping showing SL
mutants losing statistical confidence to differentiate higher pI proteins (▲) (BSA: red
and OVA: green) and causing huge data spread of PSM: dark blue and BSM: light
blue, when SLs without 2-PBA (SL5-Dab3,7A and SL5-Dab) were excluded.
This correlation between binding and the pI of proteins reflect that interaction via
charges of protein is the paramount driving force. PSM showed similar binding affinity
with all the mutants, which indicated that presence of neither of the three
1. Boronic acid (2-PBA),
2. Phenyl ring of boronic acid or
3. Dab to which 2-PBA has direct attachment
impacted binding of PSM to SL5 significantly. This also indicated the importance of
positively charged AA in SL5 structure towards stronger interactions with PSM over any
other protein. In higher pI proteins (e.g. BSA and OVA) their binding is seen to be
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reduced with SL5-Dab (red checkered bars under BSA and OVA) and SL5-(Dab)3,7A
(dark blue vertical bars under BSA and OVA) which can be seen by their fold selectivity.
The reason for this decrease in binding with higher pI proteins, may be attributed to the
absence of phenyl rings in SL5-Dab and SL5-(Dab)3,7A. The phenyl ring of the 2-PBA
may be involved in CH-π interactions that are more clearly observed in high pI proteins,
since ionic interactions are less pronounced. To further this argument, the binding of
SL5-3,7Bn (having phenyl ring, but no boronic acid) mutant with BSA and OVA was
very similar to the corresponding SL5-2PBA (SL5) binding to these proteins; thus
indicating that CH-π interactions are at play. When SL5-2PBA signal was compared with
that of SL5-4PBA, both of them appeared very similar indicating that boronic acid
moiety in SL5 was not proving very effective in binding to proteins.
Figure 2.2B shows the unguided grouping of the output obtained using the five SL5s
with the four proteins. Each circle is a different protein and indicates 95% confidence
interval. The X-axes correlates to pI of the proteins (again indicating the important role of
positively charged AA in SL5 sequence at directing greater binding towards lower pI
proteins). OVA (green ■) and BSA (red ■) are overlapping, indicating that their output
might not be significantly different from each other. This could be attributed to similar
looking signals of SL5 mutants (SL5-Dab and SL5-(Dab)3,7A) with BSA and OVA.
There signal was significantly different from the other mutants with same proteins
because while plotting of the same data in Figure 2.2A excluding those two mutants (as
shown in Figure 2.2C), loss of ability to separate higher pI proteins (95% confidence
intervals are no longer tight) is observed. So, one could do without 2-PBA and Dab in the
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SL structure. In short, simpler the design of an SL, the better is its capability in
discriminating between proteins of different pI.
2.3 COMPARING DISSOCIATION CONSTANTS OF SL5 AND ITS MUTANTS
In order to verify that the 2-PBA may not be playing a role in binding of proteins
to SL5, K d values of its structural mutants (as listed in the Table 2.3) were obtained.
Table 2.3: showing few SL5 and its mutants involved in K d investigation using
PSM.
Name

Peptide sequence

BA structure

Ac-RA(Dab)*TRV(Dab)*V-BBRMSL5
(2-PBA)

# #
R +

Kd
(µM)

3

3

0.325

3

5

0.278

3

3

0.324

5

5

0.203

a

peptide
B(OH)2

resin
Ac-RA(Dab)TRV(Dab)V-BBRM-

SL5-Dab

resin
Ac-RA(Dab)*TRV(Dab)*V-BBRM-

SL54PBA

B(OH)2

resin
Ac-RRRA(Dab)*TRV(Dab)*V-

SL5RRAc

a

peptide

a

peptide
B(OH)2

BBRM-resin

a: peptide sequence is of SL5: Ac-RA(Dab)*TRV(Dab)*V-BBRM-resin, where (Dab)*
represented Dab with boronic acid attached to it.
These SLs are on the polymeric beads when each of them are put to incubate with
different mM concentrations of fluorescently labelled PSM, ranging from 0.01 mM to 3.5
mM. The beads are imaged under a fluorescent microscope to obtain intensities that were
used to run a Michalis-Menten iteration. Imaging of these incubated beads are reported at
the same exposure time on the microscope camera (in order to avoid correction to
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fluorescence intensity due to different exposure times). Concentrations of proteins higher
than 3.5 mM, caused the fluorescence signal of the beads to saturate, thus rendering the
signal detection to show plateau effect.

Figure 2.3: Response of SL5 and its mutants with varying PSM
concentration.
Previously, soluble SLs were designed and tested8, 28, 29 against the four proteins, their
K d values were significant (>>10µM), essentially pointing out the necessity of SLs to be
on the bead platform to mimic some form of ‘multivalency’ while binding to proteins
(which are multivalent themselves).9 The fluorescent intensity responses at different PSM
concentrations are observed in Figure 2.3, where they look very similar to each other.
The corresponding K d values have been reported in Table 2.3 and all fall in low µM
range (which is usually the K d range of natural lectins as well, i.e. high nM to low µM).10
The similarity in K d values is unequivocally denying any particular advantage provided
by 2-PBA in binding assistance with PSM. These results also provide strong evidence
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that the polyvalent nature of the beads is critical and multiple SLs on a single bead are
interacting with PSM to produce high affinity binding.
2.4 PEPTIDE SEQUENCE MUTATIONS ON POLAR AND NON-POLAR AMINO
ACIDS
Sequence of SL5 contains polar charged AA like diamino butanoic acid (Dab),
polar, uncharged threonine (T) and non-polar branched AA like valine (V) residues. In
order to study their plausible impact on SL and protein binding, Alanine mutants were
generated. The AA under study was replaced with a small nonpolar AA like Alanine (A)
and then incubated as new ‘SL mutant’ with four proteins as previously described. The
SL5 mutants for this study have been listed below in Table 2.4.
Table 2.4: Showing alanine mutations on polar and non-polar AA in SL5.
#Ph
Peptide structure after BBRM- or #2# Mutant name
resin
PBA +
1
2

SL5

Ac-RA(Dab)*TRV(Dab)*V-

2

3

SL5Dab3,7A

Ac-RAATRVAV-

0

3

3

Fold selectivity
PSM/BSA PSM/BSM
2.3
1.8
2.9

1.7

SL5Ac-RA(Dab)*TRVAV1
3
2.6
1.8
(Dab)*7A
4
SL5Ac-RAATRV(Dab)*V1
3
2.9
1.9
(Dab)*3A
5 SL5-V8A
2
Ac-RA(Dab)*TRV(Dab)*A3
3.0
1.7
6 SL5-V6A
Ac-RA(Dab)*TRA(Dab)*V2
3
2.8
2.0
7 SL5-T4A
Ac-RA(Dab)*ARV(Dab)*V2
3
2.5
1.9
(Dab)* indicates diaminobutanoic acid functionalized with boronic acid; Dab
indicates diaminobutanoic acid. The naming of mutant is SL5-, AA to be replaced
followed by its position in peptide sequence and then followed by AA which replaces
it (i.e. A in this instance). Bold A’s in the mutants are the places where A has replaced
some AA in original sequence of SL5. Ac stood for acetylation of N-terminus of AA.
B stands for β-Alanine. Highlighted in grey is varied # of Ph rings.
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Since there are two Dabs in SL5, three mutants were designed, first one with both
Dabs replaced with A, and the other two where one of the two Dabs were replaced with
A. This experiment thus gave three accounts on protein binding: Firstly, the impact of
absence of two Dabs, secondly the impact of position of each Dab and hence its
corresponding 2-PBAs and thirdly impact of polar T and non-polar V on SL5 binding.
Replacing the number of Dabs with A, consequently led to fewer 2-PBA attachments,
which led to formation of mutants having different number of phenyl rings in SL5 and
was deliberately done to investigate impact of varying Ph rings on binding episode with
four proteins. The corresponding results with the four proteins is as follows in Figure
2.4. In Figure 2.4A, SL5 and its mutants bound PSM the strongest, followed by BSM,
OVA and BSA; showing that the binding of ‘SL5 peptide sequence mutants’ also
correlated with decreasing order of pI of four proteins. All these mutants have +3 charge
(from R AA residues) hence signifying the importance of charges in protein binding.
Figure 2.4B represents output with all four proteins to be significantly different from
each other. Abscissa in Figure 2.4B correlated to pI of proteins, again pointing out
importance of +3 AA in SL sequence for selective binding of PSM over other proteins.
Comparison of PSM/BSA and PSM/BSM in Table 2.4 represented the consistency
between selectivity of SL5 mutants for PSM over other proteins.
While comparing Figure 2.4B and C, there was a slight decline observed in binding
of higher pI proteins (BSA and OVA as shown by their tighter clustering in Figure 2.4C)
with SL5 mutants containing no phenyl rings from 2-PBA (e.g. SL5-(Dab)*3,7A). It
reflected an interplay of CH-π interactions of phenyl rings with proteins especially the
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ones at higher pI. This might mean that getting rid of phenyl rings could help clean-up

fold selectivity of fluorescent intensity with SL5BSA

background binding.
3

A

2.5

2

1.5

1

0.5

0

BSA
SL5

SL5-(Dab)3,7A

OVA
SL5-(Dab)*7A

BSM
SL5-(Dab)*3A

B

SL5-V8A

PSM
SL5-V6A

SL5-T4A

C

Figure 2.4: Showing response of SL5 peptide sequence mutants with four
proteins.
A. The binding capability of SL5 and its “peptide sequence mutants” correlates with
the decreasing order of pI of the four proteins. B. Showed the same output of seven
SLs with four proteins in an unguided statistical PCA grouping, (■ where from left to
right, BSA: red, OVA: green, BSM: light blue and PSM: dark blue). C. PCA
grouping (▲) not including the mutant SL5-Dab3,7A (having no phenyl rings).
Notice BSA and OVA (high pI proteins) having greater overlap because of the
model’s inability to reduce background binding of these proteins with more number
of phenyl rings in the model. Circles around each protein output represented that each
protein output (with seven SLs shown in 2.4A) is significantly different from the
other with 95% confidence.
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In Figure 2.4A, SL5 and its mutants bound PSM the strongest, followed by BSM,
OVA and BSA; showing that the binding of ‘SL5 peptide sequence mutants’ also
correlated with decreasing order of pI of four proteins. All these mutants have +3 charge
(from R AA residues) hence signifying the importance of charges in protein binding.
Figure 2.4B represents output with all four proteins to be significantly different from
each other. Abscissa in Figure 2.4B correlated to pI of proteins, again pointing out
importance of +3 AA in SL sequence for selective binding of PSM over other proteins.
Comparison of PSM/BSA and PSM/BSM in Table 2.4 represented the consistency
between selectivity of SL5 mutants for PSM over other proteins. While comparing
Figure 2.4B and C, there was a slight decline observed in binding of higher pI proteins
(BSA and OVA as shown by their tighter clustering in Figure 2.4C) with SL5 mutants
containing no phenyl rings from 2-PBA (e.g. SL5-(Dab)*3,7A). It reflected an interplay
of CH-π interactions of phenyl rings with proteins especially the ones at higher pI. This
might mean that getting rid of phenyl rings could help clean-up background binding.
The absence of one (Dab)* in each of the two mutants SL5-(Dab)*7A and SL5(Dab)*3A did not impact the PSM/BSM fold selectivity, hence stating that maybe
boronic acids are not interacting with the diols of the glycans on proteins. In fact, the
position at which (Dab)* is replaced by A does not seem to matter since the output of the
two mutants with four proteins looks very similar to each other.
When the two valines, were replaced with Alanine (A) their replacement did not
impact binding since Valine is non-polar and binding is expected to be dependent on
positively charged AA). Similarly, presence of threonine (being polar uncharged AA)
showed no impact on differential protein binding.
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2.5 PEPTIDE SEQUENCE MUTATIONS ON POSITIVELY CHARGED AMINO
ACIDS
SL5 has three arginine (R) AA residues in its peptide sequence. At neutral pH R
has a positively charged guanidinium group, thus providing the +3 overall charge to the
SL5. From previous structure and activity relationships, it is well evident that +3 charge
of SL5 is strongly assisting in differential binding of purified proteins by harnessing their
pI differences. This study is done to investigate
1. The minimum amount of positive charge that begins to create an impact to the
binding of proteins.
2. The maximum limit and hence the optimization of positive charge that may be
included while keeping the design of future SLs in mind.
Initially, we tried to investigate the binding of four proteins to acetylated tentagel
resin (polymeric beads having no AA on them). The signals from all four proteins were
too low and were registered under the limit of detection of fluorescent microscope (hence
not included in the following figures). This meant that tentagel beads on their own had no
fluorescence associated with them and they have no favourable binding preference with
any of the four proteins with fluorescent tags on them. To answer the two queries posed
above, we made seven new SL5 mutants that had different number of (R) AA residues in
them (the charges on the mutants varied from 0 to +5). The study also included two SL5s
that only had A and R AA residues on them to address ‘simplistic SL sequence design’
and its applicability. The sequences of seven ‘SL5 R mutants’ are represented in Table
2.5.
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Table 2.5: Showing SL5 Arginine (R) mutants.
The naming of mutant is SL5-(X), where X is AA to be replaced followed by its position
in peptide sequence, which is then followed by Ala (A).
Mutant sequences in bold are unique sequences containing different # of A and R.
Highlighted in gray are the positions where A has replaced R in original sequence of
SL5. Ac stood for acetylation of N-terminus of AA. B stands for β-Alanine.
Type
Name
Peptide structure
+ #Ph PSM/ PSM/ PSM/
rings BSA
OVA BSM
Low
positive
SL5Ac-AA(Dab)*TAV(Dab)*V0
2
0.9
0.8
0.8
charged R,1,5,11A
BBAM-resin
mutant
MRBB
Ac-BBRM-resin
1
0
2.8
2.4
2.6
Ac-AA(Dab)*TRV(Dab)*VSL5-R1A
2
2
2.2
1.6
1.2
BBRM-resin
Ac-RA(Dab)*TAV(Dab)*VSL5-R5A
2
2
2.3
1.6
1.3
BBRM-resin
Ac-RA(Dab)*TRV(Dab)*V3
2
SL5
3.1
2.2
1.8
BBRM-resin
Ac-RAARAARA-BBRM4R
4
0
2.9
2.2
1.7
resin
High
positive
Ac-RARARARA-BBRM5
0
5R
3.0
1.7
1.5
charged
resin
mutant
SL5RRAc

AcRRRA(Dab)*TRV(Dab)*VBBRM-resin
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5

2

2.8

1.9

1.9

The signal output of given eight SLs with four proteins is discussed below in Figure 2.5.

SL5-R1,5,11A normalised fluorescent intensity

8

low + charge mutants

high + charge mutants

7
6

BSA

OVA

BSM

PSM

5
4
3
2
1
0
SL5-R1,5,11A
(0)

MRBB (1)

SL5-R1A (2) SL5-R5A (2)

SL5 (3)

4R (4)

5R (5)

SL5-RRAc (5)

Figure 2.5: SL5 Arginine positively charged mutants.
(A). Showing low positively charged and high positvely charged mutants’ output
with four proteins. All low positive charged mutants show reduced binding than their
corresponding SL5 output with proteins. All high charged mutants show ‘plateau
effect’ in their signal with low pI proteins like PSM and BSM. (B). shows unguided
grouping of four proteins with low positively charged mutants (■). (C). showing
unguided grouping of four proteins with high positive charged mutants. (▲ left to
right, BSA: red, OVA: green, BSM: light blue and PSM: dark blue). Circles
representing 95% confidence intervals.
Low positively charged mutants: The binding of SL5-R1,5,11A (having no R
amino acid in sequence) was investigated, and the data is listed in Table 2.5. The data
shows that the mutant has the least binding with all proteins and hence its fold-selectivity
for one protein over the other reported to be the smallest out of all the SLs. This showed
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that loss of all positively charged AA residues led to loss in protein binding especially
with low pI ones, again signifying charges being important in SL-protein binding. Hence,
in Figure 2.5A, SL5-R1,5,11A was used as a built-in negative control for positive
charged AA residues against each protein. It was used as a baseline, and output of other
mutants was normalized using this SL. BBRM-resin, is a four AA long conserved residue
in every SL that we designed, which essentially acts as a ‘spacer’ moiety between the
resin bead and the ‘active’ portion of SL sequence. Therefore, we tested acetylated the Nterminus of BBRM-resin and incubated with the proteins; and it reported an increase in
binding to PSM due to one R residue in its structure.
SL5-R1A and SL5-R5A mutants, both had an overall +2 charge (from two R AA
residues) and they reported a further increase in binding with PSM over other proteins.
They both have very similar outputs with four proteins and binding followed the pI trend.
Having one less R than SL5, these two mutants do lose some selectivity of PSM over
BSM, signifying that for optimal binding to a high pI protein mixture, one might require
more than two R AA residues in SL sequence. With low positively charge mutants up to
SL5, an overall trend of increased binding is observed in with PSM, BSM and OVA.
To conclude, every protein bound less than SL5 with low positive charged pieces.
High positively charged mutants: When positive charge was increased more than
what was originally present in SL5, peaking/ plateauing of binding signal with low pI
proteins like PSM and BSM was observed. This resulted in fold selectivity of PSM/BSM
to become similar to one another. The reason may be attributed to high positive charge
rendering the SL ‘too sticky’, making it unable to differentiate between PSM and BSM. It
was also interesting to note that BSA (negative glycan control) reported as the weakest
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binding protein with all the mutants irrespective of the amount of positive charge or
number of phenyl rings (from 2-PBA). Implying that SLs might be interacting to protein
via negatively charged glycans present on low pI proteins. More on this is included as a
part of discussion in Chapter 4.
2.6 CONCLUSIONS
In the experiments above, we discussed the impact of positioning of boronic acids
both in the peptide and also on the phenyl ring of the phenyl boronic acid (PBA). It was
observed that boronic acids e.g. 2- or 4-formyl phenyl boronic acids may not be useful in
enhancing the lectin-glycan selectivity. It is hypothesized that they are too generic in
design and that they do not effectively bind to hexapyranosides (natural form in which
glycans exist in puckered ring). This might be the reason they do not mimic the nature’s
carbohydrate binding proteins i.e. lectins.11
The impact of amino acids (charged, polar uncharged and non-polar) in SL-protein
binding was also discussed. Our model SL (SL5) showed high specificity to PSM and the
major contributor to this affinity was the negative charge of this mucin protein itself.
PSM is composed of 60-90% glycans, most of those glycans are sialic acid residues
(negatively charged glycan) and it might be these that are probably being bound to the
positively charged arginine (R) residues. Other mucinous protein (BSM) also has sialic
acids, but in a lot less quantity than in PSM and hence came second at responding to SL5.
High pI proteins like OVA, have glycans, but uncharged polar ones, thus coming third to
binding with SL5, ultimately followed by BSA.
If the positive charge of SL5 mutants was kept constant (as +3) and the number of
phenyl rings were reduced from the peptide sequence (by removing 2-PBA), we observed
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a decrease binding with high pI proteins like OVA and BSA, thus confirming a possible
presence of CH-π type binding between phenyl rings of SL and polar carbons of
glycoproteins. These weak interactions are more prominent only in high pI proteins.
It is of interest to see if we could engineer SLs that bound more to low pI proteins,
therefore a few ‘simplified’ SLs were synthesized in order to pin-point some direct
correlations rather than keeping the discussion speculation-based. SLs like 4R and 5R
were mutants made entirely out of alanine and four and five arginine residues
respectively (sequence information in Table 2.5). These were made in order to test if
simplification of the SL design made any impact on binding to purified proteins.
In Figure 2.5B, when low positively charged mutants (SL5-R1,5,11A; MRBB; SL5R1A; SL5-R5A and SL5) were used the PCA was shown to be quite scattered. The low
positive charge model did not perform so well at classifying high pI proteins (red, green
and light blue circles in Figure 2.5B show greater overlap). The most probable reason for
this is the absence of adequate amounts of R in the SLs. The other reason may be that
four out of five SLs in this model, have phenyl rings in them (coming from 2-PBA), thus
increasing the CH-π background interactions with OVA and BSA, making the grouping
poor. Another reason can be that low positively charged SLs can be understood as weak
acids and high pI proteins can be considered as weak biological bases. Being weaker
acids, low positively charged mutants are not doing a good job at classifying weaker
bases. Low positively charged mutants, thus being weaker acids can only bind to strong
bases like low pI proteins and group them better.
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Whereas, in Figure 2.5C, when high positively charged mutants (SL5, 4R, 5R and SL5RRAc) were used a tighter grouping was observed. The tighter statistical grouping is
attributed to
a) greater number of R residues;
b) two out of four SLs being used in this model were devoid of any phenyl rings,
causing reduction in background binding; and
c) high positively charged SLs behave as strong biological acids and hence are able to
classify strong (PSM) as well as weak bases (BSM, OVA and BSA).
This led to formation of a hypothesis for DESIGNING SLs in future, which is as
follows:
To increase the binding affinity with low pI glycoproteins, use a greater number of
arginine residues (3-5) and reduced the number of phenyl rings (0-2) in SL sequences.
Conversely, to increase the binding affinity with high pI glycoproteins, use fewer
arginine residues (0-2) and increase the number of phenyl rings (3-6).
Using this hypothesis, several SLs were made (DESIGNED SLS) and tested
against human proteins extracted from colon, prostate and breast cell lines. These new
SLs were evaluated for their ability to discriminate the proteins with varied metastatic
potential, to further our hypotheses into a working model with applications to investigate
cancers. The discussion shall be covered in the next chapter.
2.7 FUTURE DIRECTIONS
Currently, testing for a different PBA complimentary to 2-formyl phenyl boronic
acid is required to establish further structure-activity relationship. The Hall group, have
designed peptides with bis(benzoboroxoles) as their glycan binding site.10 We can also
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use these systems (Figure 2.6A) and incorporate them in our lectins because
benzoboroxozoles target hexopyranosides/ oligosaccharides (e.g. TF Antigen) on
naturally occurring glycans in the body which simple phenyl ring substituted boronic
acids do not. Phenyl boronic acids reported greater binding affinity with furanose sugars
and not so much with glycopyranosides in glycoproteins, which have puckered rings.10

A.

B.
Z
O
B
OH

B(OH)2
H
N
Peptide
Z

C.

Y

Z= EWG -NO2, -COOR, - NR3

B(OH)2
H
N
Peptide

Y= EDG -OR, -OH
Figure 2.6: Showing boronic acid mutants, which can be evaluated either by
complementing with or by replacing 2-PBA.
Benzoboroxole ring, B & C. representing electronic mutations on 2-PBA ring.
We can investigate the impact of binding by changing the substituents on the phenyl
boronic acid moiety. Since the boron has an empty p-orbital, having an electronwithdrawing group (Z) on the phenyl ring of the boronic acids may enhance the binding
of the SLs to glycans by increasing the Lewis acidity of the boronic acid. Hence an
investigation into the electronics of phenyl boronic acids could be investigated by adding
multiple electron rich (EWG) or electron poor (EDG) functional groups on to phenyl
boronic acid (Figure 2.6 B and C).
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Extensive investigation of Phenyl-Ring scanning mutagenesis can be undertaken
during which non-polar (A, V) and polar (R, Dab, T) amino acids on SL5 can be point
mutated with Phenylalanine (F). These mutants can also be directly investigated by their
binding with cancer-associated glycans, e.g. with fucose. These mutants can provide
insight into the possible increase in background binding with high pI proteins. The size of
the aromatic surface phenyl versus naphthyl or anthryl, can be investigated as well (e.g. F
versus W).
It is still unclear whether binding affinity of the platform (in both possible cases of Rglycan salt bridge or CH-π type interaction) is univalent or multivalent. Using NMR to
investigate specific SLs for their propensity to bind pyranosides like fucose shall provide
direct insight into plausible CH-π type interactions. The challenge again is to establish a
proof-of-concept stoichiometric platform.
2.8 EXPERIMENTAL PROCEDURES
Required Chemicals for synthesis of SLs
2-Formyl phenyl boronic acid (2-PBA) and its regioisomer (4-PBA) were
purchased from Combi-blocks. All amino acids (AA) and O-Benzotriazole-N,N,N’,N’tetramethyl-uronium-hexafluorophosphate (HBTU) were purchased from Novabiochem
Corp and VWR. Glycoproteins (porcine stomach mucin, bovine submaxillary mucin and
ovalalbumin), bovine serum albumin and Fluorescein isothiocyanate (FITC) were
purchased from Sigma-Aldrich. TentaGel resin (Cat. No. MB-300-002; loading capacity
0.25- 0.3mmol/g) was purchased from Rapp Polymere. All other chemicals (e.g. solvents
for coupling amino acids) were purchased from Sigma-Aldrich and Acros Organics.
These chemicals were used without any further purification.
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General Method for Synthesis of SL5 and its Mutants
1. Peptide synthesis on Polymeric Tentagel beads
To synthesize SLs, we used an automated protein synthesizer machine PS3, which
operated under nitrogen at RT to create vacuum for a moisture-free peptide chain growth
using Fmoc chemistry. All of the SLs started with the conserved sequence of first four
amino acids, BBRM, before introducing randomized amino acids into library. B stood for
β-alanine and was used instead of alanine because this region-isomer had a longer main
chain, which offered longer spacer link between bead and the AA that followed B.
Acetylated arginine was used to cap the –NH 2 ends of SLs. The ivDde protected diamino
acids were used for introducing boronic acids to the peptide backbone by reductive
amination. TentaGel resin beads (300μm) were used in synthesizing all peptide based
boronic acid containing synthetic lectins. Standard Fmoc/HBTU chemistry employed to
extend the peptide backbone. The amino acids used had Fmoc protected amines and the
reactive side chains of the amino acids remained protected by acid-labile protecting
groups. About 20mg (0.05mmol) of resin was weighed and soaked in DMF for 10
minutes. 8 equivalents of methionine (0.4mmol, 150.6 mg) and HBTU (0.4mmol,
151.72mg) were dissolved in 10mL of 5% N-methyl morpholine in DMF for 10 min and
added to the beads. After tumbling 45min, the beads were washed with DMF, methanol
and DMF. To remove the Fmoc group, 10mL 20% piperidine in DMF was used. Using
the same procedure, arginine, β-alanine followed by another β-alanine was coupled. The
amino acids utilized in the later steps were dependent on the lectin being resynthesized.
After addition of all the amino acids by the desired sequence, acetylated arginine was
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used to cap the peptide. The acylation of N-terminal was done using 10mL of CH 2 Cl 2
containing 5% pyridine and 5% acetic anhydride.
2. Removal of protecting group on side chain –NH 2 of Dab
Diaminobutanoic acid (Dab) has a 1-(4,4-Dimethyl-2,6-dioxocyclo-hexylidene)-3methylbutyl (ivDde) protecting group on it. In order to put on the boronic acids, these
must be removed. The protecting group is removed by adding 10mL of 5% (v/v)
hydrazine monohydrate in DMF and tumbling for 1 hour.
Incorporation of Phenyl Boronic Acid onto Dab side chain
2-Formylphenyl boronic acid (8eq, 0.8mmol, 119.95mg) was dissolved in a mixture
of 0.2mL methanol and 9.8mL DMF (10% MeOH in DMF solution). The resin beads,
along with activated 3Ǻ molecular sieves, were added into the solution and tumbled at
37ºC overnight. NaBH4 (8eq, 0.8mmol, 30.26mg) was added, H 2 gas evolved and was
allowed to escape for the next 45-minutes followed by tumbling the resin beads at 37ºC
for 4-hours. This was followed by washing the beads with copious amounts of DMF,
methanol, and DMF again.
To make boronic acid mutants (SL5-4PBA and SL5-Dab3,7A resp.), 8 equivalents of
4-formylphenylboronic acid and benzaldehyde were used in place of the usual 2formylphenylboronic acid.
3. Removal of Acid Labile groups on side chains of other amino acids
Molecular sieves were removed and the resin beads were transferred to another
reaction vessel. After the boronic acid moiety was coupled, 10mL of 95% TFA, 2.5%
water, and 2.5% triisopropylsilane (9.5ml, 250µL, 250µL resp.) was added and the resin
was tumbled for 1 h to deprotect the acid-labile protecting groups. The TFA wash was
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repeated one more time. The resin was then washed with DMF, methanol, and DMF
(these beads could be stored in freezer for longer period -30ºC). In order to store the SLs
in fridge under 4ºC temperature (to reduce washing steps before incubation), we tumbled
the beads with PBS without glycerol (pH 7.25) twice for 10 minutes.
Buffer Solution Preparation
1. Phosphate Buffered Saline (PBS) with and without glycerol:
Sodium phosphate monobasic (monohydrate) (27.6g, 200mmol), sodium phosphate
dibasic (anhydrous) (28.4g, 200mmol) and sodium chloride (35.06g, 600mmol) were
dissolved in 3.5L of distilled water. 400mL of glycerol was added and the pH was
adjusted to 7.3 using 3M NaOH. Glycerol was skipped to make regular PBS. All these
steps were done at the RT. The volume of NaOH was recorded and the remaining volume
of deionised water was added to make the total volume 4L. In general, PBS (without
glycerol) was used for all washings, before and after the protein incubation, but PBS with
10% glycerol was used to make screening/pre-blocking buffer using by adding 1% BSA.
This screening buffer was also used to dilute labelled purified protein solutions to 0.1mM
concentrations before incubation.
2. Carbonate buffer
To prepare carbonate buffer, 64g sodium carbonate (604mmol) and 117.2g sodium
bicarbonate (1390mmol) were dissolved in 3.9L of de-ionized water, and the pH was
adjusted to 9.8 by the addition of 3M NaOH. The volume of NaOH was recorded, and the
solution was then diluted to 4L.
MALDI Sample Preparation
Phenyl Boronic Acid (PBA) Group Removal from SL
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This step needs to be done if you have already attached boronic acids to all the resin
beads. If PBA group was not cleaved off the resin beads, the MALDI spectra is very dirty
with no peaks. PBA group removal step may be avoided, if a small amount of beads were
taken out before the boronic acids are added. Once removed, the rest of the MALDI steps
were followed on this small amount of bead sample. However, if the boronic acids were
still attached and a MALDI was needed to be run these groups will need to be removed.
Remove PBA groups by adding 100mmol solution of H 2 O 2 to the 1.5mL Eppendorf tube
containing the beads. Tumble this tube at 50ºC for an hour. After the hour, wash the
beads with dH 2 O three times. Added 50μL of a 40mg/mL solution of Cyanogen Bromide
(CNBr) made in 0.1M HCl. All work with CNBr should be performed under the hood.
Placed this solution in the dark (usually your drawer) for 15-18 hours. Evaporated this
solution using temperature controlled speed vacuum centrifuge. There should be a small
amount of white substance at the bottom of the centrifuge tube.
MS Sample preparation and spotting
Dissolved the sample obtained from the previous section in 10μL of .1% TFA in
H 2 O. In order to make the matrix, make a saturated solution of α-cyano-4hydroxycinnamic acid (CHCA) in 50:50 acetonitrile/0.1% TFA in H 2 O. Added 1μL of
sample to the desired spot on the plate for MALDI. Added 1μL of matrix to the same
spot. Pipette the 2μL of solution up and down a few times to mix matrix and sample
uniformly. Let the plate dry and take obtain MALDI spectra.
Fluorescent Labelling of Purified Proteins/Glycoproteins
To prepare the FITC labelled glycoproteins, 50mg of the desired glycoprotein (e.g.
OVA, BSM, or PSM) was dissolved in 9mL of 0.5 M carbonate buffer (pH= 9.8) and 2
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mg of FITC was dissolved in 1 mL of DMF. The ratio of protein to FITC was kept 50:2
and ratio of carbonate buffer to DMF was kept 10:1. The two solutions were combined
together in a 15mL Falcon tube and tumbled at 37ºC in dark for an hour.
There were two methods used to remove the excess unbound FITC, one being dialysis
and the other being concentrating using centrifuge tubes. Dialysis method was typically
used for very high batch concentrations of purified proteins, for example to make 500mg
labelled protein solutions and centrifuge concentration was typically used for very small
protein, cell membrane/tissue extracts, secreted protein concentrations.
Dialysis method- The solution was then transferred to a 12,000 MW cut-off dialysis tube
and dialyzed in 0.1M PBS (pH = 7.3). The dialysis buffer was changed every 4-hours
until dialysis was complete. That was ensured by checking the fluorescence of the buffer
solution, when the buffer ran clear of any visible fluorescence under UV lamp the
dialysis went to a completion.
Centrifuge method- For smaller protein concentrations, we would employ centrifugal
spin tubes with a MW cut-off at 10kDa (saved time with small concentration of proteins).
This protocol is courtesy of Erin E. Gatrone and Kathleen O. Connell. The membrane
proteins/glycoproteins and secreted proteins were labelled separately with fluorescein
isothicyanate (FITC) in DMF and carbonate buffer. Herein we took 2.8mg of FITC and
was dissolved in 100μL of DMF. 10μL of the FITC solution was put into 200μL of
protein. The total volume of the solution was brought up to 600μL by adding 400μL of
carbonate buffer. The protein solution was tumbled for 1-hour at 37ºC and later purified
using Amicon® 10K centrifuge spin tubes. The solution was later put into a tube and spun
for about 8 minutes at 4000RPM. These tubes were devoid of minimum cut-off protein
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level and risked into complete drying out of the protein, thus causing protein loss. Hence
one had to keep an eye on the time and the scale on the spin tubes. The time spun may
change depending on protein concentration, and they were to spin until it read “3” line on
the tube. At that point, 1.5mL of PBS was put in the exchange tube and spun for 5
minutes. Again it was checked to ensure the solution is at the “3” line. At which point,
the small tube was turned inside over and spun out into a micro centrifuge tube on a
benchtop centrifuge. Added 300μL of PBS and pipette up and down. Collected all the
protein. Repeat the rinse step if you were using secreted proteins since there is a large
concentration of protein. If not, and you are using membrane extracts there would be as
big of a concentration and thus maybe rinse with 2-100μL increments of PBS. The
concentration of the FITC-glycoprotein was determined using the BCA assay.
BCA Assay
Thermo Scientific BCA kit was purchased from VWR. Standard 2% BSA protein
solution in PBS was purchased from VWR.
Known Protein Standard Preparation
BCA kit also comes with a standard 2mg/mL BSA solution. Added 100μL of this
solution into a small plastic tube. Put 50μL of PBS in several other tubes. Then take 50
μL of the 2mg/mL solution in the first tube. Vortexted each solution every time. Usually
a 0 2mg/ml series were run (2, 1, 0.5, 0.25, 0.125, 0.625, 0.3125 and 0 mg/ml). Then took
50μL of that solution and put it in the next tube. Continue this process.
Reagent Preparation

61

Follow the directions that instruct to make the reagent solution. It would be made in a
50:1 reagent B: reagent A ratio. 200μL of reagent is required for each well so the amount
of total reagent will need to be calculated (200μL x # of wells).
96-Well Plate Preparation
Typically, triplicate sampling of the standards/samples are encouraged. Put 10μL of
protein in each well of standards and samples. Then added 200μL of 50:1 reagent mix in
all of the wells. The plate should then be placed in the oven at 37ºC for 45-minutes or
until color development ceases in the standards (around 1.5-hours). The plate was then
read on the plate reader with the well plate attachment under end-point absorbance at
562nm. BCA assay is not an endpoint assay and continues to develop over the time.
General Wash and Incubation Procedure for Purified Labeled Proteins
Beads were weighed (2mg) and rinsed with 1mL of PBS with 10% glycerol in it (this
step was avoided if the resin beads were already washed with PBS and kept in 4ºC
refrigerator. The resin was then pre-blocked with screening buffer i.e. PBS with 10%
glycerol and 1% bovine serum albumin (BSA) for 15 min. The beads were then incubated
with 1mL of 0.1mg/mL FITC labelled proteins (used screening buffer to dilute the
protein solutions) for a minimum of 12 hours and maximum of 20-hours at RT (25ºC),
and then washed with PBS three times. The beads were re-suspended in some PBS to
make it easier to pipette beads on to the microscope glass slides. Images of these beads
were then taken under microscope.
Microscope Usage and Data Acquisition
All images were taken with a Leica MZ 16F microscope and a GFP filter set
(excitation 450-490 nm; emission filter 500-550nm). The image data is in a 10-bit scale.
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For a direct comparison, its suggested that shutter exposure time, intensity of the bulb and
magnification of the lens were kept constant throughout. Images were taken with Q
Capture® to obtain red, green blue and bright values for each bead. Optimize the slide to
have the largest value under the green channel without saturating the pixels on the camera
screen (value should not exceed more than 190, 255 is the absolute max). A rough
estimate of this number could be checked by drawing a circle around a bead whose
intensity you are interested in under Adobe Photoshop® and pulling up the mean value of
the area under the green channel in histogram information. It was suggested that the resin
beads remain wet with PBS at all times, which helped in reduction of ‘bead reflectance’
on glass and kept the beads spread apart without sticking to one another.
The images obtained were in tiff format, which were converted to jpeg format before
for further data acquisition. To perform batch conversions on image files, we used
Irfanview®. These jpeg files were used to churn out mathematical values for each bead by
entering the image inputs into an algorithm written using MATLAB® 2013 program
(provided by the courtesy of Dr. Andrew Greytak) and edits by Anna A. Veldkamp. The
MATLAB® code, once run, then gave valid consistent numerical values for fluorescence
(under specified microscope intensity, exposure, magnification and background
correction), hence the human error was reduced that used to occur (in protocol followed
by predecessors Kevin L. Bicker and Jing Sun) because of manually drawing circles
around images of beads to obtain a value for fluorescence. This code picked out each
bead and provided information about its area, mathematical value under red, green, blue
and composite (bright) channel. It also told information about location of the bead, which
helped to identify each bead. It also gave a circularity value for each bead, closer it was
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to value of one, more spherical was the bead, which was helpful to rule out broken and
clumped beads as well as ‘floaters’. All the bead imperfections contributed to
mathematical outliers. These outliers were removed (1.5 IQD) in excel in order to get the
array information for the SLs with each protein type. At this point, the data was entered
into varying statistical models the most common seen here in the chapter was principal
component analysis (PCA). The average of these values was taken and compared. High
average values meant brighter beads, which meant stronger binding affinity to proteins.
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CHAPTER 3:
EMPLOYING DESIGNED SYNTHETIC LECTINS IN ARRAY TO
EVALUATE METASTATIC POTENTIAL OF HUMAN COLON,
AND PROSTATE CANCER IN-VITRO
3.0 OVERVIEW
In the previous chapter, the binding of Synthetic lectin 5 (SL5) with several
proteins like Porcine stomach mucin (PSM), Bovine submaxillary mucin (BSM),
Ovalalbumin (OVA) and Bovine serum albumin (BSA) was discussed. SL5 had higher
selectivity for low pI protein like PSM and this was mainly attributed to the +3 charge
from the three Arginine residues in the SL5 peptide sequence that were in likelihood,
mediating greater affinity for sialic acid residues present in PSM. The binding of SL5
correlated with the order of pI of the proteins. But, can this charge based discerning
capability of SLs also be used to quantify changes in glycoprotein charges, which
accompany oncogenesis and/or progression of cancer? To answer this query, an array of
several SLs that could discriminate between healthy and cancerous colon proteins was
designed previously (section 1.10). The SLs that were used in making the array
previously, had the same number of charges. To assess which chemical attributes of the
SL array (charges, phenyl rings, boronic acids & multi-valency) contribute to the
differential binding of healthy and cancerous proteins, an extended lectin array was
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made. Extended lectin array included the previous SLs as well as new designed SLs with
various permutations of charge and 2-PBA (section 2.6). listed in Table 3.1.
The aim of this chapter is to investigate:
1. Response of extended SL array to different analytes from human colon cell lines
I Cell membrane proteins (ref: Section 3.1)
II Cell-secreted proteins (ref: Section 3.2)
III Cell membrane and cell secreted proteins together (ref: Section 3.2)
2. Role of 2-formylphenylboronic acid residues on enhancing arrays’ ability to classify
cell lines with different metastatic potential (ref: Section 3.4)
3. Response of extended lectin array to human prostatic cell lines (ref: Section 3.5)
4. SLs that best classify different colon and prostate cell lines and discuss the statistical
basis of classification (ref: Sections 3.2, 3.3 and 3.5)
Table 3.1: Designed SLs after structure and activity relationship evaluation.
Showing SLs with no positive charge and containing 2-formyl phenyl boronic
acids (2-PBA); or high positive charges with few 2-PBA; or high positive charges
but no 2-PBA. LC MS in APPENDIX A
SL Name
SL5R,1,5,11A

Peptide structure
Ac-AA(Dab)*TAV(Dab)*VBBAM-resin

#R

# 2+
PBA

comments

0

2

5

2

4

0

no positive charge
0 (with phenyl boronic
acids)
positive charge
5 (with phenyl boronic
acids)
4

5

0

5

4R

AcRRRA(Dab)*TRV(Dab)*VBBRM-resin
Ac-RAARAARA-BBRM-resin

5R

Ac-RARARARA-BBRM-resin

SL1-Dab

Ac-RG(Dab)VTF(Dab)RBBRM-resin

3

0

positive charge
5 (no phenyl boronic
acids)

SL2-Dab

Ac-RT(Dab)RFL(Dab)VBBRM-resin

3

0

5

SL5RRAc
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Ac-RS(Dab)VTT(Dab)R3
0
5
BBRM-resin
Ac-RR(Dab)TQT(Dab)QSL4-Dab
3
0
5
BBRM-resin
Ac-RA(Dab)TRV(Dab)VSL5-Dab
3
0
5
BBRM-resin
#R: indicates number of Arginine residues in peptide of SL. (Dab)*: diamino
butanoic acid plus 2-PBA and (Dab): diamino butanoic acid only. B: β-Alanine.
Highlighted grey SLs were the part of initial extended lectin array.
SL3-Dab

3.1 INVESTIGATING COLON CANCER USING EXTENDED LECTIN ARRAY
AND PROTEINS EXTRACTED FROM COLON CANCER CELL MEMBRANES
The initial make-up of the extended lectin array included the original five SLs
(SL1-SL5) including the ones highlighted in grey (making 9-unit array) in the Table 3.1.
Over the course of experiments, we increased the scope of the SL array to investigate a
broader array of tissue types and subsequently included additional SLs (making a 22-unit
array, some of which were made to separately investigate prostate cancer and have been
summarized in Appendix B). The un-highlighted SLs in Table 3.1 did not contain any 2PBA and were included later for experiments in section 3.4 that required SLs with
negative 2-PBA controls.
Proteins from the membranes of human colon-derived cell lines were extracted,
tagged, quantified and then incubated with the SL array beads. These beads were then
imaged using fluorescent microscopy and the intensities of individual beads in the images
were compared and analyzed in the same way as previously described in chapter 2. The
colon cell lines used are shown in Table 3.2.
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Table 3.2: Human colon cell lines used with extended lectin array.
Human colon cell line

Type

Metastatic potential

CCD 841 CoN (CONA)**

healthy/normal1

NA

HCT-116

low metastatic2

<10%

HT-29

low metastatic1

<10%

LoVo

high metastatic3

>50%

**CCD 841 CoN abbreviated as CONA
Previously, the metastatic potential of human colon cell lines was investigated using
SL1-SL5 array; and that provided a guided plot where the SLs were able to discriminate
colon cell lines into 3 categories (healthy, low metastatic and high metastatic) with 89%
classification accuracy. When the extended lectin array was used for the same cell lines,
the 3-class guided grouping (after repeated experimentation with different biological
replicates) increased to 97% (Figure 3.1A/B); where the ‘designed SLs’ proved the most
useful increased the classification accuracy (Table 3.3).
Table 3.3: SLs most significant at classifying proteins from colon cell
membrane according to their metastatic potential.
Arranged in decreasing order of grouping ability. Grouping ability explained by Fscore (greater the F-score of SL, more significant the contribution of SL to a
model)
SL Name

# of positive charges

# of (2-PBA)

# Ph rings

F-score

4R

4

0

0

83.42

SL4

3

2

2

79.56

SL5-Dab

5

0

0

51.03

SL5-RRAc
5
2
2
7.01
The SLs that were used in the extended lectin array to distinguish proteins extracted from
human colon cell membranes; were SL1-SL5 plus the designed SLs highlighted grey in
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Table 3.1. Table 3.3 shows four top ranking SLs arranged in terms of their decreasing
order of grouping ability. The grouping ability of an SL is explained by its F-score, where
greater the F-score of SL, more significant is its contribution to a model.
The output of extended lectin array with colon proteins is represented in Figure 3.2.
It showed several SLs specific for a cell line and several cross-reactive. In order to assess
the applicability of array, this output was statistically grouped using linear discriminant
analysis (LDA) and shown in Figure 3.1.1. LDA is a guided statistical plotting, where
the data-points are input in a way that they are assigned to some group (e.g. healthy, low
metastatic etc.) even before the analysis. The program then tries to cluster the similar

4

B

sc

a t

Discriminant 2

2
0

-2
-4

Discriminant 1

-6
-6

cancerous/me
cancerous/no
healthy

-4

-2

0

2

4

CONA ● HCT116 ● HT29 ● LOVO

Figure 3.1: Guided statistical plot (LDA) generated using extended lectin array
with proteins extracted from cell membranes of four different colon cell lines.
Each data point refers to cumulative output from 10 SLs in extended lectin array. The
circles around the data points are 95% confidence intervals. Where number of points
N= 119. A: 4-class grouping within different cell lines (HCT-116 and HT-29 low
metastatic cell lines overlap each other); healthy (CON A): bottom yellow (○); high
metastatic (LOVO): top red (○). B: 3-class grouping with respect to metastatic
potential of cell lines; healthy (CON A): green (+); low metastatic (HCT-116 & HT29): blue (X); high metastatic (LOVO): red circles (○)
data-points closer and separate data-points away from the other cluster.
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In Figure 3.1A, the array could distinguish between the proteins from 4 different cell
lines with 97% accuracy. It was notable that HCT-116 and HT-29 cell lines overlapped
each other probably due to their similar metastatic potential. Figure 3.1B showed the
same data classified according to type of cell line (healthy, non-metastatic or metastatic).

Fold selectivity over MRBB of fluorescence

CON A

HCT 116

HT29

LOVO

2

1.5

1

0.5

0

MRBB

SL1

SL2

SL3

SL4

SL5

SL5-Dab SL5-RRAc

4R

5R

Figure 3.2: Bar-graph showing output of extended lectin array with extracted
proteins extracted from colon cell membranes of four different cell lines.
From left to right, Healthy: CCD 841 CON (CONA), non-metastatic: HCT-116 and
HT-29, metastatic: LOVO. All data normalized with respect to resin-MRBB beads
(internal control). SL4, SL5-RRAc, 4R and SL5-Dab seem to capture the greatest
variation in output. This variance helped at discerning proteins from colon cells as
shown in Figure 3.1.
It was also notable that the same statistical parameters were responsible to show the most
discrimination in both figures and that discriminant 2 was in correlation with metastatic
potential of the four cell lines. Interestingly, as pointed out in Table 3.3, the SLs that
statistically contributed the most towards the guided grouping; were highly positive
charged SLs (+3 to +5 charge), with fewer phenyl rings (0 or 2, from 2-PBA).
As observed in Figure 3.2, SL4 (having +3 charge) selectively bound LOVO (twofold than the MRBB baseline signal), 4R (having +4 charge) bound well to cancerous cell
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lines LOVO and HT-29, SL5-RRAc bound to HT-29 and SL5-Dab bound more to CONA
and HCT-116. Together, these four SLs captured the greatest variation in binding,
whereas the rest of the SLs (like SL1, SL2, SL3, 5R) there output resembled more closely
to MRBB (baseline signal of internal array control).
Similar to the hypothesis made at the end of chapter 2; proteins in metastatic colon
cells lines bound well to Arginine-rich SLs like SL4, 4R and SL5-RRAc. This could be
due to proteins of colon cancer cells being greater negatively charged than in healthy
colon cells. The newly added SLs contributed the most to the array’s enhanced
classification. Whether the LDA was 3-class (based upon cell line virulence) or 4-class
(based on different cell line), the pattern looked similar (Figure 3.1). This highlighted
that any which way the data was viewed; the statistical model was employing the same
factors for separation.
3.2 INVESTIGATING COLON CANCER USING EXTENDED LECTIN ARRAY
AND SECRETED PROTEINS FROM COLON CELLS
Aberrant glycosylation during oncogenesis and progression of cancer occurs equally
in cell membrane and cell secreted proteins.10 During an attempt to investigate aberrant
glycosylation with SL arrays, it is also useful to design a minimally invasive diagnostic
tool. Instead of unnecessary tissue biopsies for extraction of cell membrane proteins,
testing secreted proteins directly from blood serum deems more patient friendly.
Therefore, we were interested to investigate the performance of extended lectin array on
human colon cell secreted proteins. The same four cell lines were used and after
subjecting them to 48-hour starvation, the media from the cells was collected and
concentrated in spin tubes. The proteins were precipitated using acetone, fluorescently
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labeled, quantified and incubated with the extended lectin array containing 20 SLs (old
and new ones). This number was increased to include previously found and untested SLs
(i.e. SL6, SL7, SL8, SL9, SL11 & SL11 mutants) plus SL5-R1,5,11A (as arginine control
for SLs). All the SLs and their related information is as illustrated in Table 3.4.
Table 3.4: All 20 SLs in extended lectin array.
(Dab)*: diamino butanoic acid plus boronic acid; Ac: Acetylated N-terminus of
peptide; Abu: aminobutyric acid.
SL Name

Amino acid sequence and modifications

#R #2-PBA #Ph

SL1
Ac-RG(Dab)*VTF(Dab)*RBBRM
3
2
3
SL2
Ac-RT(Dab)*RFL(Dab)*VBBRM
3
2
3
SL3
Ac-RS(Dab)*VTT(Dab)*RBBRM
3
2
2
SL4
Ac-RR(Dab)*TQT(Dab)*QBBRM
3
2
2
SL5
Ac-RA(Dab)*TRV(Dab)*VBBRM
3
2
2
SL6
Ac-RT(Dab)*NRN(Dab)*FBBRM
3
2
3
SL7
Ac-RS(Dab)*YFT(Dab)*QBBRM
2
2
4
SL8
Ac-RT(Dab)*YGN(Dab)*NBBRM
2
2
3
SL9
Ac-RT(Dab)*YQV(Dab)*ABBRM
2
2
3
SL11
R*L(Dab)*YLT(Dab)*RBBRM
3
3
4
SL11-R8A
R*L(Dab)*YLT(Dab)*ABBRM
2
3
4
SL11-T6A
R*L(Dab)*YLA(Dab)*RBBRM
3
3
4
SL11-Y4A
R*L(Dab)*ALT(Dab)*RBBRM
3
3
3
SL11-Y4F
R*L(Dab)*YLT(Dab)*RBBRM
3
3
4
SL11-T6Abu
R*L(Dab)*YL(Abu)(Dab)*RBBRM
3
3
4
SL5-R1,5,11A
Ac-AA(Dab)*TAV(Dab)*VBBAM
0
2
2
SL5-Dab
Ac-RA(Dab)TRV(Dab)VBBRM
3
0
0
SL5-RRAc
Ac-RRRA(Dab)*TRV(Dab)*VBBRM
5
2
2
4R
Ac-RAARAARA-BBRM
4
0
0
5R
Ac-RARARARA-BBRM
5
0
0
The unguided (PCA) analysis showed the pattern similarities between secreted and
cell membrane protein extracts (Figure 3.3).
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CCD841CON-normal-membrane
HCT116-low metastatic-membrane
HT29-low metastatic-membrane
LOVO-high metastatic-membrane
CCD841CON-normal-secreted
HCT116-low metastatic-secreted
HT29-low metastatic-secreted
LOVO-high metastatic-secreted

Factor 1

Figure 3.3: Unguided (PCA) plot showing output generated by extended lectin
array with four colon cell line proteins (both cell membrane and cell-secreted)
having different metastatic potentials.
Each data point refers to a cumulative output from the initial nine SLs in extended
lectin array (SL1-SL5 plus four SLs highlighted grey in Table 3.1). Where number
of points N= 115. The circles around data points represent 95% confidence intervals.
Open and closed symbols represent membrane and secreted proteins respectively.
Normal (CONA): green circles (●); low metastatic (HCT-116 and HT-29): dark blue
squares (■); high metastatic (LOVO): red triangles (▲). Some overlap observed
between HCT-116 and LOVO (both cancerous).
Figure 3.3 suggested that SL array might be targeting binding to the motifs that are
present in cell membrane and secreted proteins both. Though the PCA of HCT-116 and
LOVO in secreted and membrane proteins does not group very tightly, this might be
because the cell lines that were used to extract membrane and secreted proteins belonged
to different biological replicates. In the unguided PCA plot in Figure 3.3, the statistical
parameters that were responsible to show second-most discrimination (y-axes) were in
correlation with the metastatic potential of the four cell lines.
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Table 3.5: SLs most significant at classifying proteins secreted from colon cell
lines with metastatic potential.
Name

# of positive charges from R

# Ph rings
from 2-PBA

# Ph rings
from peptide

F-score
3-class

4R

4

0

0

6.32

5R

5

0

0

12.93

SL4

3

2

0

9.35

SL5

3

2

0

6.58

SL7

2

2

2

7.60

Again, as shown in Table 3.5, the SLs that statistically contributed the most towards
the unguided grouping of secreted colon proteins were highly positively charged SLs (in
grey), with fewer phenyl rings (0 to 2).
This trend again verified the hypotheses made at the end of chapter 2; that malignant
colon tissue tends to over-sialylate terminal glycans, thus making proteins in metastatic
colon cells overall more negatively charged than in healthy colon cells. It could be the
chemical rationale linking ability of SLs with greater positive charges (due to greater
number of R) at discerning colon proteins from cell lines having different metastatic
potentials, with most efficacy. Interestingly, SL7 showed significant binding despite only
having +2 charge. One reason for this is the greater number of phenyl rings (four in
number, bold font in Table 3.5) involved in structure of SL7. The statistical grouping
model tries to pick out the SLs that provided the greatest variability between the different
cell lines. It hypothesized that SL7 assisted the grouping by showing binding with the
proteins through employing its extensive phenyl rings showing CH-π type interactions.
While looking at the F-score in Table 3.5, it is observed that the SLs that contributed
the highest to 3-class discrimination (according to metastatic potential), seem to follow
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two distinct trends. SLs with higher number of arginines (R) and smaller number of
phenyl rings and SLs with smaller number of arginine (R) and higher number of phenyl
rings both seem important in classification.

Factor loadings

1.0

Colon secreted
Unguided PCA grouping

14% total variance
FACTOR(2)

A

SL7
SL11R8A

0.5
SL5
SL6
SL5DAB
SL8
SL3
SL5RRAC
R5
SL11
SL11T6ABU
SL5R1511A

0.0

SL11Y4F
SL1
SL9
SL11T6A
SL11Y4A R4
SL4

-0.5

SL2

-1.0
-1.0

-0.5

0.0
0.5
FACTOR(1)

1.0

Figure 3.4: Showing unguided/PCA plot using 20-unit SL array on secreted
proteins from colon cells.
Where number of points N= 81. Normal (CONA): green diamonds (♦); non-metastatic
(HCT-116 and HT-29): dark blue (solid circles ● & open squares □); metastatic
(LOVO): red triangles (▲). A. Shows component loading values of PCA output
generated by SL array, where X-axis or Factor 1 contains the greatest model variance
followed by Y-axis or Factor 2. Factor 2 correlates with metastatic potential.
Component loading values are SLs treated as individual Eigen vectors, where their
value as well as directionality contributes to their significance on the PCA model.
Before agreeing upon which SL is the most important for defining the model’s
classification, it is important to figure out a constant mathematical parameter for such
comparisons. F-scores are from guided methods like LDA, where the program tries to fit
the data to reduce the difference “within” and maximize the distance “in-between” the
groups. In doing so, one risks data skewing therefore instead of looking at F-scores from
LDA, we look at the component loading values from an unguided model like PCA.
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Higher F-scores entailing a particular SL in the array contribute highly to LDA, but
they have no significance as the grouping varies both with the number and the type of SL
included in the model. For example, in Table 3.5, the number of SLs used were 20 and it
is noticeable that the values of F-score are quite small with respect to Table 3.3, where
array has 10 SLs. This is because F-score is not a percentage and is dependent on the
number of SLs in array therefore varying every time the array size and/or constituency is
changed. This serves as a reason to look at component loading values after using an
unguided method like PCA.
Unlike F-scores, component loading values are derived from the variance of the
model, which remains constant and do not depend upon the number of SLs involved in
the statistical model. Figure 3.4 shows PCA output generated by SL array containing 20
SLs with colon cell secreted proteins, where the Factor 2 (Y-axis) represents the
metastatic potential. The component loading values (plotted in Figure 3.4A) of each SL
are actually Eigenvectors projected on a plane therefore having X and Y coordinates.
This means that not only does the magnitude of the Eigenvalue matters but the direction
of the vector matters too. The direction of the SLs in Figure 3.4A is reflected by the PCA
output (given on the left in Figure 3.4). The more diverse the relative directionality
between the component loading values of the two SLs, the greater is the significance of
the two SLs on the variance of model. Figure 3.4A shows the two greatest factors across
X-axis (Factor 1) and Y-axis (Factor 2) that try to capture the total variance of PCA
model. The variance of the model is contributed the most by the SLs that spread apart the
furthest.

77

As seen in Figure 3.4A, Factor 2 seems to correlate with metastatic potential of colon
cell lines. In Figure 3.5, Figure 3.5B. shows the breakdown of Factor 1 across X-axis
with different SLs. Interestingly SL5-R1,5,11A, an SL with no R residues, shows the
smallest value on Factor 1, closely followed by SL11-R8A and SL7 (both having the next
lowest, only two R residues). Whereas, 4R and 5R SLs (having four and five R residues
respectively) have the greatest projection on Factor 1. This states that the most important
cause of model variance to discern colon cell lines is the number of R residues in the SL
array. The positive charge on the guanidinium groups are involved in salt bridging with
negatively charged proteins/ glycoproteins.
Similarly, Figure 3.5C. depicts the breakdown of Factor 2 across Y-axis with
different SLs. Factor 2 shows two prominent areas, Area 1 (in bold) and Area 2 (in dotted
line) where the most contributing SLs exist. Area 1 correlates with SLs having low
number of arginine residues and high number of phenyl rings (SL11-R8A and SL7) and
Area 2 correlates with high number of arginine residues and low number of phenyl rings
(SL2, SL4, 4R). So both areas are important for discrimination and it is really interesting
that basically having less of an interaction matters to the discrimination too. SLs like 5R
and SL5-R1,5,11A got placed with the rest of the SLs, which corresponds without
hypothesis because SL5-R1,5,11A has no arginine residue for protein binding and 5R has
too many R’s which make it an indiscriminating binder lacking selectivity.
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Figure 3.5: Showing component loading values of PCA output generated by SL
array containing 20 SLs with colon cell secreted proteins.
A. Shows the X-axis or Factor 1 to contain the greatest model variance followed by
Y-axis or Factor 2. B. Showing breakdown of Factor 1 or X-axis with different SLs,
where the Factor 1 directly correlates to #R residues in SLs C. Showing breakdown
of factor 2 or Y-axis with different SLs, where Factor 2 contains Area 1 (correlates
with low #R and high #Ph rings) and Area 2 (correlates with high #R and low #Ph
rings).
As observed from Table 3.5 the higher F-score of SL7 led to a question whether the
positive charges of SLs were the only chemical guidance to array’s classification ability
or was there a significant role played by phenyl rings in the SLs as well?
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Figure 3.6: Showing A: unguided/PCA plot of 20-unit SL array with secreted
proteins from colon cells being impacted by B: Removal of Area ② SLs from
PCA model; C: Removal of Area ① SLs from PCA model.
The circles around data points represent 95% confidence intervals. Where number of
points N= 81. Normal (CONA): green diamonds (♦); non-metastatic (HCT-116 and
HT-29): dark blue (solid circles ● & open squares □); metastatic (LOVO): red
triangles (▲). PCA model D: containing all SLs with more # of phenyl rings and
lesser positive charge(0 to +2), causing loss of precision of grouping. Model E:
containing all SLs with greater positive charges (+4-+5) and less # of phenyl rings,
causing a decrease in accuracy of grouping especially between cancerous cell lines.
For investigation, the secreted colon data was re-modeled in several different ways. In
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Figure 3.6A, the original PCA output with colon secreted proteins and 20 SLs were
broken down into two different grouping experiments (shown in B and C).
In Figure 3.6B the PCA model excluded all SLs in Area ②, leading to loss of
precision (see widening of 95% confidence interval circle of LOVO) and causing slight
loss of discrimination between healthy and cancerous cell lines (see green and blue
circles coming closer).
Later, a PCA model was studied by including SLs with greater number of phenyl
rings (4) and lower positive charge (0 to +3) and excluding all other SLs. The result of
this extrapolation is seen in Figure 3.6D. Excluding SLs with high positive charges (+4
and higher), caused the model to lose overall precision between each cell line, making
grouping more randomized suggesting the charged SLs overall, played a significant role
interacting with proteins from different colon cells. One possible reason is highly positive
charged SLs are strong acids and can bind to proteins (bases) of any strength, thus
increasing the overall binding capability of the array but at the same time, the model
tends to lose its selectivity. Another potential reason can be correlated to proteins in
colon cells undergo changes in rate of sialylation during and after the onset of cancer.
In Figure 3.6C the PCA model excluded all SLs in Area ①, leading to loss of
accuracy (see 95% confidence interval circles of HCT-116 and LOVO merging) but the
model still maintained tight confidence ranges overall. From bar graph data, (Figure 3.7)
it was seen that SL7 and SL11-R8A, bound better to LOVO over HCT-116 cells, hence
their loss in model C led to the loss in accuracy between these two cell lines. Tight
confidence intervals, as explained earlier are due to the presence of highly positively
charged SLs.
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Figure 3.6E, likewise is the extrapolated version of C, where the unguided statistical
model was made by including SLs with greater positive charge (+3 to +5) and lower
number of phenyl rings (0-2). Consequently, SLs that contained greater number of phenyl
rings (3 or 4) and lesser positive charges (0 to +2), were excluded. As observed, modeling
with highly charged SLs led to tighter clustering between different cell lines, making the
grouping more precise than the original array output (compare with Figure 3.6A). An
overlap between non-metastatic (HCT-116) and metastatic (LOVO) was observed (in
Figure 3.6E), indicating that loss of SLs with greater number of phenyl rings and less
positive charges (SL7) caused a loss in accuracy of the model, making phenyl rings in the
SLs useful for “staging” colon cancer. SL7 and SL11-R8A were included in B and D
models and they helped in discriminating between HCT-116 and LOVO.

Fol d selectivity over fluoresecnce of SL5R1511A (Argi ni ne negative control)

0.8

HCT-116

LoVo

0.4

0.0

SL7

SL11-R8A

Figure 3.7: Showing normalized fluorescence intensity signal of SL7 and SL11R8A over SL5-R1,5,11A (negative Arginine control SL).
Both SLs bound better to secreted proteins extracts of LOVO than that of HCT-116
cells.
From this section, it was surmised that SLs with higher number of arginines and
smaller number of phenyl rings contribute to classification of colon cell lines by
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enhancing the ‘tightness’ of PCA clustering and on the other hand, SLs with smaller
number of arginines and higher number of phenyl rings seem important in ‘staging’ of
colon cancer. PCA method of analysis seems impartial at discerning various cell lines
rather than LDA. Regardless of LDA or PCA, both methods seem to use metastatic
potential of cell lines as one of the statistical parameters to define colon cancer.
3.3 IMPACT OF MANY LECTINS IN SL ARRAY ON TOTAL VARIANCE OF PCA
MODEL
As shown in Table 3.4, to investigate the metastatic potential of secreted colon
proteins, an array of 20 SLs was used. The resulting PCA output is shown in Figure 3.4
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Figure 3.8: Showing unguided/PCA plot of SL array with secreted proteins from
colon using array having A: 20 SLs. B: five “key discriminatory” SLs.
This approach factors out model redundancy, thus reducing any noise fitting.
and 3.6A. After investigation of the impact of each SL on the PCA grouping, it was
found that only five SLs contributed significantly to discern colon cancer proteins—SL2,
SL4, 4R, SL7 and SL11-R8A. A PCA containing only these five SLs was modeled.
(Figure 3.8) Figure 3.8B shows PCA model with these five SLs, wherein the X83

axis/Factor 1 is the factor that captures the greatest percentage out of the total variance of
the scatterplot. Interestingly, using only the few key SLs caused the metastatic potential
axis to align with Factor 1. This may suggest, using 20 different SLs may be introducing
redundancy to the model, therefore fitting in the noise and skewing the actual data (law
of diminishing returns). For example, in Table 3.4, the F-score of 5R was one of the
highest out of the 20 SLs, but the high F-score value had no significance to the correlate
PCA grouping to metastatic potential. As observed in Figure 3.5A, wherein Factor 2 is
shown correlating with metastatic potential, in Figure 3.5C, the Eigen vector 5R is
neither the part of Area ① nor ②. This is due to 5R binding indiscriminately to all
proteins and enhancing noise. Therefore, getting rid of such SLs from the PCA model is
useful to classification.
3.4 INVESTIGATING ROLE OF 2-PHENYL BORONIC ACIDS IN CLASSIFYING
COLON CELLS ACCORDING TO THEIR METASTATIC POTENTIAL
Previously, while classifying proteins from colon cell membrane, SL5-Dab played
a significant role even while it contains no phenyl boronic acids (2-PBA). Besides this,
during the classification of colon cell secreted proteins, there were no direct correlations
that could be drawn between changes in ability of SL array at classification of cells and
loss of boronic acid from the SL.
These observations led to the current investigation as to whether the boronic acid
moiety in 2-formyl phenyl boronic acid plays any direct role at classifying colon cells
according to their metastatic potential? In order to test this, a specialized SL array was
made that included the initial five SLs (SL1 to SL5) and the same five SLs without
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adding 2-PBA onto them (namely SL1-Dab to SL5-Dab). The sequence information has
been previously shown in Table 3.1 and Table 3.4
Colon cell membrane proteins were extracted, fluorescently tagged and incubated
with this SL array. In (Figure 3.9) Figure 3.9A, shows the unguided LDA plot of
normal, low and high metastatic colon cell lines output with SLs not containing 2-PBA,
representing clear discrimination between normal and cancerous cell lines. The 3-class
guided grouping of this model discriminated the cell lines with 91% accuracy.
Whereas, in Figure 3.9B, the PCA of cell lines using SLs that contained 2-PBA was
not as discriminating as in Figure 3.9A showing greater misclassifications between
normal and cancerous cell lines. The SLs without 2-PBA were all highly positively
charged SLs (+5) and employing that charge, they were able to pull apart normal from
cancerous cells with greater efficacy. The 3-class guided grouping of colon cell line
output using SLs containing 2-PBA was 89% (very similar to 91% of the other model).
This was indicative that 2-PBA was not directly contributing significantly to the
classification of cell lines. This may suggest that glycoproteins or proteins in the cell
lines might not be interacting with SLs via boronic acid moieties in phenyl boronic acids.
Further, 2-class guided grouping between non-metastatic and metastatic cell lines were
calculated using the same data that were used in Figure 3.9A and B. Both classified with
98% accuracy, denoting that boronic acids might not be useful in ‘staging’ of colon
cancer. Using reporter dyes like Alizarin red (ARS), which form cyclic esters with
boronic acid, a change in the color or fluorescence of the dyes is observed. For example,
Alizarin red, containing catechol in its unbound form has no fluorescence, but formation
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of cyclic esters with boronic acid moieties of SLs, showed change in emission
wavelength to 580 nm (red region)

Figure 3.9: LDA plots showing direct impact of boronic acid moiety in SLs
included in array at classifying different protein samples from colon cells.
Unguided/PCA plot with SLs A: without 2-PBA; B: with 2-PBA. Normal (CCD 841
CON): green closed circles (●); (non)/low metastatic (HCT-116 & HT-29): blue
closed squares (■); high metastatic (LOVO): red closed diamonds (♦). Circles indicate
95% confidence intervals. SLs without 2-PBA, representing clearer discrimination
between normal and cancerous cells. Where number of points N= 66.
That is because protons on catechol moiety in ARS are lost while forming the boronate
ester and these protons are the ones that normally quench ARS fluorescence.4, 5
To investigate whether glycoproteins were binding to boronic acid moieties in 2-PBA
via involvement of cyclic ester formation between boronic acid and cis-diols of glycans
in glycoproteins, Alizarin red dye was used as a signaling/reporter molecule (Figure
3.10). The premise was if glycans formed cyclic ester to boronic acid of SL, then it would
be accompanied by loss in fluorescence intensity signal of Alizarin red (since boronic
acid sites would be involved in binding to glycoproteins). SL5 (containing two 2-PBA
units) and SL5-Dab (devoid of 2-PBA), were labeled with 100µM Alizarin red solution
(ARS) in 0.1M PBS and imaged (images shown in Figure 3.10A and C).
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SL5 and SL5-Dab samples are incubated with unlabeled cell membrane proteins for
12-hours and then stained with ARS; which was followed by imaging (Figure 3.10B and
D). All the images were taken at the same exposure times and microscopic conditions.
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Figure 3.10: Alizarin red dye binding with SL5 and SL5-Dab.
A: showing free boronic acids of SL5 (unbound to glycoprotein) binding to ARS; B:
showing free boronic acids of SL5 (after incubating with glycoprotein) binding to
ARS; C: showing SL5-Dab (contains no 2-PBA) reporting baseline signal with ARS;
D: SL5-Dab (after incubating with glycoprotein) reporting baseline signal with ARS.
When signals of A and C were compared, SL5 bound more to ARS than SL5-Dab;
this was attributed to presence of two 2-PBA in SL5 which bound ARS dye by forming
cyclic esters with the dye. SL5-Dab on the other hand showed no fluorescence with ARS
because it contained no 2-PBA units.
After both the SLs were incubated with proteins/glycoproteins from cancerous cell
membrane extracts, and later stained with ARS to determine any free boronic acid sites;
SL5 registered an increase in fluorescence. This indicated that boronic acid sites on SL5
were free and that the glycans did not bind to them. It is possible that ARS dye being
negatively charged (basic), bound to the proteins and SL5 being +3 charged (possibly
through positively charged amino acid residues), ARS may be targeting the positive
charge, just as it targets Ca2+ deposits in synovial fluids.6 This may also explain why SL5Dab with protein reported slightly greater fluorescence intensity with ARS when
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compared to the SL5-Dab sample without proteins. These findings indicate that the
boronic acid functional group in 2-formyl phenyl boronic acid might not play a
significant role in binding to glycans of glycoproteins.
3.5 INVESTIGATING PROSTATE CANCER USING EXTENDED LECTIN ARRAY
AND SECRETED PROTEINS FROM PROSTATE CELLS
In a transformed cell, glycosylation changes most often arise from changes in the
expression levels of glycosyltransferases and lead to modifications in the core structure of
N-linked and O-linked glycans.17 One of the most common changes is an increase in
branching of N-linked glycans, creating additional sites for terminal sialic acid residues.
This, along with an upregulation of sialyltransferases and fucosyltransferases, ultimately
leads to an increase in global sialylation and fucosylation in a diseased cell. This results
in abundance of certain glycan structures: termed as cancer-associated glycans (CAGs).
The following Table 3.6 shows the overexpressed CAGs in malignant human tissues
from breast, colon and prostate (chapter 1 Ref).23 Breast tissue involves greater number
of CAGs reporting over-sialylation, followed by colon tissue and then prostate. Whereas,
all three tissue types report an increase in core-fucosylation.7-12
Exclusive presence of poly sialic acid in malignant breast tissue makes it most
negatively charged while malignant prostate is the least negatively charged tissue out of
the three, according to glycan composition. Hence, prostate cell line model is employed
to examine the impact of positively charged SLs and SLs with greater number of phenyl
rings in the array upon their ability to comprehend tumorigenicity.
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Table 3.6: Cancer associated glycans in malignant tissues.
*PSA stands for poly sialic acid.
Cancer
glycan CAG

Glycans present in CAG

Malignant tissue
Breast

Colon

Prostate

sLex

sialic acid, fucose, glcNAc, gal

√

√

sLea

sialic acid, fucose, glcNAc, gal

√

√

sTn

sialic acid, galNAc

√

√

√

TF

gal, galNAc

√

√

√

Ley

fucose, glcNAc, gal

√

√

√

Globo H

fucose, gal, galNAc, glc

√

√

√

*PSA

sialic acid

√

GM2

sialic acid, gal, galNAc, glc

√

√

√

Five prostate cell lines were used and after subjecting them to 48-hour starvation the
media from the cells was collected and concentrated. The proteins were precipitated
using acetone, fluorescently tagged, quantified and then incubated with the extended
lectin array containing the same array of 20-SLs used in the colon cell study. All the SLs
and their related information is shown in Table 3.4.
Table 3.7: Human prostate cell lines used with extended SL array.
Arranged according to increasing order of metastatic potential.
Cell line

Percent
Invasiveness

Type

89

Colony forming
efficiency %

RWPE-1

normal

-

-

WPE1-NA22

low metastatic

913

0.0613

WPE1-NB14

low metastatic

3013

1.8513

DU 145

high metastatic (grade II)

2311

3616

PC-3

high metastatic (grade IV)

7015

5216

Table 3.7 illustrates five prostate cell lines arranged in an increasing order of
metastatic potential. RWPE-1 cell line was taken as normal epithelial control. WPE1NA22 and WPE1-NB14 cells belong to a family of cell lines, referred to as the MNU cell
lines, which all derived from RWPE-1 cells after exposure to N-methyl-N-nitrosourea
(MNU). MNU is a direct-acting carcinogen, where WPE1-NA22 were cultured from
first-generation tumor after injecting the mice with cells treated with 50µg/ml MNU and
WPE1-NB14 cells were from second-generation tumor obtained after injecting the mice
with cells treated with 100µg/ml MNU. These three MNU cell lines are +AR and ARmediated +PSA expression, indicating prostate epithelial origin.13 AR stands for
androgen receptor. The larger family of cell lines, including RWPE-1 cells with a
common lineage, mimicking the multiple steps in progression from normal epithelium to
prostatic intra-epithelial neoplasia, and then to invasive cancer. The metastatic potential
of MNU cell lines is defined by their colony forming efficiency percent (CFE %) in soft
agar. WPE1-NA22 and WPE1-NB14 had low and moderate CFE, respectively whereas
RWPE-1 had none. DU 145 and PC-3 cell lines are from moderately and highly
aggressive adenocarcinomas, respectively. The SLs that statistically contributed the most
towards the unguided grouping of secreted prostate proteins are illustrated in Table 3.8.
These were highly positively charged SLs (highlighted in grey), with fewer phenyl rings
(0 or 2, from 2-PBA). This trend could be correlated since malignant prostate tissue tends
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to over-sialylate terminal glycans, thus making proteins in metastatic prostate cells
overall more negatively charged than in healthy prostate cells. Interestingly, SL11-Y4A
and SL7, showed significant binding even when it contained fewer positive charged
amino acid residues in them. This could be attributed to the greater number of phenyl
rings (3 and 4 respectively, bold in Table 3.8). The statistical grouping model tries to
pick out the SLs which provided the greatest variability between the different cell lines. It
could be hypothesized that SL11-Y4A and SL7 assisted the grouping by showing binding
with the proteins through employing phenyl rings showing CH-π type interactions.

Table 3.8: Showing most significant SLs at classifying proteins secreted from
prostate cells according to their metastatic potential.
(SLs highlighted in grey indicate highly positive-charged and in bold indicate SLs
with higher number of Phenyl rings).
Name
# of + charges from R # Ph rings from PBA # Ph ring from peptides
SL11-Y4A

3

3

0

SL7

2

2

2

SL4

3

2

0

SL5

3

2

0

4R

4

0

0
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A

B

C

Figure 3.11: Showing A: unguided/PCA plot of extended 20-SL array with
secreted proteins from prostate impacted by B: Positively charged SLs (charged
+4 to +5) & SLs with lower number of phenyl rings (0-2); C: SLs with greater
number of phenyl rings (4) and lower positive charge (0 to +2).
The circles around data points represent 95% confidence intervals. Where number of
points N= 160. Normal (RWPE-1): green diamonds (♦); non-metastatic (WPE1NA22 and WPE1-NB14): dark blue (solid circles ● & open squares □); metastatic
(DU 145 and PC-3): red (closed ▲ and open Δ triangles). B: Showing SLs with
greater positive charge and less phenyl rings, decreased the precision of grouping
wheras C: SLs with more phenyl rings and lesser positive charge, reduced the
accuracy of grouping.
To further investigate the role played by a greater number of phenyl rings in some SLs
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(e.g. SL11-Y4A and SL7) on the SL array’s classification ability; the prostate cell line
PCA data was re-modeled in several different ways (Figure 3.11).
In Figure 3.11B the unguided statistical model was made by including SLs with
greater positive charge (+4 to +5) and lower number of phenyl rings (0-2). Consequently,
SLs that contained greater number of phenyl rings (3 or 4) and lesser positive charges
were excluded, (e.g. SL11-Y4A and SL7). As observed, modeling with high positively
charged SLs led to a loss in the discrimination between proteins from prostatic normal
and cancerous cell lines, hence losing more precision than the original array output (see
A). An overlap between non-metastatic (WPE1-NA22) and normal (RWPE-1) was
observed indicating that loss of SLs with greater number of phenyl rings and less positive
charges (SL11-Y4A and SL7) caused a randomization of the model, making phenyl rings
in the SLs useful for grouping.
In Figure 3.11C, the unguided statistical model was made by including SLs with
greater number of phenyl rings (4) and lower positive charge (0 to +3) and removal of
SLs that were highly positively charged (+4 to +5) and low on phenyl rings (0 to 2).
SL11-Y4A and SL7 were included in this model (SL4, SL5 and 4R were excluded) and
they helped in maintaining discrimination between each cell line.
Thus SLs with greater number of phenyl rings did significantly contribute in prostate
cell line classification; although, losing SLs with high positive charges, did cause the data
to spread out more within each cell line, which meant that positively charged SLs overall,
also played a significant role interacting with proteins from different prostate cells. That
could be correlated to proteins in prostate cells undergoing changes in sialylation during
and after the onset of cancer. This sialylation expression in prostate cells was less than
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that observed in colon cells hence core-fucosylation became a relevant marker towards
discriminating prostate cell lines. It was then hypothesized that probably SLs with greater
phenyl rings might be targeting core-fucosylation changes via CH-π type interactions in
prostate cells. Meanwhile, looking at the 3-class LDA of serum proteins based on
prostate cell types used according to the metastatic potential, Figure 3.12A shows a LDA
of an overall 99% using 20 SLs. The same dataset when modeled using only SLs
containing higher number of phenyl rings in the array also gave an overall 3-class 99%
classification (see Figure 3.12B).
10

6.0

A: 3-class guided All 20 SLs

4

FACTOR(2)

FACTOR(2)

3.8

-2

-8
-8

meta prostat
non-meta pro
normal prost
-2
4
FACTOR(1)

1.6
-0.6
-2.8
-5.0
-5.0

10

with all 20 SLs
jackknife score 3-class high metastatic low-metastatic normal %correct
high metastatic
58
0
0
100
low-metastatic
0
67
1
99
normal prost
0
1
33
97
Total
58
68
34
99

B: 3-class guided SLs with 3&4
#Ph rings

-2.8

1.6
-0.6
FACTOR(1)

3.8

6.0

SLs containing 3 and 4 phenyl rings only
jackknife score 3-class
high metastatic low-metastatic normal %correct
high metastatic
58
0
0
100
low-metastatic
0
68
0
100
normal prost
0
1
33
97
Total
58
69
33
99

Figure 3.12: Showing guided/LDA 3-class plots based on cell type of secreted
proteins from prostate cell lines
A: using array with 20 SLs B: using array with SLs containing high number of
phenyl rings (3-4). Where Normal (RWPE-1): green (+); low metastatic (WPE1NA22 and WPE1-NB14): blue (X); high metastatic (DU 145 and PC-3): red circles
(●). Given below are the confusion matrices of each analyses. Each totaling up to
99% 3- class grouping of prostate cancer, where A. misclassifies one normal data set
as low/non-metastatic.
In fact, model B grouped low metastatic cell lines better than model A (where one of the
low metastatic data point misclassified under normal cell line group). This elucidates the
importance of phenyl ring containing SLs to discern prostate cell lines.
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3.6 CONCLUSIONS
Malignant colon tissue tends to over-sialylate terminal glycans, thus making
proteins in metastatic colon cells overall more negatively charged than in healthy colon
cells. It could be the reason due to which SLs with greater positive charges (from R) were
able to discern colon proteins from cell lines having different metastatic potentials with
greatest efficacy.
Extended array containing SLs with higher number of arginines and smaller number
of phenyl rings contribute to classification of colon cell lines by enhancing the ‘tightness’
of PCA clustering. Due to the great amount of positive charge, these SLs behave like
strong acids that indiscriminately bound to proteins with different pIs. On the other hand,
SLs with smaller number of arginines and higher number of phenyl rings seem important
in discriminating HCT-116 and LoVo cells. Top 6 SLs that best describes colon cancer
are SL2, SL4, 4R, SL11-Y4A, SL7 and SL11-R8A
PCA method of analysis seems impartial at discerning various cell lines rather than
LDA. Regardless of LDA or PCA, both methods seem to use metastatic potential of cell
lines as one of the statistical parameters to define colon cancer. 2-PBA was not seen to be
directly contributing significantly to the classification of colon cell lines. This may
suggest that glycoproteins or proteins in the cell lines might not be interacting with SLs
via boronic acid moieties in phenyl boronic acids.
In prostate cancer, SLs with greater phenyl rings might be targeting core-fucosylation
changes via CH-π type interactions. When prostatic cell lines were investigated by using
SLs containing higher number of phenyl rings only (99%), the array classified better than
the model containing SLs with highest F-scores (91%, all 3 SLs high in R, namely 4R,
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SL4 and SL5). Top 5 SLs that best describes prostate cancer are SL7, SL11-Y4A, SL4,
SL5 and 4R
Altered glycosylation is a hallmark of cancer that has helped to shape the
management and understanding of cancer.17 Currently, several glycan-based biomarkers
are in use worldwide18 and glycans have been established as key participants in
tumorigenesis and cancer progression.19 Knowledge of altered O-glycan structures in
cancer has led to the development of O-glycan-based biomarkers.20-23 Antibodies
targeting glycan or glycoprotein biomarkers include: CA15-3, CA125, CA19-9, and
CA72.3, against MUC1, MUC16, sLea and sTn respectively; which are up-regulated in
breast, ovarian and pancreatic cancers.24-26 However, glycans like sTn are expressed in
most carcinomas (e.g., stomach, colon, pancreas, biliary tract, ovaries, and cervix),
limiting its utility in identifying tissue of origin.27-29 Hence all these biomarkers are
agreeable prognostic methods as opposed to being used in diagnosis because they lack
tissue specificity. In general, the focus has moved from hunting for specific biomarkers
towards observation of a change in global sialylation or fucosylation.30 Alterations in
protein glycosylation associated with colon cancer have been reported; which among
several changes, included increased sialylation, and core-fucosylation.30 Similarly, there
is literature precedence supporting an observed increase in sTn and core-fucosylation in
malignant prostate tissues.31 Several groups have change in different sialyl Lewis
antigens in metastatic prostate tissues and found them to be very sporadically
expressed.32
Table 3.6, shows metastatic colon tissue being more negatively charged (due to
greater number of sialylated CAGs), followed by metastatic prostate tissue (expressing
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sialylation mainly through increased sTn expression). Meanwhile, the core-fucosylation
of N-glycans decreased in colon cancer and increased in prostate malignancy; however,
due to reduced sialylation in metastatic prostate cancer, the fucosylation becomes
important in monitoring prostate cancer.32-33 In addition to the colon and prostate cell
lines, data from a metastatic breast cell line (MDA-MB-231) was also included in this
analysis, primarily for the purpose of increasing the number of high metastatic reference
cell lines. (Courtesy: Daniel Gordon)
The extended SL array outputs (as discussed in the preceding sections) for colon and
prostate cell lines were analyzed together using PCA (unguided) to observe any trends
resulting from tissue typing. Figure 3.13 depicts the results from the 3-D unguided PCA
analysis of data from the extended SL array. Notice that normal colon and prostate cells
cluster close to each other, whereas highly metastatic prostate and highly metastatic colon
cell lines cluster on the two extreme ends. Interestingly, the highly malignant breast cell
line, MDA-MB-231, clustered close to the highly metastatic colon cell line, LOVO,
possibly due to high sialylation in these two metastatic cell lines.3, 34
As discussed in the preceding sections, the highly positively charged SLs, such as 4R,
SL4 and SL5, as well as SLs containing a greater number of phenyl rings, for example
SL11-Y4A and SL7, were the most significant contributors in classifying colon and
prostate tissues based on cell line tumorigenicity (see APPENDIX C). Positively charged
SLs contributed to the tight clustering of PCA plot, they may be targeting the difference
in sialylation between colon and prostate tissues. More on the quantification of sialic
acid residues as well as correlation of sialic acid amount and metastatic potential of
cancer is discussed in the next chapter.

97

Figure 3.13: Illustrating 3-D PCA plot of normal (green) and metastatic (red)
cell lines.
Closed circles (●) represent colon, closed squares (■) represent prostate and open
circles (○) represent breast cell-type. Malignant prostate proteins group separately
from colon and breast ones.

3.7 FUTURE DIRECTIONS
It may be of interest to investigate how the 20-unit extended lectin array behaves
against a modified cell line with minimal sialic acid expression. Another set of
experimentation is proposed with a smaller array including select SLs and some cell lines
like the Chinese Hamster Ovary (CHO) cell line. CHO cells, due to their reduced
expression of sialic acids (they have no glycoproteins with sialic acids linked via α-2,6
linkage and has only α-2,3 linked ones)35 can serve as baseline control for sialic acid
expression. In retrospect, CHO cells might not be an ideal candidate for negative sialic
acid expression control, since it still has sialic acid linked to glycoproteins via α-2,3
linkage. In order to make a better negative sialic acid control cell line, a plasmid that halt
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the complete sialic acid expression can be used to transfect the CHO cell line. Granted
that CHO cells are non-human in origin nevertheless are known to be easily transfected.
3.8 EXPERIMENTAL PROCEDURES
Details of the complete procedure for SL synthesis, incubation with fluorescently tagged
analytes, imaging, data acquisition, data analysis and statistical analysis and the
programs used are provided in the Experimental section in Chapter 2.

General Cell Culture Protocol
All cell lines were purchased from ATCC®. A total of four human colon cell lines
and five human prostate cell lines were grown following the ATCC® cell culture
protocols.36-45 The names of the colon cell lines followed by prostate cell lines are listed
below in accordance with their increasing metastatic potential. Shellab 3502 CO 2 waterjacketed incubator (by Marshall Scientific) was used to grow all cell lines in 37 °C and
under an atmosphere of 5% CO 2 .
Colon: CCD 841 CON (ATCC® CRL-1790™) {normal}, HCT-116 (ATCC®
CCL-247™) {lowly metastatic, grade II}, HT-29 (ATCC® HTB-38™) {lowly metastatic,
grade II} and LoVo (ATCC® CCL-229™) {highly metastatic, grade IV}. HCT-116 and
HT-29 were isolated from the colon whereas LoVo is metastatic colorectal cancer
isolated from a site located in left supraclavicular region.
Prostate: RWPE-1 (ATCC® CRL-11609™) {normal}, WPE1-NA22 (ATCC®
CRL-2849™)

{lowly

metastatic},

WPE1-NB14

(ATCC®

CRL-2850™)

{lowly

metastatic}. Both these cell lines are isogenic with RWPE-1 but MNU exposed to induce
tumorigenicity. DU 145 (ATCC® HTB-81™) {highly metastatic}, PC-3 (ATCC® CRL-
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1435™) {highly metastatic}. DU 145 and PC-3 were metastatic prostate cancer isolated
from sites in brain and bone, respectively.
Media Used in Cell Culture
All cell lines grown required 10% v/v Fetal Bovine Serum (FBS) and 1% v/v
antibiotic/anti-mycotic along with their specific medium (FBS and antibiotics added into
500ml cell growth media bottles). Antibiotic/ anti-mycotic used typically contains a
solution of 100IU/ml penicillin, 50-100µg/ml streptomycin and amphotericin B 2.5µg/ml.
A Complete cell growth media for the normal epithelial human colon cell line CCD 841
CoN contained Minimum Essential Media (MEM), (FBS) 10% v/v (50mL) from VWR
(45000-734) and 1% (5mL) antibiotics/anti-mycotic from VWR (45000-616). Colon
cancer cell lines HCT-116 and LoVo used a base media made up of RPMI-1640, from
HyClone (SH30605.01). To this base media the following were added: 10% v/v (FBS)
(50mL) purchased from VWR (45000-734) and 1%v/v (5mL) antibiotics/anti-mycotic
from VWR (45000-616). The colon cancer cell line HT-29 required Dulbecco’s Modified
Eagle Medium (DMEM) from VWR (45000-734), along with addition of 10% FBS v/v
(50mL) from VWR (45000-734) and 1% v/v (5mL) antibiotics/anti-mycotic from VWR
(45000-616).
For the growth of RWPE-1 and both MNU cell lines (WPE1-NA22 and WPE1NB14), the cell growth media used was by Thermo-Fischer. The Thermo-Fischerformulated growth kit Keratinocyte Serum Free Medium (K-SFM), (17005042) contained
two additives required to grow these cell lines, namely bovine pituitary extract (BPE) and
human recombinant epidermal growth factor (EGF). These components were added to the
base medium at the ratios of 0.05mg/ml BPE and 5 ng/ml EGF to make the complete
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growth media. It is recommended to not filter the complete culture media. The cell
growth media for the DU 145 cell line used was ATCC®-formulated Eagle's Minimum
Essential Medium, (30-2003™). To make the complete growth media, added 10% v/v
(50mL) of FBS from VWR (45000-734) and 1% (5mL) antibiotics/anti-mycotic from
VWR (45000-616). The cell growth medium for the PC-3 cell line used was ATCC®formulated F-12K Medium, (30-2006™). To make the complete growth media, added
10% v/v (50mL) of FBS from VWR (45000-734) and 1% (5mL) antibiotics/anti-mycotic
from VWR (45000-616).
Before addition of any FBS and antibiotic/anti-mycotic was done, approximately
50 ml of the cell growth media was pipetted out and stored under 4°C to be used later to
culture cells during their period of starvation. All media preparation used sterilized
pipettes to minimize contamination. The cell culture media was brought to the 37°C
before using. All growth conditions required 5% carbon dioxide (CO 2 ) at a temperature
of 37°C.
Thawing of Cell Stocks and General Cell Growth Protocol
This protocol was courtesy of Dr. Kathleen O’ Connell. Stored frozen cells were
thawed in a Corning® T-25 flask or a small petri-dish, the process is explained below. If
the cell viability and the growth rate of a cell stock is typically high, for example most of
the cancerous cell lines, the cells can be thawed directly into a Corning® T-75 flask.
1.

The cell culture media needs to be at 37°C before use. The cryopreservation

solution usually contains 5% v/v DMSO and is toxic to cells so thawing and suspension
of cells in fresh media, needs to be done quickly. To do so, 5mL of media at 37°C, was
used to transfer the contents from the cryogenic vial into the appropriately sized flask that
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already contained 5ml of media at 37°C. The cells were left to grow in the incubator at
37°C.
2.

After 24-hour duration, the flask containing the cells and media was inspected for

any broken, particulate-like cell debris and the media was pipetted out and replaced with
10 ml of fresh media at 37°C. It is quite likely to find cell debris at this stage because
many cells die due because they could not withstand the temperature and chemical shock
while they are frozen.
3.

The following day the old media was replaced with 10ml of fresh media added at

37°C. For the cells to maintain a healthy life cycle, continue the growth of cells in the
incubator by removing and replacing old media while keeping a check for excessive cell
debris and any possible infection until 75% confluence was reached. Typically, the cell
growth was monitored three times per week. The cells media (containing phenol
indicators) was replaced whenever the cell media in the flask would begin to turn a tinge
of orange instead of its original pink color. If the cell media turns yellow, that usually
happens when the cells have reached greater than 90% confluence levels and the cell
media is completely exhausted. At this point of time, the cells are most likely under stress
and are beyond the point of salvage. At any point of time if there was an excessive debris
formation, the media was quickly replaced.
4.

Before harvesting the cells for protein, split and passage cells 2-3 times to ensure

that cells have achieved a normal growth momentum and are no longer in quiescent
stage.
Trypsinization and Subsequent Passaging of Cells
Volumes provided are for Corning® T-75 size flasks.
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1.

After the cells reach 70% confluence levels, pipette off and discard the cell

culture medium. Briefly rinse the adherent cell layer with 2ml of 10% Trypsin-1% EDTA
solution in PBS and after rinsing, discarded the solution. To make 10% Trypsin-1%
EDTA solution, add 50ml of Trypsin 10X to a solution containing 125ml of autoclaved
1% (w/v) EDTA solution in PBS and top off with 325ml PBS to make a total volume of
500ml.
2.

Added 2-3ml of 10% Trypsin-1% EDTA solution to culture flask and left in 37°C

incubator for 5- 15 minutes. This step allows the trypsin, a proteolytic enzyme to act on
cellular surface proteins, which help the cell to adhere on to the flask. Trypsinization of
cell surface proteins cause the cells to dislodge. The time taken for trypsinization is
dependent on how firmly the cells attach to the flask. For example, CCD 841 CON cell
line takes the longest time out of all the other cell lines grown, due to their epithelial
morphology the cells firmly adhere on to the flask and take longer time to trypsinize.
Continue to observe the cells under the microscope to ensure that cells do not remain in
trypsin for too long, else causing an irreversible cellular damage. Cells are trypsinized
until layers/clumps of cells start to dislodge from the flask. Keeping the cells in the
incubator helps in trypsinization because the temperature facilitates the cell dispersal by
enhancing action of trypsin.
3.

Added some fresh warm media at 37°C to the flask containing trypsinized cells.

This addition helps to suspend the action of trypsin. Pipette the cells along with the media
and trypsin-EDTA mix into a 15 mL centrifuge tube and centrifuged for 5 minutes at 500
RPM. It is suggested not to increase the speed of centrifuge higher than 500, otherwise
cells will die.
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4.

After centrifugation, discarded the supernatant and re-suspended the cell pellet

using 1-2 ml of fresh cell culture media at 37°C.
5.

After re-suspension, pass the cells through p1000 pipette several times to break

the larger cell clumps. This ensures formation of smaller bunches of cells, so when these
cells are introduced to a new culture flask, the cells will spread out uniformly and grow in
several well spread out colonies thus causing a more regular reattachment of cells to the
flask.
6.

Added 6- 8mL of complete growth medium to the pipetted cells and aspirated the

cells by gentle pipetting. Added appropriate aliquots of the cell suspensions to new
culture vessels. The information on the ratios required for passaging of cells can be
obtained from ATCC® website. Extra cells were discarded. Added the media to the flask
to make it to the total volume for each flask type (5ml for T-25, 1 ml for T-75, and 20ml
for T-125). Checked the following day for cell attachment to the flasks. If there is too
much cell debris detected, then accordingly remove and replace fresh media 37°C.
Procedure of Cell Starvation
This step is required for cells whose media is to be collected to obtain cell-secreted
proteins. After passaging the cells until they achieve an optimal growing momentum, the
cells were starved after they reached a confluence level not less than 50% but not more
than 70%. Cell starvation involved feeding the cells an incomplete cell growth media
without FBS and supplements. The starvation period lasts for 48-hours (exact). Typically,
following the starvation protocol designed by Dr. Erin Gatrone, the cell media from one
T-75 flask is pipetted out into a 15ml falcon tube. This volume of media provides quite
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concentrated pellet of serum protein, which is more than enough for a triplicate
experiment.
Concentration of Cell Media after Starvation for Harvesting Cell-Secreted Proteins
After the cells (whose media is required for cell-secreted proteins) were starved for
48-hours, the pipetted cell media in 15 ml falcon tube was centrifuged (@1000 RPM) to
remove cell debris. The media was concentrated down using Amicon® 3-KDa centrifuge
tubes purchased from EMD Millipore. These centrifuge tubes have a cut-off volume that
does not allow the media to be concentrated below a certain threshold. This is done to
ensure that the 3-KDa membrane never dries out, else risking loss of protein.
Acetone Assisted Precipitation of Secreted Proteins from Concentrated Cell Media to
form a Protein Pellet
1.

After pipetting the cut-off volume from 3-KDa centrifuge tube, used

approximately 4X v/v of ice-cold acetone for each ml of concentrated cell media to
precipitate proteins. Using ice-cold acetone, causes the proteins to crash out of solution
the precipitated proteins were stored in the -20°C freezer overnight.
2.

After 24-hours, the protein sample was spun down and acetone was discarded.

The protein aggregate was air dried under the fume hood by lightly covering the
centrifuge tube. Protein concentration was ascertained using BCA assay, where proteins
were re-suspended into carbonate buffer before (Procedure of BCA assay and method of
making different buffers are listed under the experimental section after Chapter 2).
Extraction of Cellular Membrane Proteins
For extraction of proteins from cell membranes, larger number of cells are required
than those required for collection of cell-secreted protein from media. Hence the
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procedure involved usage of four T-75® flasks (70-75% confluent) to create one big cell
pellet.
1.

To do so, the cells were scraped off the bottom of flask using a Corning® plastic

cell scraper. Small 1-2ml aliquots of ice-cold PBS was used to assist cell transfer and
subsequent centrifugation of cells to generate a pellet from four flasks.
2.

The ice-cold PBS in supernatant was discarded and the resulting cell pellet was

stored in the -80 °C freezer for extended periods (not more than 3 months).
3.

The plasma glycoproteins and proteins were extracted from this cell pellet using

Qiagen® Plasma Membrane Protein Kit and the protocol provided with it. (Complete
detail of this protocol is listed under experimental section in Chapter 4).
4.

The protein extracted from the membrane protein kit was suspended in Qiagen®

supplied buffer and was stored in -20°C until later use. Whenever required, the protein
aliquot was thawed and its concentration was assessed using BCA assay (Chapter 2
experimental section).
5.

Assessment of protein concentration was followed by labeling the protein using

FITC involving Amicon Pro® 10-KDa centrifuge and exchange columns (Chapter 2
experimental section) and subsequent assessment of labeled protein by employing one
more BCA assay.
Labeling of SL and SL bound with protein to Alizarin-Red (ARS)
1.

Approximately 2mg of SL5 and SL5-Dab (stored in -20°C freezer) were weighed

in separate 1.5mL Eppendorf tubes and tumbled using PBS buffer for 10-minutes at RT.
PBS buffer was later discarded by pipetting.
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2.

SLs were then tumbled in 1ml PBS Screening Buffer (100mM NaH 2 PO 4 , 100mM

Na 2 HPO 4 .7H 2 O, 150mM NaCl and 10% glycerol, pH 7.2) for 15-minutes at RT.
3.

The Screening Buffer was then removed and beads were tumbled in 10µl of

100µM solution of ARS in water at 37°C by wrapping in aluminum foil. The
optimization of the quantity of ARS required was cited from Dr. Kevin L. Bicker’s
thesis (pg. 147). The incubation with ARS dye was done for 10 minutes at 37°C. SLs
were subsequently washed three times with PBS (without glycerol) at RT before being
analyzed under fluorescent microscope. Similarly, the SLs that were first bound to
protein for 12-hours and then tumbled in 10µl of 100µM solution of ARS in water at
37°C also followed the same washing and imaging steps. (Bead imaging under
microscope and image analysis is detailed in experimental section of Chapter 2).
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CHAPTER 4:
IN-VITRO CHEMICAL TARGETS OF EXTENDED SL ARRAY AND
ITS STRUCTURAL CORRELATIONS WITH CANCER TARGETS
4.0 OVERVIEW
Using statistical methods of data analysis, the previous chapter highlighted that
certain SLs, such as SL2, SL4, 4R and SL11-Y4A, due to their charges, contributed to the
precision/tightness in cancer classification, whereas SL7 and SL11-R8A – owing to their
greater number of phenyl rings- contributed to the overall accuracy of classification of
cancer. This classification aligned well with the increasing metastatic potential of the
cancer cell lines used.
Moreover, the aforementioned SLs were also useful at tissue typing the cancers of
colon and prostate, which shows that chemical basis of SLs’ interaction with the proteins,
coincides with the statistical parameters (variance) which contribute to the ability of
proteins to be classified by the array.
However, the questions which arise are:
1. What are the chemical targets of the SL array?
2. Do cancer-associated glycans (CAGs) respond to SLs? If yes, then what is the
chemical basis for it?
3. Can SL array be useful in classification of tissue targets?
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4. Can the abovementioned chemical interactions become the guiding benchmarks at
designing future SL targets specific for colon and prostate cancer?
The current chapter intends to address these questions, beginning by explaining the
chemical basis of SL interaction with colon and prostate cell lines in sections 4.1 and 4.2.
The chemical basis of CAG and SL interaction is discussed in section 4.3. The SL array
based classification of patient tissues is discussed in section 4.4. Finally, section 4.5
presents a working model for generating tissue-targeted SL development.
4.1 SIALIC ACID QUANTIFICATION OF COLON AND PROSTATE CELLS
Previous two chapters indicate that SLs target through positively charged amino
acid residues (i.e. Arginine R). The chemical target could be a negatively charged glycan
or proteins. Based on literature precedence, it is reasonable to believe that sialic acid
modifications are important in defining SL-glycan interactions.1 Previous published work
(Bicker, K. L. ACS Chem. Sci.) (Chapter1: ref 29) in the group also reports a preferred
interaction of SL5 to methylated-sialic acid over other common monosaccharides like
(methyl-fucopyranosides, methyl galactopyranoside and methyl 2-acetamido-2-deoxyglucopyranoside). Hence before delving into non-specific SL peptide-protein interactions,
it was decided to investigate for any specific glycan-SL interaction. It was likely to begin
investigation by choosing sialic acid. There were two reasons to quantify sialic acid
residues in-vitro:
1. Sialic acid (N-Acetylneuraminic acid) is a negatively charged, non-reducing sugar
(refer Figure 1.1), and since SLs have been shown to interact via their positive
charges, investigation of any possible interaction through sialic acids on protein
residues seems quite likely.
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2. Over-sialylation is commonly reported, in terminal glycans on protein structures both
during oncogenesis and cancer progression. Thus cleaving sialic acid off to quantify,
as well as to study the rest of the integral protein in their absence, seemed to be a
reasonable beginning.1 Taking this approach may cause the least intended perturbation
to the integral protein structure.
The objective of this section is to investigate the amount of sialic acid residue isolated
from glycoprotein secreted from both prostate and colon derived cell lines. Later to
investigate if the quantified sialic acid has any correlation to the virulence of both colon
and prostate cancers.
Quantification of sialic acid is broadly accomplished using two methods, chemical as
well as enzymatic. In the past, chemical cleavage of sialic acid residues from
glycoproteins has been performed in our lab using hydrazine. This chemical method
induces non-specific denaturation of purified proteins (e.g. BSM) because of higher
temperatures and usage of hydrazine. The chemical leaching method risks the protein
core to be denatured and may potentially disturb any possible protein–binding epitopes.
Therefore, enzymatic cleavage is employed in the following experiment, which offers a
softer method of removing sialic acid residues and leaves the protein core as intact as
possible. In this enzymatic cleavage, bound sialic acid residues (all types of sialic acid
linkages) from complex glycoconjugates (such as cell surface glycoproteins, polysialic
acids, and capsular polysaccharides) are released through the action of a non-specific
neuraminidase/sialidase enzyme. The free sialic acid residue is broken down into pyruvic
acid using N-Acetylneuraminic acid aldolase. The aldolase enzyme catalyzes the
following reversible reaction:
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N-Acetylneuraminic acid (sialic acid) → N-Acetylmannosamine + Pyruvic acid
Eq 1
Pyruvic acid, in turn is reduced to lactic acid using β-NADH and lactic acid
dehydrogenase enzyme as follows:
Pyruvic Acid + β-NADH → Lactic Acid + β-NAD

Eq 2

Under proper temperature conditions (37 °C), the first forward reaction predominates,
and when coupled with β-NADH reduction of pyruvic acid, the reaction goes to
completion. β-NADH oxidation can be accurately measured spectrophotometrically.
Hence, the total amount of sialic acid residue obtained from each cellular extract
correlates to the nanomoles of β-NADH oxidized. Total sialic acid counts from secreted
proteins, isolated from the media of four different colon and five different prostate cell
lines, are listed below in Table 4.1.
Table 4.1: Illustrating total sialic acid residue count of secreted proteins
extracted from media of cell lines.
Human colon cell lines

Human prostate cell lines

Cell line name
CCD 841 CoN

metastatic
potential
-

# sialic acid
residues
(nmol)
56

HCT-116

low

108

WPE1-NA22

low

102

HT-29

low

74

WPE1-NB14

low

80

LoVo

high

77

DU 145

high

270

PC-3

high

240

metastatic
Cell line name potential
RWPE-1
-

# sialic acid
residues
(nmol)
102

While other groups also have successfully quantified sialic acid from cell membrane
proteins,2, 3 our effort to determine levels secreted into the media is unique and innovative
providing an insight into the development of serum-based diagnostics. Metastatic

114

potential for each cell line from the literature is confirmed using standard cell invasion
assays (Table 3.2 and Table 3.7).4
Based on the literature precedence on the varied sialic acid expression during
oncogenesis of proteins extracted from colon cell membranes,5 it is anticipated that sialic
acid expression correlates with the metastatic potential of colon cell lines. The total sialic
acid content values (Table 4.1) show that the content increases going from normal to
cancer cells.
To further elucidate any correlation between sialic acid content and metastatic
potential, PCA outputs of colon and prostate were evaluated. In secreted colon proteins
however, this happens when we compare the PCA output of SL array containing only
highly positively charged SLs (SL3, SL4, SL5, SL5-R1511A, SL5-Dab, SL5-RRAc, 4R
and 5R) with very few (0-2) number of phenyl rings.
Figure 4.1 (same as Figure 3.6E) shows that by only using highly positively charged
SLs, different colon cells can be discerned. Factor 1 and 2 are the top two statistical
parameters that describe most of the variance of the data set. Factor 2 seems to show
correlation with metastatic potential. Figure 4.1 also attempts to correlate the sialic acid
concentration and metastatic potential of colon cell lines. It shows that sialic acid
quantification especially works well at classifying normal from cancer. This means that
one of the statistical basis of discrimination, through which the SL array is classifying
colon cell lines, is through varied sialic acid concentration, while the positive charges
derived from arginine residues of SLs assist in targeting these sialic acid residues.
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Metastatic potential

108 nmol

77 nmol

74 nmol

56 nmol

Figure 4.1: Showing amount of total sialic acid isolated from colon cell secreted
proteins on top of a PCA plot generated using an SL array.
This SL array only contains SLs having high positive charges (+3 to +5) and very
few number of phenyl rings (0 to 2). Low sialic acid count correlates well with
normal colon cell lines. Circles round the data points signify 95% confidence
intervals.
It is noted that the HCT-116 and LoVo cell lines group together, which is because the
SLs that help in tightening their clustering (SL7 and SL11-R8A) are not included in the
high positive charge-low phenyl ring model (refer Figure 3.7).
Similarly, sialic acid concentration and PCA output of prostate cell lines is illustrated
in Figure 4.2. The PCA output again makes use of the SL array that contains highly
positively charged SLs (SL5-R1511A, SL5-Dab, SL5-RRAc, 4R and 5R) with very few
(0-2) number of phenyl rings. By only incorporating highly positive SLs, the model did
not discern prostate cell lines that well, especially normal and low/non-metastatic ones.
This was expected, since to describe prostate cancer model, the SLs with greater number
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of phenyl rings were paramount and those SLs are missing from the PCA model depicted
in Figure 4.2.
It is noted that the amount of sialic acid obtained from normal prostate cell lines
exceeds even that of metastatic colon cell lines. Although, the total sialic acid content of
DU 145 and PC-3 cell lines exceeds that of RWPE-1 as seen in Figure 4.2 (same figure
as Figure 3.11B), it is also noted that RWPE-1 and WPE1-NA22 cell lines have the same
amount of sialic acid content. This may mean that using sialic acid quantification to
diagnose prostate cancer at early stage may not be very helpful. Literature also disputes
the use of sialic acid quantification for prostate cancer diagnosis.6

80 nmol

102 nmol
102 nmol

270 nmol
240 nmol

Figure 4.2: Showing amount of total sialic acid isolated from prostate cell
secreted proteins on top of a PCA plot generated using an SL array.
This SL array only contains SLs having high positive charges (+4 to +5) and very few
number of phenyl rings (0 to 2). High sialic acid count correlates well with metastatic
prostate cell lines rather than normal and low/non-metastatic cell lines.
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As mentioned in the last chapter in Figure 3.11A, for discerning various prostate cell
lines, high positively charged SLs contribute to model precision, by increasing the
tightness of the grouping. This can be explained by positive charge of arginine that
enhances binding through sialic acid residues of prostate cells. In Figure 3.11A, factor 1
roughly aligns with metastatic potential, pinpointing that the ionic interactions being one
of the predominating factors towards disease classification by the array.
But to accurately discern each prostate cell line, the SLs containing greater number of
phenyl rings and lesser positive charges play an important role, too. Which is why
Figure 4.2 model (that does not contain SLs with high number of phenyl rings) is
performing badly at classification.
RWPE-1 and WPE1-NA22 always seem to cluster nearby, which may be due to the
latter being an MNU-derived cell line from the former and is quite low in its metastatic
potential (Table 3.7). This supports the need for better SLs that specifically target
prostate cancer for future investigations.
From this section, comparing the amount of sialic acid between CCD 841 CON and
HT-29 cell lines, it is reasonable to conclude that change in sialylation correlates well
with early diagnosis of colon cancer. Whereas comparing the amount of sialic acid
between RWPE-1 and WPE1-NA22 cell lines, it can be concluded that change in
sialylation can only predict prostate cancer at its later stages and is not a predictive
marker for earlier detection of prostate cancer.
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4.2 INTERACTION OF SL-ARRAY WITH SECRETED COLON PROTEINS THAT
CONTAIN OR ARE DEVOID OF SIALIC ACIDS
The purpose of doing this experiment is to determine the source of negative
charges that SL array is targeting for its discrimination. Is the observed SL array
classification primarily from sialic acid or from lower pI protein isolated from cell culture
media? It is important to investigate whether SL array is specific to a glycan moiety or is
it simply involved in some transient non-specific interaction. This might help us
ultimately to understand and enhance the utility of the array towards diagnosing and
staging colon cancer. Since there is an evidence that global fucosylation7 and sialylation8
correlate with cell metastasis, it will be useful to compare array outputs that derive from
samples that are rich in sialic acid residues to the outputs that are not.
For this experiment, normal colon (CCD 841 CON) and highly metastatic colon
(LoVo) cell lines were used. Both the protein samples, with and without sialic acid (after
the action of sialidase enzyme) were incubated with a 20-unit SL array. Figure 4.3
below, illustrates SL array assisted, 4-class guided LDA grouping of colon cell isolated
proteins, with and without sialic acids. In the Figure 4.3 going from left to right is CCD
841 CON with sialic acid residues, followed by CCD 841 CON and LoVo after removal
of all sialic acid residues and the last cluster indicates LoVo with sialic acid residues
attached to the proteins. Close clustering of proteins devoid of sialic acid residues shows
a loss of discriminative ability of SL array. This indicated that the SLs’ primarily target
are sialic acid residues of the cell lines. Role of negative charge from protein in binding
to SL could not be evaluated because sialidase enzyme may have caused some protein

119

denaturation. Using circular dichroism spectroscopy to evaluate protein stability as a
function of added denaturants is suggested in future experimentation.

healthy cell line
protein with sialic acids
Discriminant 2

metastatic cell line
protein with sialic acids
healthy cell line
protein NO sialic acids
metastatic cell line
protein NO sialic acids

Discriminant 1

Figure 4.3: Illustrates SL array mediated 4-class guided (LDA) plot of
isolated proteins with and without sialic acid residues.
All cell lines used here are from colon. Healthy/normal cell line is CCD 841 CoN
and high metastatic cell line is LoVo. Close clustering of proteins devoid of sialic
acid residues shows a loss of discriminative ability of SL array. N= 112.
Discriminant 1 and 2 are the factors that best describe the model classification.
The circles around data points indicate 95% confidence interval.
Figure 4.3 showed LDA, a guided method to observe different protein groupings and
did not indicate the actual spread of the individual data points according to their variance.
That is because guided grouping method tries to minimize the distance within each circle
and maximize the distance between two different circles. In order to remove the statistical
bias in data, unguided grouping (PCA) with respect to variance of each data point was
conducted and is illustrated in Figure 4.4.
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UNGUIDED Protein analysis with and without sialic acid
residues
3

2

1

0

Factor 2 Y-axis 12.8%

-1

-2

-3
-2

-1

0

1

2

CONA healthy protein with sialic acid
CONA healthy protein without sialic acid
LoVo metastatic protein with sialic acid
LoVo metastatic protein without sialic acid

X-axis 31.1%

Figure 4.4: Illustrates unguided (PCA) plot of cell secreted proteins with and
without sialic acids responding to a 20-unit SL array.
All cell lines used are from colon. Closed symbols represent protein with sialic acid
residues and open symbols represent protein without sialic acid residues. CCD 841
CON (CONA) is normal colon (▲) and LoVo (■) is highly metastatic colon cell line.
X-axis correlates with increase in amount of total sialic acid. N= 112.
The greater spread out of LoVo (■ and □) may be indicating a greater amount of
protein changes associated with increased metastatic potential. In Figure 4.4, Factor 1
represents the largest factor that described the greatest variance in the model and
interestingly also correlated the amount of sialic acid residues in the different protein
samples (open symbols indicate protein samples devoid of sialic acid).
From this section, it can be concluded that the primary chemical cause for SL array
assisted classification of various colon cancer cell lines is the presence of sialic acid
residues associated with the proteins extracted from these cell lines. Future work would
involve similar investigation with prostate cancer.
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4.3 RESPONSE OF CANCER ASSOCIATED GLYCANS TO SL ARRAY
As discussed earlier in sections 1.3 and 3.5, Cancer-Associated Glycans (CAGs)
are the cause of aberrant glycosylation in oncogenic cells. The following section attempts
to evaluate the ability of the SL array to discriminate several different CAGs. Some of
these CAGs are complex glycans i.e., TF antigen, Lea, Lex, sLea, sLex and some are
simpler monosaccharides like fucose. Fucose, (refer Figure 1.1) is not a CAG, rather is a
part of several CAGs. Besides that, core-fucosylation of N-linked glycans that is also
known to correlate with metastasis.7 These glycans were chosen because they represent
some of the more common saccharide motifs over-expressed by cancerous cells. These
CAGs are also composed of many of the same monosaccharides that were also found in
glycoproteins that were used to establish proof-of-concept in chapter 1 and 2 (OVA, PSM
and BSM).
For evaluation of these six CAGs (Figure 1.1), a 19-unit SL array containing SL1SL9, SL11, SL1Dab-SL5Dab (no phenyl-boronic acids), SL5-R1,5,11A, SL5-RRAc, 4R
and 5R was used. This different SL array along with some of the SLs from extended
lectin array also contained SLs without 2-PBA in them, to investigate the direct impact
loss of PBA has during interaction of CAGs with SLs.
Firstly, the binding affinity of each SL was investigated with six different glycans for
which expression is commonly altered during prostatic and colorectal cancers. This was
done primarily to identify SLs selective towards certain glycans and then to further
comprehend the chemical basis of the selectivity. To ensure that SLs bind to glycans and
not the fluorescent dye and also to maintain the dye:glycan ratio, we made use of biotin
tagged CAGs. After incubation with the CAGs, fluorescently tagged streptavidin was
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A,

B.
200

200

100

5R

4R

SL5RRAc

SL5-dab

SL5-R1,5,11A

SL4-dab

SL3-dab

SL2-dab

SL1-dab

SL9

SL11

SL8

Lea

SL7

sLea

SL6

0

0

SL5

50

SL4

50

fucose

SL3

100

150

SL2

SL5-RR (5)

SL1

150

average bead fluorescence

average bead fluorescence

SL5 (3)

Figure 4.5: Selective binding of Synthetic Lectins (SL).
A. output of SL5 and SL5-RR with cancer associated glycans (CAGs) like sLea and
its non-sialylated counterpart Lea, illustrating that extra Arginine residues (+
charged amino acids) at the N-terminus of SL-RR help in binding to sialic acids in
sLea.
B. showing SL11 selectively binding to fucose, illustrating boronic acid on Nterminus of SL11 assisted fucose interaction (additionally, four phenyl rings in
SL11 peptide sequence also assist in hydrophobic interactions to non-polar fucose
residue).
incorporated to transduce an optical signal upon conjugation of biotin to streptavidin. The
complete output of six CAGs with 19-SLs is covered in APPENDIX D, but some
noteworthy points are discussed below.
Several chemical correlations could be drawn after investigating all the CAGs .
Figure 4.5A shows increased binding of SL5-RR over SL5 with sialylated Lea. This is an
example of the way the SL-glycan interaction is enhanced upon the introduction of
additional positively charged arginine residues (R) in the sequence of SL5-RR, thereby
leading to a stronger charge-pairing interaction with sLea over non-sialylated Lea. SL5RRAc has an overall +5 charge i.e. two extra positive charges than SL5.
Figure 4.5B displays selective binding of SL11 over 18 other SLs to non-reducing
fucose. This could be attributed to extra boronic acid present on the free N-terminus of
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SL11, thus assisting in fucose binding. SL11 also contains four phenyl rings (three from
phenyl boronic acids and one from tyrosine) that could contribute to CH-π type
interactions with fucose. SL11 was identified (courtesy Dr. Anna Veldkamp) from a
library of SL-polymeric beads when the library was incubated with extracted membranebound proteins from RWPE-1 and PC-3. PC-3 protein extract competed against RWPE-1
to bind to SL11, thus making SL11 a prostate cancer ‘hit’. The theoretical size of the SL
library was 115 peptide sequence permutations (ref: Section 4.5).
To investigate the cross-reactivity of SLs and their applicability to distinguish all six
CAGs, an array was constructed fostering the hypothesis of SL-glycan interactions and
boronic acid-diol binding. Depicted in Figure 4.6A is the output when a guided statistical
approach LDA was employed to accurately discern these six CAGs with >99%
classification accuracy. It is noteworthy that sialylated CAGs (sLea and sLex) and their
non-sialylated counterparts (Lea and Lex) are close to each other in these models where
the only structural difference is the regio-chemistry of the linkage to the core GlcNAc
moiety. Additionally, Lea also closely clustered near sLea, where the difference is merely
that of presence of sialic acid residue in the latter. This signifies the capability of the
array to discern sialyated from non-sialylated and sLea from sLex, the latter have only
small structural differences. TF-antigen (TFA) is a disaccharide and does not possess the
glycan motif shared by any other CAGs involved in this study (Galβ1-3GalNAcα1),
hence it is uniquely classified.
Based on the comparison of F-scores of all 19 SLs, the two SLs, which contributed
the most to the classification of all six CAGs are SL7 and SL2-Dab. It is hypothesized
that these two SLs dominate, primarily because of greater number of aromatic rings in
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SL7 (contributing via CH-π interactions) and the greater amount of positive charges in
SL2-Dab (contributing via ionic interactions). The F-score data from LDA can be relied
on because the LDA and PCA models picked out the same SLs that contributed to the
discernment of CAGs.
An LDA model with SLs containing a greater number of aromatic rings (and low
positive charges), similar to SL7, resulted in a decrease in the tightness of model (Figure
4.6B), indicating a loss in precision and compromising the classification accuracy,
reducing it to 83%. Interestingly, the two sialylated CAGs, sLea and sLex overlapped with
each other the moment SLs with great number of Arginine residues were removed from
the model.
Similarly, the LDA model, with SLs having a greater number of positive charges and
no phenyl-boronic acids (similar to SL2-Dab) shows a reduction in classification
accuracy to 93% (Figure 4.6C). These results suggest that boronic acid residues are
important to discriminate sLea, sLex and Lea. In addition, the model derived from
positively charged SLs retains excellent ‘tightness/precision’, indicating that these
positively charged SLs provide a microenvironment necessary for accurate binding.
The unguided (PCA) statistical models offer similar insight, indicating that positively
charged amino acids (like Arginine) in SLs are important for precision and phenyl
boronic acids are important for accuracy.
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TFA
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Figure 4.6: Guided statistical output of SL array with various CAGs.
(TF) antigen, sialyl Lewis X (sLex) and sialyl Lewis A (sLea) are some CAGs that
tend to overexpress in colon cancer. Circles reflect 95% confidence intervals. A.
shows 100% classification of all CAGs due to lectins SL7 (high no. of phenyl rings
and low positive charge) and SL2-Dab (no boronic acids and high positive charge). B.
shows loss of accuracy to 83% when modeled with SLs having only greater no. of
phenyl rings. C. shows 93% classification with SLs not containing boronic acids,
deeming boronic acid useful to discern sLea, sLex and Lea.
In Figure 4.6B, it was also noted that with SLs containing high number of phenyl rings
and low positively charged sequences, sialylated CAGs like sLea and sLex did not
classify well and grouped together. These two sialylated CAGs lost the grouping
accuracy in the model, further indicating sialic acid- arginine interactions.
One of the concerns in these experimentations is that it is possible for the SLs to
interact, not only with the glycans, but also with the protein portion of glycoproteins. To
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counteract this, in this analysis since the protein component, FITC- streptavidin, is the
same for each glycan that is being analyzed, therefore any observed difference in the
response from the array must be attributed to the glycan constituent and not to the protein
(streptavidin) component. Given the structural similarities between these glycans, it is
remarkable that there were not many misclassifications.
In summary, these results validate our ability to differentiate structurally similar
cancer associated glycans with high accuracy using a small, cross-reactive SL Array.
Sialylated CAGs are the direct targets of SLs with greater number of Arginine residues.
Loss of the SLs with greater number of Arginine residues limits the arrays’ ability to
discern sialylated CAGs. On the other hand, fucose and SL11 show an exceptional
binding interaction, that may be due to CH-π type interaction of pyranose ring with
greater number of phenyl rings in SL11.
4.4 APPLICATIONS OF SL ARRAY TO DISCERN HUMAN PROSTATE TISSUE
SAMPLES
While the current array discriminates cell lines with classification accuracies that
may be improved by refining the SLs in the array and better statistical modeling, this is
not our ultimate goal. Cell lines do serve as acceptable in vitro models for investigating
cancer, however they do not always represent the complexity of the tumor
microenvironment. To examine whether our SL array could work with clinical
specimens, patient-matched tissue from four prostate cancer patients were analyzed using
the extended SL Array. Prostate tissue was obtained from the Prostate Tissue Core
Facility at USC (courtesy: Ms. Ella Weinkle). Each patient tissue sample’s virulence was
confirmed by tissue histology (courtesy: Dr. Loulia Chatzistamou) and consisted of one
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tumor sample and one normal or healthy sample taken from an adjacent site. Out of the
four samples, two were of patients from African American (AA) and two from EuroAmerican (EA) descent. Pathologists grade prostate cancers using numbers from 1 to 5
based on how much the cells in the cancerous tissue look like normal prostate tissue
under the microscope. This is known as the Gleason system. Grades 1 and 2 are not used
for biopsies, because most biopsy samples are grade 3 or higher. If the cancerous tissue
looks much like normal prostate tissue, a grade of 1 is assigned and if cells and their
growth patterns look very abnormal, it is assigned 5. Grades 2 through 4 have features in
between these two extremes. Since prostate cancers often have areas with different
grades, a grade is assigned to two areas that make up most of the cancer. These 2 grades
are added to yield the Gleason score (also called the Gleason sum). The highest Gleason
score can be 10. The first number assigned is the grade that is most common in the tumor.
For example, the Gleason score written as 3+4=7, is understood as the majority of the
tumor being grade 3 and some of it being grade 4, when they are added together, they
make up for a Gleason sum of 7.9 Histology of the acquired tissues confirmed each
metastatic tissue sample to contain adenocarcinoma (Gleason sum (3+4=7)).
For the protein extraction, the tissues were pulverized using mortar and pestle in
liquid nitrogen and the resulting powder added to lysis buffer. The resulting tissue slurry
was centrifuged and the supernatant containing cells were collected. Membrane proteins
were extracted using the Qiagen membrane extraction kit, labeled with FITC and
incubated with extended SL array. Fluorescence intensity data were collected for each
sample using fluorescence microscopy. Outliers were rejected at 1.8 interquartile
distances (IQDs) and intensity readings were normalized to one using the brightest
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reading for each patient sample. Using de-identified patient disease data, LDA analysis
was carried out to determine the ability of the array to differentiate patient samples based
on a number of factors.

Figure 4.7: Showing unguided/ (PCA) plot discerning four patient-matched
tissue samples having prostate cancer using 22 unit SL-array.
Green samples indicate normal and red samples indicate adenocarcinoma (Gleason
score 3+4 =7). Open and closed symbols indicate patients with Euro-American (EA)
and African-American descent respectively. Same symbols indicate the patientmatched samples. Green arrow indicates sample-12 prostate tissue whose histology
report showed presence of prostatic intra-epithelial neoplasia (PIN).
The previously used SLs (20 in extended lectin array) and two new SLs, found from
newer library screenings (i.e. SL15, SL16), were used together to make a 22-SL array
that was employed to distinguish between two African American (AA, denoted by solid
color) and two Euro American (EA denoted by open color) prostate tissue samples. (Ref:
APPENDIX B).
Each tissue sample was patient-matched, making i.e. eight samples, whose histology
was first confirmed, were pulverized and proteins were extracted from them. These
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protein samples were then tested using the SL array. Figure 4.7 illustrates an unguided 3D classification. The guided (LDA) 8-class model was >99% accurate at predicting
cancer (red) from normal tissue (green). The most useful chemical tool which correlated
with statistical separation of healthy and adenocarcinoma samples, was phenyl ring
gradation. This was true since SL9, SL7 and SL11-Y4F were the most useful SLs and all
are having large number of phenyl rings in SL sequence.
In Figure 4.7, all the four red highlighted samples were histologically confirmed to
have moderately differentiated adenocarcinoma and were positive for elevated PSA after
surgery. Patient sample 9 and 11 (red▲ and ○) had leftover microscopic primary tumors
at the surgical margins at the primary tumor site, whereas patient samples 1A and 3B (red
■ and ◊) had clear surgical margins at the primary tumor site after surgery. This indicated
the utility of SL array as prognostic tool by indicating cancer even when it became
invisible to the surgeon. Green samples were patient-matched normal prostate tissue,
except for patient sample 12 (green ○, indicated by green arrow) which was low-grade
prostatic intraepithelial neoplasia (PIN) with no adenocarcinoma. As observed, it grouped
a bit closer to the healthy region, needing further investigation where more tissue samples
containing PIN can be investigated and checked how they classify.
In the future work, the proteins being expressed by these tissue samples, can also be
investigated. For example, fucosyltransferase (FUT8) catalyzes glycan transfer of α1.6fucose (core fucose) to glycoproteins. It is known in the literature that both corefucosylation and FUT8 expression are positively correlated to prostate-tissue
malignancy.10-11 The donor and acceptor substrates for FUT8 are GDP-fucose and a
biantennary N-glycan, respectively. One of the ways to test for FUT8 activity is by
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monitoring enzymatic activity by radiolabeling the oligosaccharide as the acceptor
substrate. Literature suggests a convenient and sensitive assay method using 2aminopyridine (PA)-labeled asialo-, agalacto-biantennary sugar chain as an acceptor
substrate. N-Linked sugar chains can be prepared in relatively large amounts from egg
yolk, and after the removal of sialic acid and galactose residues by glycosidases, the
sugar chain can be labeled with PA and analyzed by HPLC.12
Thus making use of a 22-unit SL array, healthy and cancerous samples were
distinguished with >99% accuracy. These initial results demonstrate that SL-array not
only discriminates between cell types effectively in in vitro cell line models but also in
tissue samples. This promising data suggests that the development of the array for clinical
utility is possible.
4.5 DESIGNING FUTURE SL TARGETS FOR COLON AND PROSTATE CANCER
As of now the ability of SL array, not only to discriminate between healthy and
cancerous cell lines but also between different cancer types has been discussed. In the
beginning of this chapter, a possible chemical basis for SLs to distinguish between colon
and prostate malignancies has also been discussed. The SLs that could bind to one type of
carcinoma over the other, are termed as SL ‘hits’. In the light of these events, it is
required to investigate the structural basis of the SL ‘hits’ which enables them towards
this ability of “tissue-typing”.
To do so, some new SLs sequences were invented by interaction of different peptideboronic acid based SL libraries to tissue specific targets. For e.g. two libraries (2-BA and
3-BA) were designed where the numbers indicate the total number of the phenyl-boronic
acid (BA) attachments per SL sequence.
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Each SL polymeric bead consisted of multiple copies of the same peptide-BA
sequence. The difference between the two is that 2-BA library, instead of having a third
phenyl-boronic acid has a free –NH 2 at the N-terminus. In order to keep the N-terminal
free, it was protected using (BOC) 2 O anhydride (TFA sensitive). Using (BOC) 2 O
protection, enabled orthogonal cleavage of ivDde (basic de-protection), The ivDde was
the protecting group on the –NH 2 side chains of (Dab), which were removed for the
subsequent attachment of phenyl boronic acid (BA) on the diamino butanoic acid.
Unprotected N-terminal –NH 2 , causes attachment of a third phenyl boronic acid residue
on it. The rest of the peptide sequence for both libraries is generic:
(NH 2 -R or R*)-X-(Dab)*-X-X-X-(Dab)*-X-B-B-R-M-Resin.
Here, phenyl-boronic acid (BA) moieties are fixed and denoted by * while R* and
(Dab)* denoted 2-phenyl-boronic acid functionalized R and Dab, respectively. B
represented β-alanine and acts as spacer since it is insensitive to Edman degradation.
Methionine (M) is added on to C-terminus to avail orthogonal cleavage of the whole
peptide using CNBr while X is any one of the 11 random amino acids (A, N, Q, G, L, F,
S, T, Y, V and R). R is the only positively charged amino acid, which is incorporated
because its guanidinium charge assisted in MS/MS sequencing and creation of salt
bridges to sialic acid as well. The standard Fmoc strategy was used for peptide synthesis.
Previous lab members established this generic library design to contain the greatest
bead sequence diversity at the same time also maintaining the ease of sequencing while
using MS/MS or Edman techniques. Sequence diversity of each SL bead is introduced by
five randomized amino acid spot (X) in the peptide sequence. Since there are 11 different
amino acid choices, it would mean 115 sequence diversity of each SL bead.
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Both the libraries were devoid of C-terminal acylation because that hindered with
sequencing. Dab was used in place of Lysine because the shorter side chain of the former
assists to reduce background binding and increase interactions between the glycoproteins
and the peptide backbone. (Dab)* moieties also were fixed to further aid in MS/MS
sequencing. The randomized amino acids were coupled using a split-and-pool method as
described in Figure 4.8. To do so, the polymeric resin was split into 11 tubes and a
different amino acid is added to each tube. After the amino acid was coupled, all of the
resin is combined again for a collective de-protection, before splitting again.
The remaining nine amino acids (out of 20), i.e. M, C, I, P, H, D, E, K and W, were
excluded from the randomized positions. Methionine was not repeated in the rest of the
peptide sequence and cysteine was not used in the randomized amino acid positions to
eliminate the chance of cutting the peptide sequence into pieces due to CNBr cleavage.
Isoleucine was omitted to eliminate the chance of disambiguation with leucine when
sequencing for the unknown SLs. Proline was excluded to avoid having ‘kinks’.
Histidine, glutamic acid, aspartic acid, and lysine were avoided to reduce interference of
charge during MS/MS. Tryptophan was not included because of its big and bulky side
chain. Glutamate and Aspartate were not used to remove molecular weight
disambiguation with their corresponding amine counter parts.
In order to identify SLs that could bind differently to non-cancerous versus cancerous
samples, the protein extracts (from healthy and cancerous samples) were fluorescently
labeled with two different colored tags, then combined together and interacted with the
SL libraries.
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Figure 4.8: Illustrating Split and Pool combinatorial method.
Portion of polymeric beads are split. Different colors indicate different amino acids.
The procedure enhances bead sequence diversity by allowing attachment of random
amino acids to create all possible 115 peptide sequences in the library.
This procedure of competing non-cancerous and cancerous analytes to identify SL
beads that are selective hits for cancer: is termed as a DUAL DYE LIBRARY
SCREENING (see Figure 4.9). The SL that bound specifically to healthy and cancerous
proteins was termed a ‘healthy hit’ and ‘cancerous hit’ respectively. After these SL ‘hits’
were manually isolated under the microscope, the individual SL beads were prepared for
peptide sequencing. In order to look out for colon as well as prostate specific hits,
different healthy and metastatic protein targets that were used against the two libraries,
and are below:
1. Colon cell secreted proteins (CCD 841 CoN versus LoVo)
2. Prostate cell secreted proteins (RWPE-1 versus DU-145) and
3. Prostate patient-matched tissue proteins (including race related diversity)

134

The healthy protein analyte was labeled with FITC (green) and metastatic analyte was
labeled with rhodamine (red). All the three different targets were separately incubated
with 3-BA and 2-BA SL libraries. Figure 4.9 shows a typical workflow of incubation.
This process generated tissue-specific, healthy and metastatic hits.
Sequence with
Edman’s
degradation

HIT!
healthy

healthy cell
proteins
(Green)

D: SL17

B

D

SL libraries
2-BA and 3-BA

metastatic
cell proteins
(Red)

B: SL20

Competitive Binding
during Incubation

HIT!
metastatic

Sequence with
Edman’s
degradation

Figure 4.9: Flowchart showing the incubation of different SL libraries with
different healthy and metastatic dual-labeled protein analytes.
Both the libraries (2-BA and 3-BA) underwent the same treatment of incubation,
subsequent imaging, manual bead picking of hits and edman degradation. Two hits
were generated, SL17 (healthy hit) and SL20 (metastatic hit). Individual bead
intensities in APPENDIX E.
To ensure that there was no specific dye-based discrepancy while finding SL hits,
reverse dual-dye screening was carried out as well, where healthy protein analyte was
labeled with rhodamine (red) and metastatic analyte was labeled with FITC (green). It
was noted that there were no impartialities related to dye charge towards affinity for a
specific analyte. There are advantages to using secreted proteins rather than proteins
extracted from cell membranes because once a membrane-bound protein is extracted, the
native protein tends to lose its integral structure. Using cell-secreted proteins rather than
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cell membrane isolated proteins also tests the ‘sensitivity’ of SLs (because the actual
protein of interest is low in concentration in a secreted protein mixture).

Figure 4.10: Schematic depicting Edman degradation.
The bound protein was washed away from the SL (by alternatively washing the resin
using 70% TFA in H 2 O and 0.1 M NaOH). To sequence hits from library screenings
against different protein analytes, Edman degradation was used. Edman peptide
sequencing, involves immobilization of resin bound peptide followed by removal of one
amino acid at a time and subsequent analysis using high-performance liquid
chromatography (HPLC).
In the first step of Edman Degradation, the N-terminal –NH 2 reacted with phenyl
isothiocyanate to form a phenyl thiocarbamyl-peptide derivative (Figure 4.10). If the Nterminus is acylated, this reaction cannot take place, making sequencing obsolete.
The presence of phenyl-boronic acid causes difficulty at obtaining peptide sequences
using MALDI due to H-bonding with water causing messy signal with great signal-tonoise ratio. To avoid this situation several techniques for removing the PBA moiety from
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the SL prior to MS-based sequencing, were used. One of them was treating resin bound
SL with hydrogen peroxide in water to enable oxidation of BA to phenol.13 Since Edman
method was used and the location of boronic acid was already known, there was no need
to cleave off boronic acids prior to sending them for sequencing.
The 2-BA library peptide hits were easier to sequence than 3-BA hits. In all of the
hits procured from 3-BA library, the N-terminal R, was inconclusive from the
chromatogram, probably due to signal interference from the attached third boronic acid.
Nevertheless, the position of the N-terminal R was fixed in the library design thus
confirming the attachment of third BA there. To verify the presence of R on the Nterminus, while making the SL library, R was manually coupled and its complete
attachment was verified through a subsequent ninhydrin test. It is also hard to distinguish
the Dab positions when referring to the sequencing chromatograms but it is similar to the
last AA position. It is most important to look for changes from cycle to cycle within the
SL sequence. The absolute quantities of the AAs in a single cycle is not as important due
to the fact that different AAs have different background levels.
Proteins concentrated from normal cell lines of prostate (RWPE-1) were labeled
green using FITC and proteins from metastatic non-androgenic, non-PSA expressive (DU
145) were labeled red with rhodamine. Competitive binding dual dye tests were done on
two libraries one involving an extra boronic acid at the N-terminus, thus having three
boronic acid residues on SLs(3-BA) and the other having free N-terminus (2-BA). 3-BA
libraries consequently have one extra phenyl ring in SL sequences and both the libraries
were tested on prostate and colon cell proteins.
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Figure 4.11: Binning chart representing population diversity of bead fluorescent
intensity in 3-BA and 2-BA SL libraries
with A. human prostate metastatic (DU 145) and B. human prostate normal cell line
(RWPE-1). More variable the fluorescent intensity of library beads, better suited the
library is to find a ‘hit’. Hits are highlighted using red boxes
It was observed that, more variable the fluorescent intensity of library beads, better
suited is the library to find a ‘hit’. In Figure 4.11, a binning chart with bead population
diversity has been shown by plotting fluorescent intensity of each bead in 3-BA and 2BA SL libraries. Where, Figure 4.11A is SL library against human prostate metastatic
(DU 145) and Figure 4.11B against human prostate normal cell line (RWPE-1). After
calculating the fluorescent intensity of each individual bead in the library, it was observed
(Figure 4.11A) that 3-BA library had greater binding variability with prostate cancer
cells and 2-BA had better diversity with normal prostate cell lines (Figure 4.11B). This
might be due to extra phenyl rings in 3-BA library, causing greater CH-π type interaction
with metastatic prostate proteins (which have greater fucosylation expression than normal
prostate cell lines).
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Figure 4.12: Binning chart representing population diversity of bead fluorescent
intensity in 3-BA and 2-BA SL libraries
under the same dye (rhodamine) and same microscope filter set (DSR) with metastatic
human colon cell line (LoVo). Dye does not interfere with bead binding, it is the type
of analyte that matters to binding. More variable the fluorescent intensity of library
beads, better suited the library is to find a ‘hit’. SL 16 (red) was isolated from colon
metastatic 2-BA library. Dotted white squares over the image represent region-of
interest under fluorescent microscope with maximum pixel information.
Similarly, normal cell colon cell lines (CCD 841 CON) and metastatic (LoVo) were also
labeled green and red, respectively. Figure 4.12 shows a binning chart representing
population diversity of bead fluorescent intensity in 3-BA and 2-BA SL libraries under
the same dye (rhodamine) and same microscope filter set (DSR), with human colon
metastatic (LoVo). More variable the fluorescent intensity of library beads, better suited
the library is to find a ‘hit’. This concludes that 2-BA library had better fluorescent signal
diversity with metastatic colon cell proteins. Since increased virulence in colon cells is
understood by change in sialylation, using a library with lesser number of phenyl rings
(e.g. 2-BA) proves useful.

139

In Figure 4.12 both libraries are interacting with proteins from metastatic colon cell
line, thus showing that type of fluorescent dye used does not interfere with the binding
affinity of SL hit with the analyte. SL 16 was isolated from colon metastatic 2-BA
library. Dotted white squares over the image represent region-of interest under
fluorescent microscope with maximum pixel information.
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Figure 4.13: SL dual-dye library screens to investigate racial health disparities
between African American (AA) and Euro-American (EA) prostate cancer
patients.
Left panel shows library-screening results using normal AA (green) and EA (red)
pooled prostate tissue. Right panel shows library screening results using pooled
adenocarcinoma (Gleason score 7) prostate tissue from EA (green) and AA patients
(red). SL 18 hit (bead E) was isolated from healthy pool and SL 19 hit (bead G) was
isolated from adenocarcinomia pool. Bar graphs indicate corresponding red and green
fluorescence for the same bead under different filters (DSR and GFP). No error bars
indicated because each bar is representing individual bead fluorescence.
SL dual-dye library was also used to further investigate genetic health disparities
amongst African American (AA) and Euro American (EA) prostate cancer patients (see
Figure 4.13). Left pool shows proteins pool using normal prostate tissue of AA patients
(green) and EA patients (red):
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Table 4.2: Showing Malignancy specific SL ‘hits’.
Hits from 2BA and 3BA library screens using secreted proteins from human prostate
or human colon cell lines, or membrane extracts from human prostate tissue samples
(patient-matched normal and adenocarcinoma GS7), illustrating amino acid
composite trends, e.g. charged amino acids, number of aromatic rings and boronic
acids. (EA+AA): stands for Euro-American plus African-American patient sample.
(2xAA): two African-American patient sample pool.
#(R)

#Ph
ring
s

Polar
S,T,
N,Q

3

2

2

2

2

4

colon
cell
colon
cell

NH2RA(Dab)*NAQ(Dab)*NBBRM

2

2

3

prostate
tissue

2

NH2RN(Dab)*VLS(Dab)*GBBRM

2

2

2

prostate
tissue

SL16

3

R*R(Dab)*AYR(Dab)*YBBRM

4

5

0

colon
cell

SL19

2

NH2RY(Dab)*RYF(Dab)*LBBRM

3

5

0

prostate
tissue

SL20

2

NH2RY(Dab)*YYY(Dab)*RBBRM

3

6

0

prostate
tissue

Bead 1

3

R*G(Dab)*SGR(Dab)*QBBRM

3

3

1

Bead 3

2

NH2RY(Dab)*FFL(Dab)*RBBRM

3

5

0

Name

#BA

SL15

2

Bead B

2

SL17

2

SL18

Sequence
NH2RT(Dab)*RGG(Dab)*TBBRM
NH2RS(Dab)*NLS(Dab)*QBBRM

Library

prostate
cell
prostate
cell

Proteins
from
healthy
colon
healthy
colon
healthy
prostate
(EA+AA)
healthy
prostate
(2XAA)
metastatic
colon
metastatic
prostate
(2XAA)
metastatic
prostate
(EA+AA)
metastatic
prostate
metastatic
prostate

SL hit 18 was found and isolated from healthy tissue pool and could be used for
investigation of race-related normal health disparities in future. Right pool shows proteins
pooled using adenocarcinoma (Gleason score 7) prostate tissue of EA patients (green)
and AA patients (red): SL hit 19 was found and is unique in nature because it could
discriminate between complex tissue protein mixtures of different cancer patients. This
can be used as a future target to investigate personalized vectors for chemotherapeutic
targets. Sequences in Table 4.2.
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After sequencing all the hits (shown in Table 4.2) the hits, SL15-20 was designed,
along with bead B, 1 and 3 (all 9 of these are colon and prostate specific SLs). The
sequence analyses of these SL-hits surmised that specific amino acids play an important
role to assist in “tissue-typing” the array. Several different glycoprotein sources were
screened including those from secreted cell lines and ones from pooled clinical tissue
samples, producing a new series of SL hits exhibiting some interesting trends. It was
observed (Table 4.2) that SL hits for normal prostate and colon glycoproteins, had a
higher ratio of polar amino acids e.g. S, T, N and Q (bold numerical values). SL hits for
metastatic colon cancer had a greater number of arginine residues (R) (light grey). SL hits
for metastatic prostate cancer had a greater number of aromatic rings (from amino acids
like F and Y and/or from phenyl boronic acid) in the isolated SL sequences (dark grey).
4.6 CONCLUSIONS
The beginning of this chapter established some of the chemical targets of
proteins/glycoproteins that bind to SLs to cause cancer virulence based discrimination. It
has been shown that by using SLs sequences with greater number of Arginine residues
and lesser number of phenyl groups, different colon cells lines can be discerned and a
varied sialic acid concentration. It has been shown that varied sialic acid concentration is
one of the statistical basis of discrimination among colon cell lines by the array.
However just the opposite is true for accurately discerning each prostate cell line
where the SLs sequences containing greater number of phenyl rings and lesser number of
Arginine residues, play an important role. Since the SLs bind through guanidinium
groups to sialic acid residues, both in colon and prostate cell lines, it was proved that
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stripping away of the sialic acid residues takes away the SL array’s unique ability of
colon cancer discrimination.
SL array uses positively charged SLs for pre-organization of negatively charged
cancer-associated glycans (e.g. sLea and sLex) by increasing the overall binding of
charged pieces. As the model derived from positively charged SLs retains excellent
‘tightness/precision’, it indicates that these positively charged SLs provide a
microenvironment necessary for accurate binding. Besides that, the SL array uses SLs
with N-terminal phenyl boronic acids to covalently target diols of cancer glycans like
Lea, sLea and sLex, These SLs also enhance CH-π type interaction through the large
number of phenyl rings associated with them. One such SL (SL11) having high number
of phenyl rings bound exceptionally well to fucose. The results have suggested that
boronic acid residues are important to discriminate sLea, sLex and Lea.
Guiding structural epitopes in SL peptide sequences are discussed to see if they can
be used selectively to target colon and prostate cancers. In light of this, two new libraries
were synthesized (3-BA and 2-BA). These libraries were screening against colon and
prostate specific analytes (both cells and tissues). After sequencing the hits, SL15-20 was
designed, along with bead B, 1 and 3 (all colon and prostate specific SLs).
The sequence analyses of these SL-hits surmised that specific amino acids play an
important role to assist in “tissue-typing” the array. Polar amino acids (S. T, N and Q)
target healthy analytes while R targets colon cancer through the tissue’s proclivity to
over-express sialylation and sialylated cancer-glycans. Increasing the number of phenyl
rings (by increasing phenyl ring containing amino acids (F &Y), or by incorporating
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phenyl-containing boronic acids), the SL-hits achieve an increased core-fucosylation of
prostate cancer.
In total, these results validate our ability to differentiate structurally similar cancer
associated glycans with high accuracy using a small, cross-reactive SL Array. At times it
indicates the utility of SL array as prognostic tool by indicating cancer even when it
became invisible to the surgeon.
4.7 FUTURE DIRECTIONS
The glycan motifs that are targeted by the SLs require evaluation. One way to
approach the analysis of glycan would be to isolate and enrich the glycoprotein sequences
that bind to the SLs (using hydrazide columns that can capture N-linked glycans) and
then investigate them. A methodology is required that ensures the protein integrity is not
compromised during the isolation of glycoprotein from the column. Using circular
dichroism spectroscopy to evaluate protein stability as a function of added denaturants is
suggested in future experimentation.
One of the challenges is to establish the stoichiometry of the SL-glycan interaction.
This is because the SL works due to its multivalent display of peptides. Singular SL
peptide sequence has a negligible binding (>>10 µM), therefore the peptide needs to be
on the polymeric resin bead during interaction. One way to approach this question is to
develop Biotinylated SLs on the beads, detach them from beads and then interact them
with streptavidin platforms. This allows for calculation the number of binding events
once the streptavidin-bound SL tetramer is interacted with a purified glycoprotein or a
CAG of choice.
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Currently, work on patient blood is underway, which is the next step to make
headways into converting SL-array to a plausible diagnostic. Investigating the optimal
blood sample size required to determine the virulence, is paramount considering that the
K d of SL beads is in the similar range as that of natural lectins.
4.8 EXPERIMENTAL PROCEDURES
Details on the complete procedure for SL synthesis, incubation of SLs with fluorescently
tagged analytes, imaging of SL beads, data acquisition and statistical programs used for
image analysis are listed under the experimental section after chapter 2.
Details on complete procedure for human colon and prostate cell-culture, protein
extraction from cell membrane as well as concentration of cell-secreted proteins from
cell growth media, protein quantification, fluorescently tagging and incubation with SLs
are listed under the experimental section after chapter 3.

Procedure for Sialic Acid Quantitation
The Sialic Acid Quantitation Kit (Sigma Aldrich®) (Catalog Number SIALICQ) was
used to provide a rapid and accurate determination of total N-acetylneuraminic acid, also
known as sialic acid. The kit can provide a simple and reliable method for the
quantitation of total sialic acid concentration in sera and specific glycoconjugates to study
disease states and virulence potentials in many pathogens. The kit contains all reagents,
including a proprietary α-(2→3, 6, 8, 9)-neuraminidase, which was required to quantitate
the amount of sialic acid present in cell surface glycoproteins, polysialic acids, and
capsular polysaccharides consisting of only polysialic acid. One unit of the
neuraminidase enzyme catalyzes the release of 1µmole of 4-methylunbelliferone from 2’-
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(4-methylunbelliferyl) alpha-D-N-acetylneuramin acid per minute. This kit is unsuitable
for use with glycolipids or gangliosides. The α-(2→3, 6, 8, 9)-Neuraminidase cleaves all
sialic acid linkages, including α-2→8 and a-2→9 linkages, as well as branched sialic
acid. Variants of sialic acid such as N-glycolyl or O-acylneuraminic acid were cleaved as
well. Digestion with α-(2→3, 6, 8, 9)-neuraminidase generated total free sialic acid from
glycoconjugates without incurring losses that are typically associated with chemical
hydrolysis. The millimolar extinction coefficient of β- NADH is 6.22 at 340nm.
Therefore, each nmole of sialic acid will cause a drop of 0.00622 absorbance units in a
1mL reaction, a quantity that can be reliably measured on a digital spectrophotometer. If
the extinction coefficient level is exceeded (using too much protein), β-NADH will be
exhausted from the reaction mix. In these experiments, 100µL of 0.01 mg/ml of crude
cell-secreted protein sample was used.
To make Tris Reaction Buffer - Diluted the 1M Tris-HCl (Catalog Number T3946) 40fold with distilled water to make a 25mM solution. The pH of Tris Reaction buffer is 7.5.
To make β-NADH Solution - Just prior to use, added 640µL of Tris Reaction Buffer to
one 5mg vial of β-NADH (Catalog Number N8129) to make a 0.01M solution (A 340 =
62.2).
For optimal performance, freshly prepared β-NADH solutions should be used.
Prepared solutions should be discarded if the A 340 drops 20% or the solution turns
yellow.
Proceeded by dissolving the glycoprotein or polysialic acid in 40µL of distilled water and
then add 1µL of Sialidase Buffer (250mM sodium phosphate, pH 5.0, Catalog Number
S7189 ready-to-use). Added 1mL of a-(2→3, 6, 8, 9)-Neuraminidase and incubated for at
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least 3-hours in a 37°C water bath. Added 930µL of Tris Reaction buffer to the tube.
Pipetted the reaction mixture into a cuvette and blank the spectrophotometer. Added
20mL of the β-NADH Solution and mix by inversion several times. Read and recorded
the initial β-NADH absorbance (triplicate). Initial A 340 should read ~1.25. The
absorbance according to Beer’s law directly correlates to the path length of the cuvette.
Therefore, if using 1mL cuvette, A 340 should read out 1.25, but if using 0.5 mL cuvette,
A340 should read out ~0.625. Returned the reaction mixture to the original Eppendorf
tube. Added 1µL of N-Acetylneuraminic Acid Aldolase (Catalog Number A0849, readyto-use) and 1µL of Lactic Dehydrogenase (Catalog Number L9889, ready-to-use) and
mixed by inversion several times. Incubated in a 37°C water bath for a minimum of 1hour. This can go up to 3-hours. Pipetted the reaction mixture back into the cuvette. Read
and recorded the final A 340 . Calculated the nmoles of sialic acid using the formula:
nano moles of total cleaved sialic acid = {(A 340 Initial - A 340 Final) X 1,000}/6.22
To prevent any carryover of lactic dehydrogenase, which might result in a low initial
absorbance reading, always wash the cuvette thoroughly between assays. Positive
glycoprotein control of Bovine Fetuin (Catalog Number F4301) sample was used to
perform positive controls before proceeding with analysis of unknowns. When the entire
sample of Bovine Fetuin was digested with α-(2→3, 6, 8, 9)-neuraminidase, the amount
of sialic acid should be ~48nmoles.
Labeling protocol for secreted proteins after subjection to sialidase enzyme leach
After sialic acid quantitation was completed using UV-spectroscope, each tube
contained intact protein samples from each cell line in Tris reaction buffer along with
total free sialic acid residues, 1µM quantity of each sialidase, aldolase and dehydrogenase
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enzymes. To get rid of the total free sialic acid from the leftover intact protein sample and
consequently tag the leftover proteins, we added 10µL of FITC dissolved in 10:1 ratio of
PBS: DMF. To make FITC solution, weighed out 2.8 mg of FITC, dissolved it in 100µL
of 99% DMF, and added 900µL PBS. 10µL of this FITC solution was added to 1 ml
leftover intact protein sample (with a concentration of 0.01mg/ml and volume of 100µL
in Tris reaction buffer). Therefore, the protein: FITC ratio was 10:1. This protein solution
was covered and tumbled at 37°C for 1-hour. Later, the protein solution was centrifuged
at 4000 RPM using Amicon® 10-KDa centrifuge tubes. The buffer was exchanged from
Tris buffer (pH 7.5) to PBS (pH 7.3) using the buffer exchange tube, by addition of 1.5
mL of PBS. The leftover intact-labeled protein was collected and a BCA assay was run
before using the labeled protein for further experimentation.
General Screening Procedure for Biotinylated-Cancer Associated Glycans
Approximately 2mg of SL polymeric beads (from freezer) were incubated in
Phosphate Buffer Saline (PBS) without glycerol for 10 minutes at RT. Then the SL beads
were pre-blocked with 1mg/mL BSA and 10% glycerol containing PBS (Screening
Buffer) for 15-minutes at RT. The resin beads were later incubated with 0.01 mg/mL
biotinylated-glycans for 12-19 hours at 37°C. Just 2-hours before the completion of the
incubation, 6μL of 100nmol/L FITC-streptavidin was added and tumbling was continued
at 37°C. After washing with PBS three times, the beads were imaged using a fluorescent
microscope and analyzed as previously described. Assuming that 2mg of 300-micron
tentagel macrobeads contain roughly 100 beads and each bead has roughly 0.004µmole
capacity. Further, assuming that each SL copy on the bead can bind to five glycans (this
was done by assuming that each SL has a maximum of +5 charge), it was calculated that
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2mg of beads have a bead capacity of 0.002mmoles. Therefore, 0.01mg/mL of
biotinylated-glycans were used instead of 0.1mg/mL because even by using 0.01mg/mL
concentration, the glycan concentration was still roughly 10-times higher than
concentration of the number of binding sites calculated per peptide per polymeric bead.
The reduction in the fold-concentration of biotinylated glycans was done because at the
time a small quantity was available.
Frozen Prostate Tissue Procurement, Handling and Fixation
Obtained eight pairs of patient-matched frozen prostate sample (Courtesy: Ms. Ella
Weinkle at Prostate tissue core facility, CLS 508). A confirmed histology report was
provided (Courtesy: Dr. Loulia Chatzistamou, Instrumentation Resource Facility
Building 1 room # B-60, USC School of Medicine). The paraffin tissue blocks needed to
be made (courtesy: Benny Davidson IRF, USC School of Medicine) for sectioning.
Before sending the tissues for sectioning, each frozen tissue sample required fixing using
neutral buffered formaldehyde (NBF) for 24-hours.
Preparation of neutral buffered formaldehyde (NBF)- Mixed 100ml formalin (37-40%
stock solution) with 900ml deionized water, 4g/L NaH 2 PO 4 (monobasic) and 6.5g/L
Na 2 HPO 4 (dibasic and anhydrous) at RT. The stock was stored at 4°C. It is suggested to
prepare fresh NBF solution each time, to maintain 10% w/v ratio of formaldehyde gas:
water. Do not use paraformaldehyde because, it is not a fixative.
Alternatively, paraformaldehyde can be broken down into its basic building block
formaldehyde and be used for the same purpose. This could be done by heating or basic
conditions until paraformaldehyde became solubilized in order to act as a fixative.
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To slice the frozen tissue, -20°C microtome at PSC 621 (courtesy: Dr. Hexin Chen)
was used, so that the un-fixed frozen tissue does not thaw during the slicing and NBF
fixing. The tissue was sliced using a scalpel and immediately placed in a 15-mL falcon
tube containing 5mL of NBF at RT. The other half of each tissue was saved in the
original tubes and carried using dry ice. Unused tissue, required for actual
experimentation was stored under -80°C conditions (Dr. Mythreye Karthikeyan Lab).
Almost 50% of prostate tissue from each slice was used for fixing and subsequent
paraffin-blocking and sectioning to determine its histology. Each piece of tissue makes
one paraffin block. This was because of the nature of prostate cancer, as it exists in small
discrete areas in the tissue. The number of sections mounted per slide were two and were
further H&E stained by IRF for evaluation. (Leftover paraffin blocks were stored in
GSRC435 refrigerator at 4°C).
Procedure for Prostate Tissue Pulverization Using Liquid Nitrogen
All the pulverization was handled under the sterilized fume-hood cabinet. A liquid 4L
Nitrogen tank was set nearby. Tin foil was applied all over the fume-hood to ensure a
safer clean up after working with tissue (potential biohazard). All the necessary supplies
were kept under the hood after spraying with 70% ethanol mixture (sharps container, box
of ice, autoclaved-pipette tips, 1000 µL pipette, towels/tampons, 16 G needles, mortar
and pestle, lysis buffer with protease inhibitor). The mortar and pestle was pre-chilled by
pouring in liquid nitrogen and allowing it to evaporate. The tissue was place along with a
little amount of nitrogen; the tissue must remain in nitrogen at all the times. Before,
pulverization by twisting motion, it was ensured that the tissue had completely frozen or
attained a stone like form. Then it was lightly crushed by tapping from the top (this
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needed to be done carefully, else the tissue piece could bounce out of the mortar. Used
tap and turn technique for pulverization while adding small aliquots of nitrogen (extreme
care!).
Scooped up all the pulverized tissue using the scalpel and transferred into an
Eppendorf containing 1mL of cold lysis buffer with protease inhibitors. The crushed
sample was passed through the 16 G needle several times, to break any larger chunks of
tissues. This step was done to homogenize the tissue slurry for greater action of lysis
buffer. The sample was rested in the buffer, meanwhile the next tissue piece was
pulverized. Mortar and pestle were bleached each time before working with a new tissue
to avoid contaminations.
The tissue slurry in the lysis buffer was centrifuged using 4°C centrifuge for 20
minutes. The supernatant was removed carefully leaving the tissue pellet behind and the
supernatant was further used for membrane protein extraction.
Prostate tissue may contain a layer of adipose tissue, which floats as fat layer on the
top of the supernatant during the centrifuge. In that case, carefully positon the pipette to
only collect the middle layer of supernatant.
Extraction of Protein from Colon Cell Membrane and Prostate Frozen Tissue and its
Corresponding Fluorescent Labeling using FITC
The Qiagen® Plasma Membrane Protein Kit was used to extract plasma membrane
proteins and glycoproteins from cells as well as tissues; this is because out of five
commercially available membrane extraction kits, it gave the highest membrane protein
yield and the second least amount of cytosolic protein contamination.

14

The starting

material for one fractionation procedure is 1 x 107 adherent cells. That corresponded to
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four 75-cm2 cell flasks at 70% confluence. Cells were incubated in a hypotonic lysis
buffer, causing them to swell. After the addition of a mild detergent, the cells burst and
the resulting cell suspension was homogenized by mechanical disruption using a needle
and syringe. Intact cells, cell debris, nuclei and the major organelles were removed by
centrifugation under 4°C temperature at 12000X g for 20 minutes. The resulting
supernatant contained cytosolic proteins and microsomes (i.e. small vesicles (20–200 nm
in diameter) formed from the endoplasmic reticulum, Golgi vesicles, and plasma
membranes). In case of tissue samples, skip this step containing lysis buffer and
centrifugation and resumed with the next step.
A ligand specific for commonly expressed antibody molecules on the plasma
membrane was added to the supernatant. The ligand bound to the plasma membrane
vesicles and the ligand–vesicle complexes were precipitated using silane coated magnetic
beads that bound to the ligand. Silane coating prevents non-specific binding. The 1-4µm
diameter of magnetic beads provided for enough surface area to volume ratio for the
ligand to bind to the magnetic beads. The plasma membrane vesicles were captured on to
the bead surface. After washing, plasma membrane vesicles were eluted under native
conditions and the ligand remained bound to the beads. The membrane protein remained
in elution buffer and could be stored in -20°C temperature until required.
The protein extract was centrifuged and buffer exchanged into carbonate buffer pH
9.8 using Amicon® 10-KDa spin tubes. Later, a BCA assay was performed to obtain the
concentration of the protein extract. The required amount of protein was added to
carbonate buffer to make up a total volume of 600 µL. Depending on which dye was
being used to label, 0.07 µmol FITC or NHS-rhodamine was added and the solution was

152

incubated at 37°C and tumbled for 1-hour. After an hour, the labeled protein was spun
down using a second Amicon® 10-KDa spin tubes at 4000X g for approximately 15
minutes. The buffer was exchanged to PBS at RT. The final labeled protein sat in PBS at
pH of 7.3.
General Incubation Protocol of Labeled Proteins Extracted from Prostate Tissue
Approximately 2mg of library resin was tumbled in PBS twice at RT and then preincubated with 1% BSA in PBS containing 10% glycerol for 15-minutes at RT. This preincubation was performed, to reduce the nonspecific binding between the SL and
proteins. The 1% BSA in PBS with 10% glycerol solution was then removed from the
beads and 1mL of a 0.0002mg/mL solution of the fluorescently labeled prostate tissue
extract in PBS was incubated with the beads for 12-hours at 37°C.
Procedure for (BOC) 2 O Protection to Design 2-BA Library
The two designed libraries (2-BA and 3-BA) were both fixed position libraries. The
2-BA library had a free –NH 2 at the N-terminus. To keep the N-terminus –NH 2 free even
during the ivDde de-protection (basic de-protection), the N-terminus was protected using
(BOC) 2 O protecting group. The ivDde were the protecting groups on the amino side
chains of diamino butanoic acids, which were removed for the subsequent attachment of
phenyl boronic acid on the diamino butanoic acid. Not protecting the N-terminal –NH 2 ,
causes the attachment of a third phenyl boronic acid residue on the N-terminus.
Correspondingly, the (BOC) 2 O protection and avoiding of (BOC) 2 O protection led to
formation of 2-BA and 3-BA libraries respectively. Where “2” stood for two of the
phenyl boronic acid (BA) attachments per SL sequence.
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Calculate

the

amount

of

(BOC) 2 O

(Di-tert-butyl

dicarbonate)

and

DIEA/DIPEA/Hünich’s required. The ratio of tentagel beads (bead capacity
0.25g/mmol): (BOC) 2 O: DIEA is 1eq: 15eq: 15eq. 15eq was used because (BOC) 2 O and
DIEA are quite cheap and the ratio of tentagel beads to bulkiest amino acid (R) was 1eq:
10eq.
After calculating for 1000mg of tentagel beads (bead capacity 0.25g/mmol) used
818.44mg of (BOC) 2 O and 653.16µL DIEA. After transferring the tentagel beads with
peptide (free –NH 2 group on N-terminus) into falcon tube poured in 6ml solution
containing (BOC) 2 O. Added approximately 30 molecular sieves (4X8 mesh size). Using
a syringe under nitrogen gas environment added the required amount of DIEA. Quickly
cap and tumble the tube for 3-hours. Be sure to vent the tube initially after 15-20 minutes.
The beads were washed using DMF followed by MeOH and DMF again. To ensure
complete (BOC) 2 O coupling, performed ninhydrin test. The bead should be clear/ yellow
tinge. If the bead is purple, repeat the coupling again before proceeding to ivDde deprotection step.
Library Screening for Dual Dye Analytes
The library screening for dual dye analytes followed the same protocol in terms of
sample concentrations, be it for colon cell membrane extracts, prostate cell secreted
proteins or prostate tissue proteins. Typically, healthy protein extract was labeled using
FITC and cancerous protein extract was labeled using NHS-Rhodamine. 0.0001 mg of
each labeled protein analyte was used to make a total concentration of 0.0002 mg/mL per
tube. This dual labeled protein mix was then incubated with 2-5 mg of either of the
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libraries for 12 hours. The standard wash protocol using PBSX 3 times and imaging
under microscope was done.
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APPENDIX A: LC-MS OF PEPTIDE SEQUENCES OF SELECT SLS
LC-MS OF PEPTIDE SEQUENCES OF SELECT SLS WITHOUT BORONIC ACIDS,
IVDDE OR ACID LABILE SIDE CHAIN GROUPS
a) Peptide# 91

SL5

Molecular Weight: 1325

b) Peptide#100 SL5-RRAc

Molecular Weight: 1637

c) Peptide#114 SL5-R1,5,11A

Molecular Weight: 1069

d) Peptide#131 4R

Molecular Weight: 1265

e) Peptide#132 5R

Molecular Weight: 1352
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APPENDIX B: 22-UNIT SL ARRAY
22-UNIT SL ARRAY USED FOR PROSTATE TISSUE INVESTIGATION
SL Name

Amino acid sequence and modifications

#R

#2-PBA

SL1
Ac-RG(Dab)*VTF(Dab)*RBBRM
3
2
SL2
Ac-RT(Dab)*RFL(Dab)*VBBRM
3
2
SL3
Ac-RS(Dab)*VTT(Dab)*RBBRM
3
2
SL4
Ac-RR(Dab)*TQT(Dab)*QBBRM
3
2
SL5
Ac-RA(Dab)*TRV(Dab)*VBBRM
3
2
SL6
Ac-RT(Dab)*NRN(Dab)*FBBRM
3
2
SL7
Ac-RS(Dab)*YFT(Dab)*QBBRM
2
2
SL8
Ac-RT(Dab)*YGN(Dab)*NBBRM
2
2
SL9
Ac-RT(Dab)*YQV(Dab)*ABBRM
2
2
SL11
R*L(Dab)*YLT(Dab)*RBBRM
3
3
SL11-R8A
R*L(Dab)*YLT(Dab)*ABBRM
2
3
SL11-T6A
R*L(Dab)*YLA(Dab)*RBBRM
3
3
SL11-Y4A
R*L(Dab)*ALT(Dab)*RBBRM
3
3
SL11-Y4F
R*L(Dab)*FLT(Dab)*RBBRM
3
3
SL11-T6Abu
R*L(Dab)*YL(Abu)(Dab)*RBBRM
3
3
SL5-R1,5,11A
Ac-AA(Dab)*TAV(Dab)*VBBAM
0
2
SL5-Dab
Ac-RA(Dab)TRV(Dab)VBBRM
3
0
SL5-RRAc
Ac-RRRA(Dab)*TRV(Dab)*VBBRM
5
2
4R
Ac-RAARAARA-BBRM
4
0
5R
Ac-RARARARA-BBRM
5
0
SL15
NH 2 -RT(Dab)*RGG(Dab)*TBBRM
3
2
SL16
R*R(Dab)*AYR(Dab)*YBBRM
4
3
R* indicates N-terminal Arginine residue having 2-fprmyl phenyl boronic acid
attachment Ac indicates acylated N-terminus
NH 2 indicates free N-terminus
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#Ph
3
3
2
2
2
3
4
3
3
4
4
4
3
4
4
2
0
2
0
0
2
5

APPENDIX C: TOP SEVEN SLS FOR ALL TISSUES TOGETHER
TABLE SHOWING TOP SEVEN SLS THAT CLASSIFY 13 DIFFERENT CELL
LINES FROM DIFFERENT TISSUES.
Table showing top 7 (out of 20) SLs that significantly classified 13 cell lines
(from colon prostate and breast) according to the cell line metastatic potential.
F-scores are used as statistical markers of important classifier. (SLs with F-score in
single decimal place and below were not considered significant).
Number of Ph rings
(from PBA and
peptides)

SL Name

F-Scores

Number of positive charges
(from R and free Dab)

SL4
4R
SL5-Dab
SL5
SL11-Y4A
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APPENDIX D: BAR GRAPHS OF OTHER FIVE CAGS WITH 20 SLS

BAR-GRAPHS OUTPUTS OF OTHER FIVE CANCER-ASSOCIATED GLYCANS
WITH 20 SLS
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Raw average fluorescent intensity values. Standard deviation error bars. Exposure times
used for each CAG were different and mentioned above in title of each bar-graph. Colors
correspond to LDA color scheme in Figure 4.5.

182

APPENDIX E: BEAD INTENSITY BAR GRAPH FOR SL17 AND SL20
INDIVIDUAL BEAD INTENSITY BAR GRAPH FOR SL17 AND SL20.

individual bead fluorescent intensity

250

Prostate Adenocarinoma GS7 (all races)

Normal (all races)

200
150
100
50
0

B: SL 20

D: SL 17

Raw fluorescent intensity values of individual beads shown in Figure 4.9. Red
intensity of metastatic proteins labelled using Rhodamine under DSR filter set:
DsRED excitation filter: 545/30 nm (510–560 nm) barrier filter: 620/60 nm (590–650
nm). Green intensity of healthy proteins labelled using Fluorescein under GFP filter
set: GFP excitation filter: 425/60 nm (395–455 nm) barrier filter: 480 nm. Exposure
times used for each image was same.
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